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Overview 
Volume  1  of  this  thesis  evaluates  the  development  of  a  low  intensity 
Cognitive Behavioural Therapy (CBT) intervention for Generalised Anxiety Disorder 
(GAD), its feasibility and acceptability. This volume consists of three parts. 
Part  1,  the  literature  review,  examines  using  meta-analysis  and  network 
meta-analysis the effectiveness of psychological treatments for pathological worry in 
Generalised  Anxiety  Disorder  (GAD)  using  the  Penn  State  Worry  Questionnaire 
(PSWQ) as a primary outcome measure. The review also considers the relative 
effectiveness  of  currently  available  psychological  treatments.  The  quality  of  the 
current  evidence  base  and  methodological  issues  are  discussed  and  further 
research suggested. 
Part 2, the empirical paper, is a pilot study, which examines the feasibility 
and acceptability of the delivery of a brief guided self-help intervention for excessive 
worry and GAD, which drew on Behavioural Change Theory (Michie, Van Stralen & 
West, 2011) following a review of current interventions for GAD. The results showed 
that  there  was  a  clinical  need  for  a  specific  worry  and  GAD  intervention,  that 
Understanding Worry (UW) was as acceptable to patients as Treatment as Usual  
(TAU) as there was no significant difference in drop out, attendance, cancellations 
or DNAs. There was no significant difference in post-treatment scores between UW 
and TAU in observed clinical contact and at session four as predicted by the Mixed 
Methods Linear Model (MMLM). Implications for treatment and further research are 
discussed.    
Part  3,  the  critical  review,  explores  critically  the  empirical  study,  the 
background to the research, conceptual issues in the intervention design and the 
challenges of conducting research in NHS clinical settings. The review particularly 
focuses on recruitment and the involvement of clinicians the research process and 
future directions for research.   3 
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Part 1 – Literature Review 
 
The effectiveness of psychological treatments for 
pathological worry in Generalised Anxiety Disorder 
(GAD). 
     7 
Abstract 
 
Aims:  The  current  review  sought  to  update  and  expand  previous  reviews  of 
psychological treatments for GAD focusing on pathological worry as a treatment 
outcome.  The  review  considered  the  relatively  effectiveness  of  available 
psychological treatments for GAD. Method: Studies had to satisfy inclusion criteria 
relating to i) disorder ii) research design and iii) outcome measures. Twenty-eight 
studies  were  identified  from  four  electronic  databases  (PsychInfo,  OvidMedline, 
Embase  and  the  Cochrane  Central  Register  of  Controlled  Trials  register)  and 
references in previous systematic reviews. Available data was synthesised using 
standard two-way meta-analysis and network meta-analysis. Results: The review 
supported the findings of previous reviews suggesting that psychological therapy 
led  to  reliable  improvement  in  worry  post-treatment.  There  was  evidence  that 
suggested CBT was superior to waitlist but was not superior to applied relaxation. 
Evidence  pointed  towards  longer  CBT  treatments  reporting  greater  differences 
compared  to  short  duration  treatments.  There  was  limited  evidence  for 
psychodynamic  therapy  and  behavioural  activation.  Despite  reliable  changes  in 
worry, post-treatment reductions did not reach a non-clinical level of worry. Network 
meta-analysis  indicated  that  meta-cognitive  therapy  was  probably  the  best 
treatment.  Conclusion:  The  current  review  supported  the  findings  of  previous 
reviews, suggesting that psychological treatments led to reliable reductions in worry. 
CBT and AR were found to be equally effective and there was limited evidence for 
psychodynamic and behavioural activation. The network meta-analysis suggested 
that MCT is probably the best treatment of GAD.  
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1. Introduction 
1.1 History of GAD 
Generalised  Anxiety  Disorder’s  (GAD)  diagnostic  history  is  not  without 
controversy and is a relatively recent addition to the diagnostic taxonomy (Tyrer & 
Baldwin, 2006).  The validity of GAD as a distinct disorder has been widely debated. 
It has been argued that GAD and Major Mood Disorder (MDD) are indistinguishable 
due to the high degree of association and substantial overlap and therefore GAD 
should be classified as agitated depression (Mennin, Heimberg, Fresco & Ritter, 
2008; Watson et al., 1995). However, a large longitudinal study questioned whether 
GAD and MDD were strongly related and concluded that GAD was associated more 
with anxiety disorders than depression and was a distinct disorder (Beesdo, Pine, 
Lieb & Wittchen, 2010). The key differentiating symptom of GAD is uncontrollable 
and pathological worry, which distinguishes GAD from other anxiety disorders and 
mood disorders (Abel & Borkovec, 1995; Brown, Antony, & Barlow, 1992; Ladoucer, 
Blasi,  Freeston  &  Dugas,  1998).  Previously  GAD  was  subsumed  under  ‘anxiety 
neurosis’ and was a residual category, used when an anxiety disorder could not be 
classified  under  any  other  diagnosis.  GAD’s  recognition  as  a  distinct  psychiatric 
disorder is relatively recent. It was not until the DSM-III revision in 1987 (APA, 1987) 
that GAD was classified as an independent anxiety disorder. With the introduction of 
DSM-IV  (APA,  1994)  the  diagnostic  criterion  was  refined  further,  introducing 
excessive, uncontrolled pathological worry as a diagnostic marker. This has been 
maintained  in  the  current  diagnostic  manual  DSM-5  (APA,  2013),  which  has 
retained the diagnostic criterion of DSM-IV.  
1.2 Symptoms, Course, Co-morbidity and Prevalence of GAD 
GAD is characterised by excessive  worry that is difficult to control, and can 
result  in  reduced  social  and  occupational  functioning  (Tyrer  &  Baldwin,  2006).  
These  worries  are  typically  widespread,  involve  everyday  issues  and  focus  on 
unlikely or remote events in the future (Dugas et al., 1998). To meet DSM-5 criteria   9 
for GAD, excessive worry and anxiety about a number of events must be present for 
most days for at least six months, causing distress and impaired functioning. The 
worry experienced is difficult to control and is accompanied by at least three out of 
six  symptoms:  restlessness,  fatigue,  difficulty  concentrating,  irritability,  muscle 
tension  and  disturbed  sleep.  GAD  is  frequently  comorbid  with  other  mental 
disorders. The rates of comorbidity between epidemiological studies estimate that 
between 68% to 93% of individuals who meet a diagnostic criteria for GAD will also 
meet criteria for another Axis 1 mental health disorder (Carter, Wittchen, Pfister & 
Kessler,  2001;  Hunt,  Issakidis  &  Andrews,  2002).  The  most  common  comorbid 
conditions are depressive disorders and other anxiety disorders (Carter et al., 2001; 
Dugas  &  Robichaud,  2007;  Hunt  et  al.,  2002; Kessler,  Chiu,  Demler & Walters, 
2005).  
  GAD is a chronic condition with symptoms that wax and wane in response to 
life stressors (Kessler, Keller & Wittchen, 2001). Clinical studies suggest that there 
is  little  remission  in  symptoms  of  GAD  in  the  short  and  medium-term  (Yonkers, 
Warshaw,  Massion  &  Keller,  1996;  Greenberg  et  al.,  1999;  Kessler,  Keller  & 
Wittchen, 2001). Long-term remission from GAD symptoms is reported to be limited, 
with  only  40%  of  those  diagnosed  with  GAD  reporting  recovery  after  12  years 
(Tyrer, Sievewright & Johnson, 2004).  GAD is associated with a substantial burden 
of disability that is equivalent to that of depression and other chronic conditions 
(Wittchen,  2002).  Individuals  with  GAD  experience  diminished  quality  of  life, 
reduced work productivity, impaired social relationships and increased reliance on 
state support. Individuals with GAD are also more likely to make frequent medical 
appointments,  undergo  diagnostic  testing  and  represent  the  most  costly  patient 
group in respect to other anxiety disorders (NICE, 2011).   
  In the United Kingdom it is estimated that 4.4% of the population will meet a 
diagnosis  of GAD (McManus  et  al.,  1999). Wittchen  and  colleagues  (2011)  in a 
European  review  of  mental  health  disorders  estimated  that  GAD  affects   10 
approximately 8.9 million individuals per year. In primary care it is estimated that 8% 
of  individuals  seeking  treatment  meet  the  diagnostic  criteria  for  GAD  (Wittchen, 
2002).  Individuals  with  GAD  may  account  for  up  to  account  for  25%  of  primary 
attendances for psychological problems, and as such it is the most frequent anxiety 
disorder  presenting  in  primary  care  settings  (Barret,  Oxman  &  Geber,  1988). 
However, despite its high prevalence in primary care settings GAD is significantly 
under-detected and undertreated (Wittchen & Jacobi, 2005). Stein and colleagues 
(2004)  suggest  that  due  to  the  limited  recognition  of  GAD  in  primary  care  that 
general practitioners (GPs) frequently do not provide psychological evidence-based 
treatment as often as may be indicated. This finding has been supported by the 
most recent Psychiatric Morbidity survey (McMannus et al., 2009), which reported 
that only 34% of those with GAD were receiving any treatment. Of those, over half 
were  receiving  medication  and  less  than  a  quarter  were  receiving  psychological 
treatment.   
1.3 Development of Treatment for GAD 
Treatments for GAD have reflected changes in the theoretical understanding of 
GAD.  Treatments  initially  developed  for  GAD  drew  on  non-specific  interventions 
such  as  relaxation  training  and  supportive  psychotherapy  (NICE,  2011).  Initial 
Cognitive Behavioural Therapy (CBT) treatments for GAD developed in the early 
1990s (Barlow, Rapee & Brown, 1992; Borkovec & Costello, 1993) focused on the 
reduction  of  physical  arousal  and  the  modification  of  dysfunctional  cognitive 
appraisals.  First  wave  CBT  approaches  focused  primarily  on  addressing  the 
consequence  of  worry,  rather  than  worry  as  an  underlying  process  maintaining 
anxiety.  Early cognitive and behavioural interventions applied techniques such as 
applied  relaxation,  stimulus  control  and  cognitive  restructuring (Wilkins,  Mears  & 
Freeston,  2011).    More  recent  second  wave  CBT  treatment  packages  have 
emphasised the specific role of worry and the processes of thought and behaviour 
that maintain anxiety and somatic symptoms (Dugas, Gagon, Ladoucer & Freeston,   11 
1998; Wells, 1999). Second wave CBT approaches focus on reducing behavioural 
and emotional avoidance, beliefs about worry and problem solving skills. Third wave 
approaches, which consist of acceptance-based or mindfulness approaches, have 
also been adapted to address GAD (Behar, DiMarco, Helke, Mohlman & Staples, 
2009).  The  third  wave  approach  focuses  on  changing  the  relationship  with 
experience of worry rather than the modification of underlying thinking styles and 
appraisals. 
1.4 Previous Reviews 
Several  meta-analyses  and  systematic  reviews  focusing  on  therapeutic 
interventions for GAD have been conducted since 2000. The majority of reviews 
have had a narrow focus on cognitive therapy (CT) or CBT outcome studies for 
GAD.    Borkovec  and  Ruscio  (2001)  reported  that  CT  was  effective  in  reducing 
anxiety in comparison with placebo, and treatment gains were maintained over time 
and supported the long-term efficacy of CT as clinical treatment for GAD.  Western 
and Morrison (2001) reported CBT was effective in reducing anxiety at the end of 
treatment,  but  treatment  gains  were  not  maintained  at  long-term  follow  up.  
However, early reviews, and Western and Morrison’s (2001) review in particular, 
have been criticised in their analysis of anxiety outcomes, which did not address 
changes in pathological worry  which is a key symptom in GAD (Atkins, Hazlett-
Stevens, & Craske, 2001). Colvin and colleagues (2008) subsequently conducted a 
review that focused on evaluation of the effectiveness of CBT interventions for GAD 
and used the Penn State Worry Questionnaire (PSWQ) (Meyer, Miller, Metzger & 
Borkovec,  1990)  to  evaluate  changes  in  pathological  worry.  Colvin  et  al.  (2008) 
reported that CBT interventions led to a significant reduction in self-reported worry 
in  comparison  to  non-treatment  controls.  They  also  reported  that  the  largest 
treatment gains  were found  in  younger  adults and  that  individual  treatment  was 
superior  to  group  treatment.  More  recently  Hanrahan  and  colleagues  (2012) 
conducted a meta-analysis, which focused on evaluation the efficacy of CBT for   12 
GAD  and  pathological  worry.  The  authors  reported  that  CBT  was  superior  in 
reducing  worry  in  comparison  with  non-therapy  controls,  and  57%  of  individuals 
were  classed  as  recovered  at  12  months.  They  concluded  CBT  treatment 
approaches were effective in the treatment of GAD.  
  Two recent systematic reviews conducted focused on the evaluation of all 
psychological  therapies  for  GAD  (Hunot  et  al.,  2007;  NICE,  2011).  Hunot  and 
colleagues’  Cochrane  Review  for  psychological  therapies  for  GAD  reported  that 
psychological therapy based on CBT principles was effective in reducing anxiety in 
comparison with waitlist controls. However, the authors cautioned that the evidence 
for the effectiveness of CBT in comparison with other psychological therapies was 
small,  heterogeneous,  and  did  not  allow  any  firm  conclusions  about  which 
psychological therapy was more effective in the treatment of GAD to be made. The 
more recent National Institute of Clinical Excellence guideline (NICE, 2011) for the 
treatment  of  GAD  reviewed  both  Low  Intensity  (LI)  and  High  Intensity  (HI) 
psychological  treatments  for  GAD.  The  review  reported  that  there  were  large 
treatment effects in the reduction of anxiety for CBT based guided self-help and 
computer CBT (cCBT) interventions, and that there was a smaller treatment effect 
for psycho-educational groups. However, the majority of the studies included in the 
review contained a mixture of diagnoses and the studies were deemed to be of low 
quality. In regards to the HI interventions the review reported a large effect in the 
reduction of anxiety for CBT in comparison with waitlist controls and that CBT was 
equally  as  effective  as  applied  relaxation  (AR),  although  the  evidence  for  AR’s 
effectiveness was less robust. The review also reported that CBT was superior to 
psychodynamic therapy, usual care or an active comparator. However, both reviews 
did not focus specifically on changes in pathological worry as a treatment outcome 
and  analysed  anxiety  measures,  which  arguably  focus  on  somatic  symptoms  of 
anxiety. 
   13 
1.5 The Current Review 
The  current  review  seeks  to  update  and  expand  previous  reviews  of 
psychological treatments for GAD and focuses on levels of pathological worry as a 
treatment  outcome.  The  review  will  also  consider  the  relative  effectiveness  of 
available psychological treatments for GAD. The most recent systematic review of 
psychological  therapy  for  GAD  conducted  as  part  of  the  NICE  guideline  (2011) 
identified a relatively small and heterogeneous number of studies, which included 
mixed  anxiety  disorders  rather  than  limiting  the  search  to  GAD.  The  literature 
search  for  the  NICE  review  was  concluded  in  early  2010;  four  years  have  now 
passed  and  over  this  time  there  has  been  renewed  interest  in  psychological 
treatments for GAD and the publication of several new randomised studies in this 
area. The current review aims to incorporate these new trials into a broader review 
of psychological therapy rather than focusing on determining the effectiveness of 
CBT  for  GAD  in  reducing  pathological  worry.  It  will  also  seek  to  delineate  CBT 
approaches into first wave CBT, second wave CBT and third wave approaches. The 
review  defines  first  wave  approaches  as  traditional  Beckian  approaches,  which 
focus on worry as a consequence of anxiety. Second wave approaches focus on 
worry as a maintaining process in anxiety and  treatment focuses  on addressing 
intolerance of uncertainty and beliefs about worry. Third wave approaches include 
acceptance  and  mindfulness  approaches  that  do  not  attempt  to  restructure 
cognition.  
  The  review  uses  a  network  meta-analysis  (NWA)  to  evaluate  the 
comparative  effectiveness  of  different  psychological  treatments  for  pathological 
worry  in  GAD.  NWA  is  a  methodological  approach  that  allows  the  relative 
effectiveness  of  treatment  to  be  assessed  when  they  have  not  been  directly 
compared in head-to-head in a randomised trial but have been compared to other 
treatments  (Cipriani,  Barbui,  Rizzo  &  Salanti,  2012;  Lumley,  2002).  NWA  is  a 
generalisation of standard pairwise meta-analysis.  One of the basic assumptions of   14 
NWA  is  direct  and  indirect  evidence  estimate  the  same  parameter,  that  is,  the 
relative effect between A and B measured directly from an A versus B trial, is the 
same with the relative effect between A and B estimated indirectly from A versus C 
and  B  versus  C  trials.  NWA  techniques  strengthen  inferences  in  regards  to  the 
relative  effect  of  a  treatment  by  including  both  indirect  and  direct  comparisons 
between treatments, and at the same time, allowing simultaneous inference on all 
treatments examined in the pairwise trial while respecting randomisation (Caldewell, 
Ades  &  Higgins,  2005).  The  simultaneous  estimation  of  the  relative  effect  of  a 
number of treatments is possible and is part of a single ‘network of evidence’, that 
is, every treatment is linked to at least one other treatment under assessment by a 
direct or indirect comparison.  The NWA method allows treatments that have never 
been directly compared in a trial head-to-head to be compared against each other 
and  a  hierarchical  order  of  relative  effectiveness  to  be  considered  (Barth  et  al., 
2013). An additional strength of NWA is that it allows the opportunity to understand 
how much evidence is available for each treatment and a comparison of why and 
where more research is needed. This method of analysis has yet to be employed in 
the evaluation of the relative effectiveness of interventions for GAD. 
2. Method 
2.1 Identification and Selection of Studies 
Studies for the current review were identified in a number of ways. Firstly the 
databases PsychInfo, OvidMedline, Embase and the Cochrane Central Register of 
Controlled Trials (Central) Trial register were searched for English language studies 
using  an  adapted  search  terms  and  filters  reported  in  the  NICE  (2011)  GAD 
guideline. The search included the use of three search filters that specified GAD, 
randomised study design, High intensity (HI) psychological therapy, which includes 
CBT, applied relaxation, psychodynamic therapy, non-directive therapies and are 
delivered by a qualified clinician and Low intensity therapy (LI), which include brief   15 
guided self-help, psychoeducational groups, computer based CBT (cCBT) and are 
facilitated by healthcare professionals and graduate level workers. The search filters 
consisted of a combination of medical subject headings (MESH), explosions (exp), 
subheadings (sh), and text words (ti,ab/tw). A full summary of the terms and filters 
used  can  be  found  in  Appendix  1.  The  filters  used  in  the  NICE  GAD  guideline 
(2011)  were  selected  to  identify  studies  as  they  had  previously  been  shown  to 
provide  a  comprehensive  coverage  in  the  identification  of  psychological  therapy 
studies for GAD and mitigated dissimilarities in bibliographic databases in thesaurus 
terms, indexing practices and imprecise reporting of study populations by authors. 
Studies  identified  in  the  search  were  initially  included  or  excluded  based  on 
relevance of title and abstract; following this the remaining studies were included or 
excluded  after  a  review  of  the  complete  paper.  Secondly,  the  reference  list  of 
previous  meta-analyses  and  systematic  reviews  were  searched  to  identify  any 
additional studies suitable for inclusion that had not been identified from electronic 
database searches. This identified a further two studies. 
2.2 Inclusion Criteria 
Following  the  searches,  studies  were  included on  the  basis  of the following: 
population,  intervention,  comparison  and  outcomes  (PICO)  criteria  (Pettigrew  & 
Roberts,  2006);  Adults  (18  years  old  and  above),  with  a  DSM  III  or  DSM  IV 
diagnosis  of  GAD  or  those  with  a  baseline  score  of  above  44  on  the  PSWQ; 
interventions received were psychological therapies for GAD including both HI and 
LI  interventions;  studies  included  a  comparator  arm  which  was  either  a  waitlist 
control or comparative psychological treatment; reported the PSWQ as a primary or 
secondary outcome measure. Studies were only included if they were a randomised 
trial design and had been published in an English language peer reviewed journal.  
2.3 Exclusion Criteria 
Studies were excluded on the basis of the following criteria: if patients had a co-
morbid diagnosis of psychosis, bipolar-affective disorder, panic disorder, seasonal   16 
affective disorder, organic brain disorder, study design was not randomised (e.g. 
case series designs or single arm trials); studies did not report the PSWQ as either 
a  primary  or  secondary  outcome  measure;  studies  did  not  report  GAD  only 
outcomes for all arms of studies; studies which included participants under the age 
of 18 years old and studies that were not in the English language.   
2.4 Search Strategy  
All  databases  were  searched  from  the  database  inception  to  the  third  of 
January  2014.  Studies  were  initially  screened  by  title  for  relevance,  remaining 
studies were screened by abstract against PICO criteria and final full text articles 
identified were screened. Of the studies reviewed by full text, approximately 18% 
were  excluded  for  not  reported  GAD  specific  outcome  data  and  not  providing 
appropriate data after written request to the author. A further 19% of studies were 
excluded  for  not  reporting  the  PSWQ  or  using  a  composite  measure  of  anxiety 
rather than separate anxiety measures, 12% of the studies were excluded as the 
papers reported a trial protocol without subsequent published data. A single study 
was excluded as the paper reported a physical exercise as a treatment, which did 
not constitute a psychological intervention for GAD. A summary of studies excluded 
after  assessment  by full text  can  be found  in  Appendix  2.  Figure  1  outlines  the 
exclusion process by numbers included and excluded at each end point.    17 
 
Figure 1: Flowchart of study selection 
2.5 Risk of Bias 
Risk of bias was conducted using Review Manager (Revman) Version 5.2 
(http://ims.cochrane.org/revman) using the Cochrane Collaboration risk of bias tool. 
Studies were rated for selection bias, performance bias, outcome bias, detection, 
attrition bias, reporting bias and other sources of bias. Ratings of bias were high 
risk, unclear risk or low risk. A rating of high risk of bias was made when plausible 
bias that would seriously weaken the confidence of the study results was present, 
for example a failure to employ random allocation.  A rating of unclear risk of bias   18 
was  made  when  plausible  bias  that  could  raise  doubts  was  identified  by  the 
information provided by the study authors and did not allow a clear decision to be 
made. A rating of a low risk of bias was made when the plausible risk of bias was 
unlikely  to  seriously  alter  the  confidence  of  the  study  results  (Higgins  &  Green, 
2011).  
2.6 Meta-Analysis and Network Meta-Analysis 
Studies  included  in  pairwise  comparisons  were  grouped  by  common 
intervention. Studies that reported two or more arms were split into separate two-
way  comparisons  and  the  waitlist  control  group  was  split.    Meta-analyses  were 
conducted for class of interventions using Review Manager (RevMan) Version 5.2 
for all time points where sufficient data was available. In order to assume a more 
conservative  assessment  of  treatment  effect  intent-to-treat  (ITT)  data  was  used 
when reported. The comparisons conducted used baseline and end of treatment. 
The  PSWQ  was  used  as  the  outcome  measure  of  interest,  all  analysis  used 
reported mean end-point scores on the PSWQ and 95% confidence intervals were 
calculated.  
All available within-study comparisons were then synthesised into a network 
meta-analysis. The NWA analysis of the available data was conducted using the 
mean change and standard deviation of change (SD of change) from baseline to 
post-treatment  when  reported.  If  the  mean  change  and  SD  of  change  was  not 
reported  or  could  not  be  calculated  using  methods  described  in  the  Cochrane 
handbook (Higgins & Green, 2011) then the study reported post-treatment outcome 
and  post-treatment  standard  deviation  (SD)  was  used  (Dias,  Welton,  Sutton,  & 
Ades, 2011; Senn, Gavini, Magrez and Scheen, 2012). Study interventions included 
in  the  network  meta-analysis  were  coded  according  type  of  intervention.  This 
resulted in study interventions being classified into 11 different types: first wave, 
CBT, second wave CBT – Intolerance of Uncertainty (IoU), second wave CBT – 
Metacognitive Therapy (MCT), third wave CBT, iCBT, Enhanced CBT, Behavioural   19 
Activation (BA), Applied Relaxation (AR), Psychodynamic, Non-Directive Supportive 
Intervention  and  Waitlist  Control.  A  description  of  each  intervention  type  is 
presented in Table 1. Studies, which used variations of the same treatment, such as 
two  iCBT  conditions,  were  separated  into  paired  comparisons  with  the  common 
comparator.  R  version  3.2  (http://www.r-project.org/)  and  WinBUGS  Version  1.4 
(Lunn, Thomas, Best & Spiegelhalter, 2000) were used for analysis. 
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Table 1: Description of intervention classification 
Intervention Type  Description 
 
  
1st Wave CBT 
 
Traditional  Beckian  Cognitive  Behavioural  Therapy.  Interventions 
include cognitive restructuring, overcoming avoidance and relaxation. 
The focus of the interventions is on worry as a consequence of anxiety 
rather than a process that maintains it. Delivered either via group or 
individual treatment. 
 
 
2nd Wave CBT - 
IoU  
Second wave CBT that focuses on the worry as a process, focus on 
problem solving, positive and negative beliefs about worry, intolerance 
of  uncertainty  and  emotional  avoidance.  Intervention  applies  the 
Dugas et al. (1997) model in either individual or group treatment. 
 
 
2nd Wave CBT – 
MCT 
Second wave CBT treatment that focuses on worry as a process and 
the  high  order  meaning  and  beliefs  associated  with  worry. 
Interventions employ the Wells (2009) MCT model in either individual 
or group treatment. 
 
3rd Wave CBT 
 
Interventions  that  focus  on  Mindfulness,  Acceptance  and  do  not 
attempt to restructure cognitions. Interventions adopt a more accepting 
relationship with cognitions and experience. This may also include a 
spiritual element within the intervention framework, but retains a clear 
focus  on  acceptance/  mindfulness.  (Romer  and  Orsillo,  2007)  
Delivered either via group or individual treatment. 
 
 
iCBT 
 
CBT  models  that  are  primarily  delivered  using  an  Internet  based 
computer program with or without clinician support. 
 
 
Enhanced CBT 
 
First  wave  CBT  with  additional  elements  added  to  increase 
effectiveness.  This  may  include  interpersonal  elements,  motivation 
enhancement, behavioral enhancement or emotional focus. Delivered 
either via group or individual treatment. 
 
 
BA 
Behavioural  Activation  approaches  where  the  main  focus  of  the 
intervention is increasing activity and employing manualised treatment 
such as Addis and Martell’s (2004) BA protocol. Delivered either via 
group or individual treatment. 
 
 
AR 
 
The primary focus of Applied Relaxation is the physical de-arousal of 
the individual and teaching techniques to induce relaxation in response 
to stimulus. Interventions focus on using protocols such as Öst (1987). 
Delivered either via group or individual treatment. 
 
Psychodynamic 
 
Interventions  that  apply  psychodynamic  theory  to  the  treatment  of 
GAD.  The  primary  objective  is  to  enhance  the  individual’s 
understanding,  awareness,  and  insight  about  repetitive  conflicts 
(intrapsychic  and  interpersonal).  Delivered  either  via  group  or 
individual treatment. 
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Table 1: Continued 
 
Intervention Type  Description 
 
 
Non-Directive 
Supportive 
intervention 
 
Interventions that apply non-directive intervention such as the group 
or individual discussion. Therapists assume a supportive, facilitative 
role  encouraging  individuals  to  share  experiences  and  to  provide 
support for each other, discuss coping skills and think about anxiety 
symptoms  and  experience.  Therapists  teach  no  specific  skills  or 
provide differential reinforcement for any particular mode of coping.  
 
Waitlist Control  No intervention or delayed treatment condition with no intervention. 
This includes no intervention control. This includes Minimal Contact 
conditions with no therapeutic intervention. 
 
3. Results 
3.1 Description of Studies 
Twenty-eight studies met the inclusion criteria. Participants were drawn from 
populations within the USA (9), Australia (5), Sweden (5), Canada (5), Germany (4), 
the UK (1), the Netherlands (1) and Iran (1).  Gender distribution between studies 
was highly variable, ranging from 100% women to 48% women. Ninety-six percent 
of  the  studies  included  in  the  review  reported  a  gender  distribution  of  50%  or 
greater. The mean age of participants also varied across studies, ranging from 20.1 
to 68.3 years old. Twenty-four studies reported the use of a general adult sample 
with inclusion criteria of 18 years and above.  Five studies reported using an older 
adult sample. The older adult studies varied in the definition of an older adult. Two 
studies defined older adults as 60 years and over, two studies defined older adults 
as 65 years and above and a single study used a definition of an older adult as 55 
years  and  above.  The  mean  age  of  participants  in  older  adult  studies  varied, 
ranging from 66.20 to 70.6 years old. The rate of medication use between studies 
also  varied  substantially  and  ranged  from  0%  to  68.18%.  Treating  clinicians 
included  clinical  psychologists;  licensed  therapists,  doctoral  clinical  psychology 
students,  counsellors  and  masters  level  therapists.  Table  2  outlines  the 
demographic features of each study.     22 
  All  studies  employed  a  randomised  control  design  or  randomised 
assignment design. All studies reported a DSM-III or DSM-IV primary diagnosis of 
GAD as a study inclusion requirement. A variety of diagnostic methods were used in 
establishing  a  diagnosis  of  GAD.  These  ranged  from  using  self-reported 
questionnaires  to  use  of  standardised  diagnostic  clinical  interviews  for  anxiety 
disorders. Table 3 outlines the design features of each study. 
  All of the included studies reported the delivery of at least one psychological 
intervention.  Twenty-one studies employed a two-arm trial design; seven studies 
employed  a  three-arm  trial  design.    Studies  varied  in  comparison  conditions, 
ranging  from  waitlist  control,  minimal  contact  control,  usual  care  to  an  active 
psychological  treatment.    Sixteen  of  the  included  studies  employed  a  waitlist  or 
minimal contact control and 11 studies employed an active treatment comparator. 
All studies included at least one validated self-report measure, which included the 
PSWQ. Twenty-seven studies reported the PSWQ as a primary outcome measure; 
a  single  study  (Leichsenring  et  al.,  2009)  reported  the  PSWQ  as  a  secondary 
outcome  measure.  Table  4  summarises  the  reported  outcomes  of  each  study’s 
primary outcome measure at post-treatment and follow up, attrition in studies and 
the number of individuals judged to be no longer meeting clinical criteria at each 
time point and risk of bias of each. 
3.2 Quality Assessment and Risk of Bias 
The standard reporting of each study design was mixed. To quantify this the 
quality of study methodology and reporting were assessed for risk of bias using the 
Cochrane collaboration risk of bias tool using RevMan version 5.  Twelve studies 
were at low risk for sequence generation and 10 of these were at a low risk of bias 
for  allocation of concealment. Two studies (Newman et  al., 2011; Westra et al., 
2009) were at high risk of bias for allocation of concealment as they both reported 
that  a  study  researcher  used  a  numbers  table  to  allocate  participants.    Fifteen 
studies were at an unclear risk of sequence generation and in 14 of these studies   23 
there was an unclear risk of bias for allocation of concealment, as authors reported 
randomisation,  but  reported  no  specific  details  of  the  randomisation  process.  A 
single study (Dugas et al., 2003) was at low risk of allocation of concealment as the 
authors  reported  that  an  independent  researcher  conducted  randomisation  and 
allocation occurred at assessment with an independent assessor prior to entry into 
the  study.  Two  studies  were  at  high  risk  of  bias  for  sequence  generation  and 
allocation  of  concealment.  One  study  (Borkovec  et  al.,  1993)  reported 
randomisation of participants in waves based on therapist availability. One study 
(Westra et al., 2009) reported the use of a numbers table in allocation by a member 
of the research team. 
All  studies  were  assessed  as  having  high  risk of  bias for  the  blinding of 
participants and personnel, as it was not possible to blind either the participant or 
therapist to the intervention received. All studies reported self-rated outcomes as 
primary  measures  of  assessment  and  were  considered  a  high  risk  of  bias  as 
blinding  of  researchers  to  treatment  allocation  until  after  data  analysis  was  not 
reported. A number of studies reported the use of clinician assessment and this was 
considered separately. Ten studies were at low risk of bias for assessors, reporting 
the use of independent assessors blinded to the treatment condition. Nine studies 
were at an unclear risk of bias for assessors, as they did not report sufficed detail to 
determine if assessors were blind to participant allocation. For incomplete outcome 
data  21  studies  were  at  low  risk  of  bias  and  three  were  at  high  risk  of  bias.  
Eighteen  studies  were at  a  low  risk  of bias for  selective  reporting (for  example, 
reporting intent-to-treat data in analysis).  Eight studies were a high risk of bias for 
selective reporting as they reported completer data only.  Nineteen studies were at 
low risk of other sources of bias as they reported the use of adherence measures 
and treatment manuals in studies, eight studies were at high risk of bias as it was 
not reported if adherence and integrity checks for the study interventions had been 
made or reported checks where made as part of clinical supervision by therapist   24 
supervisors.  Six studies reported a CONSORT compliant RCT design. Figure 2 
provides a summary of the assessed risk of bias of all included studies.   
The risk of bias for individual studies is summarised in table 4. Studies were 
rated as high risk of bias if they reported high risk of bias in areas additional to 
blinding of participants and personnel and self-repot outcome assessment. Studies 
were  rated  as  unclear  risk  if  they  reported  unclear  risk  in  one  or  more  areas.  
Studies were classified as low risk if the study rated all domains as low risk outside 
blinding of participants and personnel and self-report outcome assessment.  
 
Figure 2: Risk of bias summary 
3.4 Pairwise Meta-Analysis 
The 28 included studies explored the effect of different types of treatments 
(CBT,  AR,  Psychodynamic,  BA)  with  21  studies  providing  data  for  two-way 
comparisons. Where insufficient data was available for comparisons findings are 
reported narratively. Analysis of CBT was also further delineated into first wave, 
second wave and third wave CBT treatments, iCBT treatments and CBT treatment 
for older adults. All comparisons used study post-treatment end point data to assess 
mean difference between comparators and determine the reduction of self-reported 
pathological worry as captured by the PSWQ (summarised in Table 5).   24 
Table 2: Summary of studies’ demographic features 
Study  Population  Mean age at 
recruitment 
Size and gender ratio at start of 
trial 
Psychoactive 
medication use 
Treating clinicians 
Andersson et al., 
2012 
Swedish, adult 
community 
41.3  81, 76.5% female  32.1%  Therapists in final year of clinical doctorate, 
licensed psychologists, CBT therapists. 
 
Borkovec et al., 1993  US, adult community  37.5  63, 65.5% female  19.0%  Therapists with mean experience of 9 
years, advanced clinical graduate students. 
 
Chen et al., 2013  Australian, adult 
community 
39.3  49, 77.6% female  6.1%  Psychologist with 2 years experience. 
Psychology interns with 4 years 
experience. 
 
Dugas et al., 2003  Canadian, adult 
community 
41.2  52, 71.0% female  26.9%  Licensed clinical psychologists with mean 
experience 6 years (range 2 to 12 years). 
 
Dugas et al., 2010  Canadian, adult 
community 
38.5  66, 66.2% female  55.4%  Licensed clinical psychologist with 5 years 
clinical experience. 
 
Hayes Skelton et al., 
2013 
US, adult community  32.9  81, 65.5% female  28.4%  Post doctoral fellows and advanced 
doctoral students. 
 
Hoyer et al., 2009  German, adult clinical  45.4  98, 78.0% female  9.6%  Clinical psychologists in postgraduate 
psychotherapy training. 
 
Kozycki et al., 2009  Canadian, adult 
community 
43.5  20, 60.0% female  68.2%  CBT therapist and counsellor. 
 
 
Landoucer et al., 
2000 
Canadian, adult 
community 
39.7  26, 76.9% female  34.1%  Licensed psychologists, post-doctoral 
researcher, and doctoral students. Mean 
experience of 4.7 years (range 2 to 10 
years. 
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Table 2: continued 
Study  Population  Mean at 
recruitment 
Size and gender ratio at start of 
trial 
Psychoactive 
medication use 
Treating clinicians 
Leichsenring et al., 
2009 
German, adult clinical  42.5  57, 80.7% female  0.0%  Licensed CBT therapists with mean 
experience of 16.3 years (range: 12 to 30 
years), licensed psychodynamic therapists 
with mean experience of 18.7 (range: 4 to 
26 years). 
 
Newman et al., 2011  USA, adult community  37.1  83, 75.0% female  33.7%  Doctoral level psychologists with 2 years 
experience. 
 
 
Newman et al., 2013  USA, adult community  42.1  34, 58.8% female  38.2%  Post doctoral fellow, graduate students 
with CBT training with a year experience of 
GAD treatment protocol. 
 
Öst et al., 2000  Swedish, adult 
community 
40.1  33, 77.2 female  45.0%  Therapists with 8 and 16 years clinical 
experience. 
 
Paxling et al., 2011  Swedish, adult 
community  
46.9  89, 79.8% female  37.1%  Final year psychology trainee. 
 
 
Rezvan et al., 2008  Iranian, adult university 
clinical  
20.1  36, 100.0% female  Not reported  University counseling service therapists. 
 
 
Robinson et al., 2010  Australian, adult 
community 
46.9  150, 68.3% female  32.4%  Clinician, background not described.  
 
 
Roemer et al., 2008  USA, adult clinical  33.6  31, 71.0% female  25.8%  Doctoral students under supervision of 
study authors. 
 
Stanley et al., 1996  USA, older adult 
community 
68.3  46, 70.8% female  0.0%  Advance level graduate students trained in 
both treatment interventions. 
 
Stanley et al., 2003  USA, older adult 
community 
66.2  80, 75.0% female  0.0%  Post doctoral psychological fellows and 
advanced graduate students trained in 
CBT. 
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Table 2: continued 
Study  Population  Mean at 
recruitment 
Size and gender ratio at start of 
trial 
Psychoactive 
medication use 
Treating clinicians 
Stanley et al., 2009  USA, older adult clinical  66.9  134, 78.4 female  41.8%  Masters level CBT therapists, pre-doctoral 
intern, post-bachelors level therapist with 
mean experience 2.8 years. 
 
Titov et al., 2009   Australian, adult 
community 
44.0  47, 76.0% female  29.0%  Clinical psychologist. 
 
 
Titov et al., 2010 
 
Australian, adult 
community 
 
 
40.0 
 
34, 68.0% female 
 
47.4% 
 
Clinical psychologist. 
 
 
Van Der Heiden et 
al., 2012 
 
Netherlands, adult 
clinical 
35.0  126, 73.0% female  28.0%  Staff psychologists and CBT therapists 
with a mean experience of 5.6 years. 
Wells et al., 2010  UK, adult clinical  49.1  20, 48.0% female  55.0%  Therapist’s background not reported. 
 
Westra et al., 2009  Canadian, adult 
community 
41.5  100, 67.0% female  22.4%  Clinical psychologist, doctoral clinical 
psychology students. 
 
Wetherell et al., 2003  USA, older adult clinical  67.1  75, 80.0% female  40.0%  Clinical psychologist and advanced 
doctoral clinical psychology students. 
 
Wetherell et al., 2011  USA, older adult clinical  70.8  22, 47.5 female  19.0%  Post doctoral and master level therapists 
with 2 years clinical experience.  
 
Zinbarg et al., 2007  USA, adult community  41.9  20, not reported  38.8%  Doctoral level therapists, clinical post-
doctoral fellow. 
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Table 3: Summary of studies’ design features 
Study  Design 
 
Comparison 
Group 
Intervention  Individual/ 
Group 
delivery  
Duration  Manual/ Integrity 
Checks 
Outcomes 
measures 
Assessment 
points. 
Andersson 
et al., 2012 
RCT  Waitlist   Internet-based Psychodynamic 
therapy (PT): Focus on 
breaking unconscious patterns 
contributing to emotional 
difficulties 
 
Internet Based CBT (iCBT): 
Focus on applied relaxation, 
problem solving, cognitive 
restructuring 
Individual   8 sessions, 
 
PT = 113 
minutes 
 
CBT = 92 
minutes. 
 
PT-.Based on Make the 
Leap self-help book.  
 
iCBT- Based on Paxling 
et al. 2011 treatment 
 
Integrity: Checks not 
reported 
PSWQ, 
GAD-Q-IV, 
MADRS-S, 
QOLI, 
STAI, BDI-
II, BAI 
Pre- and 
post- 
treatment, 3 
and 18 
months 
Borkovec et 
al., 1993 
 
Random 
assignment 
Non-directive 
control: 
exploration of 
life experience 
Applied Relaxation (AR): 
Focus on physical relaxation 
 
CBT: Focus on exposure, 
cognitive restructuring 
challenging dysfunctional 
assumptions 
Individual  12 sessions, 4 
X 90 minutes, 9 
X 60 minutes 
AR: Berstien & Borkovec 
(1973) manual 
 
CBT: Beck & Emery 
(1985) 
 
Integrity: Assessed from 
audiotapes from 20% of 
sessions. Checked by 
clinical graduate students 
 
PSWQ, 
STAI, 
ZSRA, 
RRAQ, 
BDI 
Pre- and 
post- 
treatment,  
6 and 12 
months 
Chen et al., 
2013 
RCT  Waitlist   Behavioural Activation for 
Worry (BAW): Focus on 
creating awareness of 
avoidance relating to worry 
and developing alternative 
goals  
Group  8 sessions, 
length not 
reported 
Adaption of Addis & 
Martell (2004) 
Overcoming depression 
one step at a time  
 
Integrity checks not 
reported 
PSWQ, 
GAD-Q-IV, 
DASS-21, 
W&SAS, 
IUS, CBAS 
Pre- and 
post- 
treatment, 3 
months 
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Table 3: continued 
Study  Design 
 
Comparison 
Group 
Intervention  Individual/ 
Group 
delivery  
Duration  Manual/ Integrity 
Checks 
Outcomes 
measures 
Assessment 
points. 
Dugas et al., 
2003 
 
 
RCT  Waitlist 
 
AR: Focus on physical 
relaxation 
 
CBT: Focus on recognition of 
uncertainty, cognitive 
exposure, re-evaluation of 
usefulness of worry 
Individual  12 sessions,  
60 minutes  
AR: Based on Berstein & 
Borkovec (1973) & Öst 
(1987) 
 
CBT: Based on Dugas et 
al. (1998) 
 
Integrity: Assessed by 
audio recording. Checked 
by research assistant 
 
PSWQ, 
WAQ, 
STAT-T, 
BDI-II, 
CGII- SL 
Pre- and 
post-
treatment 
6,12 and 24 
months 
Dugas et al., 
2010 
 
 
RCT  Waitlist  CBT: Focus on recognition of 
uncertainty, cognitive 
exposure, re-evaluation of 
usefulness of worry 
Group  14 sessions, 
120 minutes  
Based on Dugas & 
Roichaud (2007) 
 
Integrity: Assessed by 
audio recording Checked 
by advanced graduate 
student 
 
PSWQ, 
WAQ, IUS, 
BAI, BDI, 
SAS 
Pre- and 
post-
treatment 6, 
12 and 24 
months. 
Hayes 
Skelton et 
al., 2013 
 
 
Random 
assignment 
AR: focus on 
physical 
relaxation 
Acceptance Based 
Behavioural Therapy (ABBT): 
Focus on modifying 
problematic relationship with 
internal experience 
Individual  16 sessions,  
4 X 90 minutes, 
12 X 60 
minutes 
AR: Based on Bernstein, 
Borkevec, Hazlett-
Stevens (2000) & Öst 
(2007) 
 
ABBT: Based on Orsillio 
& Roemer (2011) 
 
Integrity: 198 sessions 
rated for adherence by 
clinical psychology 
doctoral students 
 
PSWQ, 
DASS-
21,STAI, 
BDI-II, 
QOLI 
Pre- and 
post-
treatment, 6 
months 
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Table 3: continued 
Study  Design 
 
Comparison 
Group 
Intervention  Individual/ 
Group 
delivery  
Duration  Manual/ Integrity 
Checks 
Outcomes 
measures 
Assessment 
points. 
Hoyer et al., 
2009 
 
 
 
 
RCT  Waitlist   AR: Focus on physical 
relaxation 
 
Worry Exposure (CBT): Focus 
on psycho-education, 
overcoming avoidance and 
habituation 
Individual  15 sessions, 
duration not 
reported 
AR: Based on Öst (1987) 
 
CBT: Based on Becker 
and Margraf (2002) 
 
Integrity: 25% of sessions 
reviewed rated by 
independent clinicians  
 
HAMA, 
STAI-T, 
PSWQ, 
MCQ, 
WBSI 
GSI, 
HAMD, 
BDI 
 
Pre- and 
post-
treatment, 6 
months, 12 
months 
Kozycki et 
al., 2009 
Random 
assignment 
CBT: relaxation, 
cognitive 
restructuring 
and worry 
exposure  
Spiritually Based Intervention 
(SBI): Focus on spiritual 
wellbeing, meditation, 
acceptance and problematic 
internal experience 
Individual  12 sessions,  
50 minutes 
CBT:  Based on Zinbarg, 
Craske & Barlow (2006) 
 
SBI: Based on Walsh 
(1999) Essential 
Spirituality 
 
Integrity checks not 
reported 
 
PSWQ, 
HAMA, 
CGI, BAI, 
IUS, BDI, 
SAS-SR 
Pre-and  
post- 
treatment, 3 
months, 6 
months 
 
 
 
Ladoucer et 
al., 2000 
RCT  Waitlist  CBT: Focus on recognition of 
uncertainty, cognitive 
exposure, re-evaluation of 
usefulness of worry 
 
Individual  16 sessions,  
60 minutes 
CBT: Based on Dugas  
(1998) 
 
Integrity: Audio recording 
of 3 sessions for each 
participant. Rated by 
graduate student 
 
PSWQ, 
WAQ, BAI, 
BDI, SORS 
Pre- and 
post- 
treatment, 6 
months, 12 
months 
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Table 3: continued 
Study  Design 
 
Comparison 
Group 
Intervention  Individual/ 
Group 
delivery  
Duration  Manual/ Integrity 
Checks 
Outcomes 
measures 
Assessment 
points. 
Lieschernig 
et al., 2009 
RCT  Waitlist  Short Term Dynamic 
Psychotherapy (STTP): Focus 
on core conflictual relationship 
themes associated with 
symptoms 
 
CBT: Focus on relaxation 
training, worry exposure, 
cognitive restructuring 
Individual  30 sessions,  
50 minutes 
STTP: Based on Crits-
Christoph et al. (1995) 
 
CBT: Based on Borkovec 
& Ruscio (2001) 
 
Integrity: All session 
audiotaped. 57 sessions 
were rated by between 3-
9 independent raters 
 
HARS, 
PSWQ,  
STAI-T, 
BAI, 
HADS, 
BDI, IIP 
Pre- and 
post- 
treatment, 6 
months  
 
 
 
Newman et 
al., 2011 
Random 
assignment 
CBT+ 
Supportive 
Listening (SL) 
CBT + Interpersonal Emotional 
Processing (IEP): Focus on 
relaxation, cognitive 
restructuring, addressing 
interpersonal problems and 
emotional processing 
 
Individual  14 sessions, 50 
minutes CBT, 
50 minutes SL 
or IEP 
CBT: Based on Borkovec 
& Ruscio (2001) 
 
IEP: Based on Safran 
and Segal (1990) 
 
Integrity: Audiotapes 
checked by graduate 
coders using treatment 
manuals 
 
PSWQ, 
HARS, 
STAI, 
RRAQ, 
HADS, IPP 
Pre- and 
post-
treatment 
6,12 and 24 
months 
 
 
Newman et 
al., 2013 
Random 
assignment 
Group CBT 
(gCBT) 
6-session gCBT: (CBGT): 
Focus on relaxation training, 
worry exposure, cognitive 
restructuring challenging 
dysfunctional assumptions  
 
6-session computer assisted 
gCBT (CAGCBT): As above 
with computer prompted 
homework tasks 
Group  CBGT and 
CAGCT: 6 
sessions, 120 
minutes 
 
gCBT: 12 
sessions, 120 
minutes 
 
CBT: Based on Beck & 
Emery (1985), Bernstien 
et al., 2000) 
 
Integrity checks not 
reported 
HARS, 
PSWQ,  
STAI-T 
Pre- and 
post- 
treatment 6 
and 12 
months 
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Table 3: continued 
Study  Design 
 
Comparison 
Group 
Intervention  Individual/ 
Group 
delivery  
Duration  Manual/ Integrity 
Checks 
Outcomes 
measures 
Assessment 
points. 
Öst et al., 
2000 
Random 
assignment 
AR: focus on 
physical 
relaxation 
CBT: Focus on exposure and 
cognitive restructuring, and 
challenging dysfunctional 
assumptions 
Individual  12 sessions, 60 
minutes 
AR: Based on Öst (1987) 
 
CBT: Based on Beck, 
Emery & Greenberg 
(1985) 
 
Integrity: Checks not 
reported 
 
HAMA, 
BAI, 
PSWQ, 
CSAQ, BDI 
Pre- and 
post-
treatment, 12 
months 
 
 
 
Paxling et 
al., 2011 
RCT  Waitlist   iCBT: Focus on relaxation, 
cognitive restricting, worry 
exposure and problem solving 
Individual  8 modules, 
mean clinician 
time: 91 
minutes  
 
Integrity: 
checks not 
reported 
 
iCBT: Guided self-help 
based on  Borkovec & 
Costello (1993) and Öst 
(1987) 
 
STAI-T, 
BDI, BAI, 
PSWQ, 
GAD-Q-V, 
QOLI, 
MADRS-S 
Pre-  and 
post- 
treatment, 12 
and 36 
months 
 
 
Rezvan et 
al., 2008 
RCT  Control  CBT: Focus on relaxation, 
cognitive distancing, worry 
awareness 
 
CBT+IPT: Focus on relaxation, 
cognitive distancing, worry 
awareness. Clarification 
interpersonal difficulty, 
communication analysis and 
reappraisal of interpersonal 
problems 
 
Individual  8 Sessions, 
duration not 
reported 
 
 
No reported manual 
treatment is based on. 
 
Integrity: No check 
reported  
PSWQ, 
OHI, GAD-
Q-V 
Pre- and 
post-
treatment, 12 
months 
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Table 3: continued 
Study  Design 
 
Comparison 
Group 
Intervention  Individual/ 
Group 
delivery  
Duration  Manual/ Integrity 
Checks 
Outcomes 
measures 
Assessment 
points. 
Robinson et 
al., 2010 
RCT  Waitlist   iCBT: Challenging core beliefs 
and meta beliefs, graded 
exposure 
 
iCBT Clinician Assisted (CA): 
Challenging core beliefs and 
meta beliefs, graded exposure  
 
Individual  6 sessions, 
iCBT CA- 
weekly email or 
telephone 
contact no 
longer than 10 
minutes 
iCBT: Based on Worry 
program (Titov et al., 
2009) 
 
Integrity: Checks not 
reported 
PSWQ,  
GAD-7,  
PHQ-9,  
K-10, SDS  
Pre- and 
post-
treatment, 3 
months 
 
 
 
Roemer et 
al., 2008 
RCT  Waitlist  ABBT: Focus on increasing 
awareness of habitual 
responding, experimental 
avoidance, engaging in value 
directions 
Individual  16 sessions,  
4 X 90 minutes, 
12 X 60 
minutes 
ABBT: Based on Roemer 
& Orsillo (2007) 
 
Integrity: Two sessions 
from each participant 
randomly selected and 
reviewed by graduate 
students 
 
PSWQ, 
DASS, 
BDI, QOLI, 
AAQ, 
MAAS 
Pre-and  
post-
treatment, 3 
and 9 months 
 
 
Stanley et 
al., 1996 
Random 
assignment 
Supportive 
Psychotherapy: 
focus on non-
directive 
discussion of 
anxiety 
symptoms. 
CBT: Focus on relaxation, 
cognitive restructuring, 
exposure and challenging 
dysfunctional assumptions 
Group  14 sessions,  
90 minutes 
CBT: Based on Borkovec 
& Costello (1993) and 
Craske, Barlow & O’Leary 
(1992) 
 
Integrity: Monitored using 
checklist for each 
treatment condition. 
Videotape monitored by 
clinical psychologist 
 
WS, 
PSWQ, 
STAI-T, 
HAMA, 
BDI, 
HAMD, FQ 
Pre- and 
post- 
treatment, 1 
and 6 months 
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Table 3: continued 
Study  Design 
 
Comparison 
Group 
Intervention  Individual/ 
Group 
delivery  
Duration  Manual/ Integrity Checks  Outcomes 
measures 
Assessment 
points. 
Stanley et 
al., 2003 
Random 
assignment  
Minimal contact:  
weekly 
telephone check 
 
CBT: Focus on relaxation, 
cognitive restructuring, 
exposure and challenging 
dysfunctional assumptions 
Individual  15 sessions, 
duration not 
reported 
CBT: Based on Borkovec 
& Costello (1993) and 
Craske, Barlow & O’leary 
(1992) 
 
Integrity: 20% of video 
taped session rated for 
competence and 
adherence by 
independent expert rater 
 
PSWQ, 
WS, STAI, 
HAMA, 
BDI, 
HAMD, 
FQ, QOLI, 
Pre- and 
post- 
treatment, 3, 
6 and 12 
months 
 
 
Stanley et 
al., 2009 
Random 
assignment 
Enhanced usual 
care: Bi weekly 
telephone 
symptom check 
 
CBT: Focus on relaxation, 
cognitive restructuring, 
exposure, sleep management, 
problem solving, motivational 
interviewing 
Individual  10 sessions, 
duration not 
reported 
CBT: Based on Hopko 
and Diefenbach (2004) 
 
Integrity: 20% of session 
audiotapes rated by 
treatment manual authors 
(Hopko & Diefenbach.) 
 
PSWQ, 
GADSS, 
HARS,  
BDI-II, 
SF-12 
Pre- and 
post-
treatment 
6,9,12 and 
15 months 
 
 
Titov et al., 
2009 
RCT  Waitlist   iCBT: Challenging core beliefs 
and meta beliefs, graded 
exposure. Clinician assisted 
contact via email 
Individual  6 sessions, 
over 9 weeks. 
Mean time per 
patient 130 
minutes 
CBT: Worry Program 
(Titov et al., 2009) 
 
Integrity: Checks not 
reported 
GAD-7, 
PSWQ, 
PHQ-9, 
K-10, 
SDS 
 
Pre- and 
post-
treatment. 
 
 
 
Titov et al., 
2010 
RCT  Waitlist   iCBT: Generic CBT, disorder 
specific material GAD, social 
phobia and panic disorder 
Individual  6 sessions, 
over 8 weeks, 
duration not 
reported 
iCBT: Based on Andrews 
et al., (2003), Titov et al., 
(2009), Titov et al., 
(2008), Wims et 
al.,(2010) 
GAD-7, 
PHQ-9,  
PSWQ, 
PDSS-SR, 
K-10, 
DASS-21, 
NEO-FFi-N 
 
Pre- and 
post- 
treatment, 3 
months 
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Table 3: continued 
Study  Design 
 
Comparison 
Group 
Intervention  Individual/ 
Group 
delivery  
Duration  Manual/ Integrity 
Checks 
Outcomes 
measures 
Assessment 
points. 
Van Der 
Heiden et 
al., 2012 
RCT  Waitlist  CBT  Intolerance of 
Uncertainty (IUT): Focus on 
worry awareness, problem 
orientation, exposure, re-
evaluation of belief about 
worry 
 
CBT – Metacognitive Therapy 
(MCT): Focus on identifying 
metacognition, negative and 
positive metacognition, 
modifying cognitive bias and 
attention training 
 
Individual  14 sessions, 
duration not 
reported 
IUT: Based on Dugas & 
Robichuad (2007) 
 
MCT: Based on Wells 
(1997) 
 
Integrity: Review of 71 
randomly selected 
session recording by 
trained clinical 
psychology students 
PSWQ, 
STAI-T, 
SCL-90, 
BDI-II, 
MCQ, IUS 
Pre- and 
post- 
treatment, 6 
months 
 
 
Wells et al., 
2010 
Random 
assignment 
AR: focus on 
physical 
relaxation 
MCT: Focus on identifying 
metacognition, negative and 
positive meta cognition, 
modifying cognitive bias 
Individual  8 to 12 
sessions,   
45 to 60 
minutes 
AR: Based on Öst (1987). 
 
MCT: Based on Wells 
(1997) 
 
Integrity: Therapy notes 
and active case reviewed 
in fortnightly supervisor 
for adherence 
 
STAI-T, 
PSWQ, 
BAI, BDI, 
MCQ 
Pre- and 
post- 
treatment, 6 
and 12 
months 
 
 
 
Westra et 
al., 2009 
Random 
assignment 
CBT: focus on 
relaxation, 
cognitive 
restructuring, 
exposure 
challenging 
dysfunctional 
assumptions 
CBT+ Motivational 
Interviewing (CBT+MI): Focus 
on relaxation, cognitive 
restructuring, exposure 
challenging dysfunctional 
assumptions. Understanding 
ambivalence, developing self 
efficacy 
Individual  8 sessions,  
6 X 120 
minutes,  
2 X 60 minutes 
CBT: Borkovec &  
Costello (1993) 
 
MI: Based on Miller & 
Rollnick (2002) 
 
Integrity: Assessed using 
CTRS (Young & Beck, 
1980) 20% rated by 
clinical graduate students 
PSWQ, 
DASS-21, 
SDS, 
MCQ, GCI, 
CMOTS 
Pre- and 
post- 
treatment, 6 
and 12 
months 
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Table 3: continued 
Study  Design 
 
Comparison 
Group 
Intervention  Individual/ 
Group 
delivery  
Duration  Manual/ Integrity 
Checks 
Outcomes 
measures 
Assessment 
points. 
Wetherell et 
al., 2003 
RCT  Waitlist  CBT: focus on relaxation, 
cognitive restructuring and 
worry exposure and 
challenging dysfunctional 
assumptions 
 
Discussion group (DG): 
Discussion of worry provoking 
topics 
Group  12 sessions, 
duration not 
reported 
CBT: Based on Craske, 
Barlow & O’Leary (1992) 
 
DG: Based on Hyman 
(1980) 
 
Integrity: All session 
audiotaped and review by 
CBT expert in anxiety 
disorders. 
 
HARS, 
PSWQ, 
BAI, 
HAMD, 
BDI, SF-36 
Pre- and 
post- 
treatment, 6 
months 
 
 
 
 
Wetherell et 
al., 2011 
Random 
allocation 
CBT: Focus on 
symptom 
monitoring, 
attention 
training, thought 
stopping, 
relaxation 
ACT: Focus on willingness and 
non-judgmental observation of 
worry, core values, 
mindfulness and acting in 
value directions 
 
Individual  12 sessions,  
60 minutes 
CBT: Based on Wetherell 
et al (2009) 
 
ACT: Based on Hayes, 
Strosahl &Wilson (1999) 
 
Integrity: Sessions 
videotaped and reviewed 
in weekly supervision, 
external rater evaluated 
adherence 
 
HAMA, 
PSWQ, 
BDI-II, SF-
36 
Pre- and 
post-
treatment, 6 
months 
 
 
 
 
Zinbarg et 
al., 2007 
RCT  Waitlist   CBT: Focus on relaxation 
training, cognitive 
restructuring, exposure and 
challenging dysfunctional 
assumptions 
 
Individual  12 Sessions, 
60-75 minutes. 
CBT: based on Master 
Your Worry (Craske & 
Barlow, 1994) 
 
Integrity: Audio or video 
tapes were randomly 
selected for 16 patients, 
Rated against protocol by 
two graduate students 
PSWQ, 
BAI, 
DASS-21,  
Not reported 
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Table 4: Summary of studies’ outcomes and risk of bias 
Study  Outcome at end of treatment  Outcome at follow up  Total study 
attrition (%) 
Percentage rated as 
recovered* 
Study 
risk of 
bias 
 
Andersson et 
al., 2012 
 
Both CBT and Psychodynamic treatment 
showed moderate within group effects. 
Waitlist control showed a small within group 
effect. Post-treatment between group effect 
sizes were small for both CBT and PD. 
There was no statistical difference between 
CBT and PD. 
 
3 months: continued mean reduction on 
PSWQ for CBT and PD condition. Increase in 
reported worry in waitlist condition. Moderate 
between group effect size between 
intervention and waitlist. Small between group 
effects favoring CBT over PD, this was not 
statistically significant. 
 
18 months:  further mean reduction in PSWQ 
score in CBT and PD conditions. Large within 
group effect sizes reported for both treatments 
pre-treatment to follow up.  
 
7 (8.64)  End of treatment: 26.1% in 
CBT condition, 15.4% in the 
psychodynamic and waitlist 
conditions were rated as 
recovered. 
 
3 months: 52.2% in CBT 
condition, 50% in 
psychodynamic condition 
and 10% in waitlist condition 
were rated as recovered. 
 
18 months: 54.5% in CBT 
condition and 62% in 
psychodynamic condition 
were rated as recovered. 
 
 
Low 
Risk 
 
Borkovec et al., 
1993 
 
 
Mean reductions on both the HARS and 
PSWQ for treatment conditions. CBT and AR 
were superior to ND. There was no 
difference between CBT and AR. 
 
All treatments showed large within group 
effect on HARS ND showed a medium within 
group effect in the reduction on the PSWQ. 
CBT and AR showed large within group 
effects in reductions on the PSWQ.  
 
 
CBT and AR conditions were superior to ND. 
All treatments continued to show reductions in 
mean HARS and PSWQ score. There was no 
statistical difference between CBT and AR. 
 
 
 
11 (17.01)  12 months 57.9% of CBT 
clients reached high-end 
state functioning status as 
opposed to 26.7% in ND 
condition and 37.5% in AR 
condition. 
High 
Risk 
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Table 4: continued 
Study  Outcome at end of treatment  Outcome at follow up  Total study 
attrition (%) 
Percentage rated as 
recovered* 
Study 
risk of 
bias 
 
Chen et al., 
2013 
 
Greater reduction in worry symptoms in BAW 
condition in comparison to waitlist with large 
between group effect sizes.  Reduction in 
depression symptoms with a large effect 
size. Improvements in cognitive avoidance 
and intolerance of uncertainty.  
 
 
Reductions in self-reported worry maintained 
at follow up. Continued to improvement in self-
reported functioning. 
 
0 (0)  At end of treatment 56% of 
BAW group achieved 
significant reduction in worry 
compared to 33% in waitlist 
condition. 
 
High 
Risk 
Dugas et al., 
2003 
 
Reduction on the ADIS-IV, PSWQ, WAQ, 
IUS, BAI, BDI and SIS. Large pre-post 
treatment effect sizes for all measures. 
 
Treatment gains were maintained on all 
measures at all follow up points. Self-reported 
worry significantly decreased over follow up 
period in the CBT condition 
 
5 (10.10)  60% of participants no longer 
met GAD criteria post-
treatment, 88% at 6 months 
follow up and 83% at 12-
month follow up and 95% at 
24 month follow up. 
 
Low 
Risk 
Dugas et al., 
2010 
 
Both AR and CBT conditions were superior 
to waitlist. Significant reductions in CBT 
condition compared to waitlist on PSWQ, 
CSR, WAQ and CGI.  Significant reduction 
on CSR in AR condition in comparison to 
waitlist.  
 
Treatment gains in GAD severity, pathological 
worry and clinical improvement were 
maintained, only CBT condition continued to 
improve. No significant between group 
difference between CBT and AR conditions. 
7 (10.77) 
In CBT condition 70% 
remission post-treatment, 
76% at 6-month follow up, 
84% at 24 months.  
 
In AR condition 55% were in 
remission post-treatment, 
68% at 6 months, 65% at 12 
months and 61% at 24 
month follow up. 
 
Unclear 
Risk 
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Table 4: continued 
Study  Outcome at end of treatment  Outcome at follow up  Total study 
attrition (%) 
Percentage rated as 
recovered* 
Study 
risk of 
bias 
Hayes Skelton 
et al., 2013 
Improvements on PSWQ, DASS, STAI with 
large within group effect sizes. No 
differences between the ABBT and AR 
conditions. 
Treatment gains were maintained at follow up 
with small effect size post-treatment to follow 
up.  No difference reported between ABBT and 
AR conditions. 
19 (23.45)  Post treatment 90% in ABBT 
condition and 69.7 % in AR 
of participants reported 
meeting diagnostic change 
criteria post treatment. At 
follow up 72% in ABBT and 
70% in AR conditions no 
longer met diagnostic 
criteria. 
 
 
Low 
Risk 
Hoyer et al., 
2009 
Reduction on all primary treatment measures 
pre-post treatment in CBT and AR condition 
in comparison to waitlist. No difference 
between CBT and AR conditions. 
 
Treatment gains maintained at follow up. 
Significant improvement on PSWQ in CBT 
condition. No significant difference between 
CBT and AR at either follow up points. 
19 (23.45) 
Post treatment 56% in CBT 
condition and 48% in AR 
condition reached full end-
state functioning on HARS. 
  
Unclear 
Risk 
Kozycki et al., 
2009 
Reduction in HAM-A, BAI and PSWQ post-
treatment in both CBT and SBI conditions 
with large within group effect sizes. There 
was no difference in treatment outcome 
between interventions. 
 
Treatment gains maintained at follow up for 
both CBT and SBI conditions with large pre-
treatment to follow up effect sizes. No 
differences between treatment conditions at 
either follow up time point. 
4 (19.18) 
Remission rate for CBT at 
post-treatment and 3 month 
follow up were 72.7% and 
63.6% at 6 months. For SBI 
remission was 63.6% post-
treatment and 45.4% at 3 
and 6 months. 
 
Unclear 
Risk 
Ladoucer et al., 
2000 
Reduction on ADIS-IV, PSWQ, WAQ, BAI, 
BDI and SORS. Reductions in CBT condition 
on all measures with large effect sizes. 
 
Treatment gains maintained and further 
reduction on all measures at 6 and 12 month 
follow up. No significant difference in post-test 
and follow up scores on all measures. 
 
0 (0) 
In CBT condition 77% did not 
reach diagnostic criteria for 
GAD post-treatment and 12 
month follow up. 
Unclear 
Risk   39 
 
 
Table 4: continued 
Study  Outcome at end of treatment  Outcome at follow up  Total study 
attrition (%) 
Percentage rated as 
recovered* 
Study 
risk of 
bias 
 
Lieschernig et 
al., 2009 
 
Improvement on HARS, PSWQ, STAI, BAI, 
HAD, BDI and IIP for both CBT and STTP 
with large within group effect sizes.  CBT 
was superior to STTP on reduction in PSWQ 
and STAI. 
 
 
Treatment gains were maintained at 6-month 
follow up with large within group effect sizes. 
CBT superiority in reductions on PSWQ and 
STAI was maintained. 
 
5 (8.77)  Not reported.  Unclear 
Risk 
 
Newman et al., 
2011 
 
Reduction on all primary measures pre-post 
treatment with large within group effect sizes.  
CBT + IEP was not superior to CBT on any 
measure. 
 
Treatment gains were maintained across 2 
year follow up, with large effect size pre-
treatment to follow up on HARS. No statistical 
difference between CBT + IEP condition and 
CBT. 
 
13 (15.66)  Post-treatment 73.5% in 
CBT - IEP condition and 
55.6% in CBT condition did 
not meet criteria for GAD. 
 
At 2 year follow up 75% in 
CBT + IEP condition and 
63.6% in CBT condition no 
longer met the criteria for 
GAD. 
High 
Risk 
 
Newman et al., 
2013 
 
Reduction on all anxiety measures in all 
treatment conditions with large within group 
effect sizes. Six-session computer assisted 
gCBT was superior to six session gCBT on a 
composite measure of anxiety (PSWQ, 
HARS, STAI-T). Neither brief group condition 
was superior to 12 sessions CBT on the 
anxiety composite. 
 
 
Computer assisted gCBT was no longer 
superior to 6 session gCBT. Treatments did 
not differ at 6 and 12 months. 
 
0 (0)  Not reported.  High 
Risk 
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Table 4: continued 
Study  Outcome at end of treatment  Outcome at follow up  Total study 
attrition (%) 
Percentage rated as 
recovered* 
Study 
risk of 
bias 
 
Öst et al., 2000 
 
Reduction on BAI, STAI, CSAQ, BDI, PSWQ 
scores in both CBT and AR conditions. No 
difference between treatment conditions. 
 
Reductions in BAI and CSAQ were maintained 
at follow up for both CBT and AR conditions. 
Improvements on BDI, STAT-T was 
maintained at follow up in CBT condition but 
not in AR condition. The AR group showed 
significant change on PSWQ post-treatment to 
follow up, CBT showed no change on PSWQ 
post-treatment to follow up.  
 
 
3 (8.33) 
 
Not reported. 
 
Unclear 
risk 
Paxling et al., 
2011 
Reductions on PSWQ, GAD-Q-IV, STAI, 
BAI, BDI, MADRSS-R and QOLI scores with 
large within and between treatment effect 
sizes for iCBT condition.  ICBT was superior 
to waitlist. 
Treatment gains maintained at follow 1 year 
and 3 year follow up with large effect sizes at 1 
year follow up.  
7 (7.97)  Post-treatment 42% 
receiving CBT and 2.3% of 
the waitlist reached recovery. 
 
At 1 and 3 years follow up 
48.2% and 57.1% of the CBT 
group were classified as 
recovered. 
 
Unclear 
Risk 
Rezvan et al., 
2008 
Reduction in PSWQ and increase in OCI 
scores in CBT and CBT + IPT conditions. 
Both treatment conditions superior to control, 
there was no difference between treatment 
conditions. 
 
Treatment gains were maintained at follow up 
there was no significant difference between 
treatment conditions. 
0 (0.00)  Not reported.  Unclear 
risk 
Robinson et al., 
2010 
Reduction in mean score on all measures 
with large within group effect in treatment 
condition. No difference between treatment 
groups.  
 
Treatment gains maintained at follow up with 
large pre-treatment to follow effect size for 
treatment conditions, no difference between 
treatment groups. 
22 (14.57)  Post-treatment 34% of 
treatment group and 10% of 
the control group were 
classified as recovered on 
GAD-7. At follow up 64% 
were classified as recovered. 
Low risk   41 
 
 
Table 4: continued 
Study  Outcome at end of treatment  Outcome at follow up  Total study 
attrition (%) 
Percentage rated as 
recovered* 
Study 
risk of 
bias 
 
Roemer et al., 
2008 
 
Reduction in means score on GAD-CSR, 
PSWQ, DASS, BDI and increase in QOLI 
with large within group effect sizes. ABBT 
treatment superior to waitlist. 
 
Treatment gains were maintained for all 
outcomes with large effect sizes. 
 
6 (19.35)  Post-treatment 78% of the 
treatment group no longer 
met GAD criteria. At 3 
months 84% and at 9 
months 76% were rated as 
no longer meeting GAD 
criteria. 
 
 
Low risk 
Stanley et al., 
1996 
Reductions on PSWQ, WS, HAMA, STAI, 
BDI and HAMD, there was no significant 
differences between CBT and SP conditions, 
both conditions reported large treatment 
effects. 
Treatment gains were maintained for all 
outcome measures and no difference between 
CBT and SP conditions. 
15 (32.6)  Recovery not reported. 
11% (CBT) and 12% (SP) 
post-treatment and 22% 
(CBT) and 31% (SP) at 
follow up reached high end 
state functioning. 
 
Unclear 
risk 
Stanley et al., 
2003 
Improvement in worry, anxiety, depression 
and quality of life. CBT was superior to MCC 
conditions post-treatment. 
 
Treatment gains were maintained at follow up 
for worry, anxiety, depression and quality of 
life.  
10 (11.76)  Not reported.  Unclear 
risk 
Stanley et al., 
2009 
Improvement on PSWQ in CBT conditions 
compared to EUC group. Improvement on 
GADSS in both CBT and EUC conditions. No 
difference between conditions. 
 
Treatment gain maintained at 3 to 15 month 
follow up for both group. 
18 (13.43)  Not reported.  Low risk 
Titov et al., 
2009 
Improvement in post-treatment GAD-7, 
PSWQ, PHQ-9, K-10 and SDS favoring 
iCBT. With large pre-post treatment between 
group effect. 
 
.  
N/A  9 (19.14)  63% of treatment group and 
10% of controls met 
definition of recovery. 
Low risk   42 
Table 4: continued 
Study  Outcome at end of treatment  Outcome at follow up  Total study 
attrition (%) 
Percentage rated as 
recovered* 
Study 
risk of 
bias 
 
Titov et al., 
2010 
 
Improvement post-treatment on GAD-7, 
PSWQ, PHQ-9, K-10, DASS-21, NEO—FFI-
N with medium within group treatment effects 
for GAD subgroup. 
 
Continued improvement on all measures with 
larger treatment effect.  
 
3 (8.82) 
 
40% of treatment group and 
8% of control group met 
remission criteria. ** 
 
Low risk 
 
Van Der Heiden 
et al., 2012 
 
Improvement post-treatment on PSWQ, 
STAI-T with large between group effect 
sizes, Improvement on SCL-90 and BDI-II. 
CBT intervention was superior to waitlist. 
MCT was superior to IUT on all outcome 
measures. 
 
Maintenance of treatment gains MCT superior 
to IUT on PSWQ, STAI-T and SCL-90 
measures. 
 
32 (25.39) 
 
91% IN MCT condition, 80% 
in IUT condition and 5% in 
waitlist group no longer met 
diagnostic criteria post-
treatment. 
 
93% in MCT condition and 
90% in IUT condition no 
longer met diagnostic criteria 
at follow up. 
 
 
Unclear 
risk 
Wells et al., 
2010 
Reductions on PSWQ, STAI-T, BAI, BDI and 
MCI for both AR and MCT conditions. MCT 
superior to AR. 
Treatment gains maintained at 6 and 12 
months on PSWQ, STAI-T and MCQ. MCT 
superior to AR. MCT improved on all 
measures, AR improved on 3 measures. 
0 (0.00)  Post-treatment: 80% 
recovery in MCT condition 
and 10% in AR condition on 
PSWQ. 
 
Follow up: recovery in MCT 
condition 70% (6 months) 
and 60% (12 months). AR 
condition 20% (6 and 12 
months). 
 
High risk 
Westra et al., 
2009 
CBT-MI group outperformed CBT group over 
treatment with a moderate between group 
effect size on PSWQ.  Both CBT-MI and 
CBT showed improvement on BDI, DASS, 
SDS, MC-30 and SDS. 
 
Treatment gains maintained at follow up. 
There was no difference between MI-CBT and 
CBT at 6 and 12 month follow up.  
14 (15.55)  At 12 months 74% of the 
CBT-MI and 61% of CBT 
condition no longer met GAD 
criteria. 
High risk   43 
 
 
 
 
Table 4: continued 
Study  Outcome at end of treatment  Outcome at follow up  Total study 
attrition (%) 
Percentage rated as 
recovered* 
Study 
risk of 
bias 
 
Wetherell et al., 
2003 
 
Improvement on PSWQ and BDI with large 
within group treatment effects. DG group 
showed medium treatment effect on PSWQ 
and BDI. CBT superior to DG and waitlist. 
 
 
Treatment gains were maintained for active 
treatment conditions, no difference between 
conditions at follow up. 
 
18 (24.00) 
 
At 3 months 78% of the CBT, 
61% of DG and 14% of 
waitlist conditions no longer 
met GAD criteria. 
 
High risk 
Wetherell et al., 
2011 
All participants in ACT condition showed an 
improvement in worry and depression. 5 out 
of 9 in the CBT condition improvement in 
anxiety and depressive symptoms, some 
reduction in worry but not significant. 
 
Post-treatment gains maintained at follow up 
for both conditions.  
6 (28.57)  Not reported.  Unclear 
risk 
Zinbarg et al., 
2007 
Improvement on PSWQ, DASS with a large 
effect size. Moderate effect of treatment on 
BAI. CBT condition superior to Waitlist 
condition.  
Not reported.  1 (5.26)  Not reported.  Unclear 
risk 
 
Note: *Studies vary in reporting recovery and remission, **Remission reported whole sample, which includes individuals with Social Phobia, Panic Disorder and GAD. 
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3.4.1 CBT versus Waitlist Control 
Fifteen studies compared CBT with waitlist. These included individual CBT 
(Dugas et al., 2003; Hoyer et al., 2009; Ladoucer et al., 2000; Rezvan et al., 2008; 
Stanley et al., 2003; Stanley et al., 2009; Van der Heiden et al. 2012; Wetherall et 
al., 2011, Zinbarg et al., 2007); group CBT (Dugas et al., 2010; Wetherall et al., 
2003) and internet based CBT (iCBT) (Andersson et al., 2012; Paxling et al., 2011; 
Robinson et al., 2010; Titov et al., 2009; Titov et al., 2010). Individual and group 
treatments lasted between 8 to 15 sessions and iCBT treatments ranged between 6 
to 8 sessions. Overall the post-treatment difference between treatment and waitlist 
groups was statistically significant, favouring CBT (MD= -10.33, 95% CI: -12.57 to -
8.10).  However  there  was  considerable  heterogeneity  (I2=  64%,  Chi2=  46.73, 
p<0.01) and difference between studies. Twelve studies (Andersson et al., 2012; 
Dugas et al., 2003; Dugas et al., 2010: Ladoucer et al., 2000; Paxling et al., 2011; 
Rezvan et al., 2008; Robinson et al., 2010: Stanley et al., 2003; Stanley et al., 2009; 
Titov et al., 2009; Van der Heiden et al. 2012; Zinbarg et al., 2007) reported reliable 
improvement using the Reliable Change Index of a change score on the PSWQ of 
seven  or  more  points  (Fisher,  2006)  and  three  studies  (Hoyer  et  al.,  2009; 
Wetherall, et al. 2003; Titov et al., 2010) did not report reliable change. In relation to 
clinical recovery, which is defined as a patient reporting a score under the clinical 
cut-off  of  45  (Behar,  Alcaine,  Zuelling  &  Borkovec,  2003),  which  differentiates 
dysfunctional  from  functional  populations  and  also  reports  a  statistically  reliable 
change  (Jacobson,  Revernstorf  &  Follette,  1984;  Fisher,  2006).  Only  one  study 
(Rezvan et al., 2008) reported mean post-treatment scores under the clinical cut-off 
score of 45 on the PSWQ. The remaining studies all reported mean post-treatment 
scores above the PSWQ clinical cut-off indicating that at mean post-treatment worry 
remained at a clinically significant level.   
Moderator  analysis  using  meta-regression  did  not  find  effects  for  the 
percentage of medication; mean severity of self-reported worry at baseline and year   45 
of publication. However, there was a trend for more recent studies to report smaller 
post-treatment differences. 
3.4.2 CBT versus Applied Relaxation (AR) 
Six  studies  compared  directly  CBT  with  AR  (Figure  3).  Five  studies 
(Borkovec et al., 1993, Dugas et al., 2010; Hayes Skelton et al., 2013; Hoyer et al., 
2009; Öst et al., 2000) reported that CBT was neither superior nor inferior to AR. A 
single study (Wells et al., 2010) reported a large between group effect size favoring 
CBT (d= 2.64, 95% CI: 1.35 to 3.71).  Combining the studies the post-treatment 
difference between CBT and AR was not statistically significant (MD= -4.59, 95% 
CI= -11.54 to 2.36). Heterogeneity was high (I2= 87%, Chi2= 35.05, p<0.00001) and 
there  was  difference  between  studies.  Exploratory  analysis  revealed  one  outlier 
(Wells et al., 2010) with a large effect size; this might be explained by the small 
sample size (N= 20). Other explanations include the quality of treatment received 
and possible researcher or clinician allegiance to the CBT treatment.  Without this 
study  the  heterogeneity  within  the  comparison  was  reduced  and  there  was  no 
difference between studies (I2= 24%, Chi2= 5.27, p= 0.20) and the overall mean 
difference  between  CBT  and  AR  was  reduced  but  did  not  alter  the  conclusions 
about CBT and AR’s relative effectiveness (MD= -0.27, 95% CI= -3.29 to 2.75). 
Overall  five  studies  reported  reliable  improvements  on  the  PSWQ  post-
treatment  for  the  CBT  treatment  arms  and  three  studies  reported  reliable 
improvements post-treatment for AR treatment arms. A single study did not find a 
reliable  improvement  for  either  the  CBT  or  AR  treatment  arms  and  two  studies 
reported post-treatment improvements that did not meet the reliable change criteria.  
A single study (Wells et al., 2010) reported post-treatment improvements for CBT 
treatment  of 25.5 points on the  PSWQ and a mean post-treatment score of 39, 
which reached the criteria for clinical recovery. 
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Figure 3: Post-treatment mean difference CBT compared to applied relaxation 
3.4.4 CBT versus Psychodynamic Psychotherapy 
Two  studies  directly  compared  CBT  with  psychodynamic  psychotherapy 
(Andersson et al., 2012; Leichsering et al., 2009).  Both studies compared a Short-
Term Dynamic Psychotherapy (STDP) with a first wave CBT treatment. Both studies 
suggested  that  CBT  was  neither  superior  nor  inferior  to  psychodynamic  therapy 
reporting small between group effects for CBT (d= 0.08, 95 % CI: -0.65 to 0.81; d= 
0.32,  95%  CI:  -0.21  to  0.84,  respectively).  Andersson  et  al.  (2012)  reported  a 
reliable improvement on the PSWQ for both CBT (MD= 7.11) and Psychodynamic 
(MD=  7.53)  treatment  arms  post-treatment.  However,  neither  treatment  reported 
reductions that would meet the criteria for clinical recovery of a score of 44 or below 
on the PSWQ.  Leichsering et al. (2009) reported reliable improvements in self-
reported  worry  for  the  CBT  treatment  post-treatment  (MD=  13.62),  the 
psychodynamic treatment reported an improvement (MD= 6.10), however this did 
not meet reliable change criteria. Neither treatment condition met the criteria for 
recovery post-treatment.   47 
Table 5: Study information of studies included in comparison 
 
  CBT versus 
Waitlist 
CBT versus 
applied 
relaxation 
CBT versus 
psychodynamic 
Psychotherapy** 
CBT versus other 
treatment 
comparator** 
CBT versus CBT 
with other 
additional 
element** 
Psychodynamic 
psychotherapy 
versus waitlist** 
Behavioural 
activation 
versus 
waitlist** 
Number of 
Studies 
16  6  2  3  3  1  1 
Study  1.  Dugas et 
al., 2003 
2.  Hoyer et al., 
2009 
3.  Ladoucer et 
al. 2009 
4.  Rezvan et 
al., 2008 
5.  Stanley et 
al., 2003 
6.  Stanley et 
al., 2009 
7.  Van Der 
Heider et 
al., 2012 
8.  Wetherall et 
al., 2003 
9.  Dugas et al. 
2010 
10. Zinbarg et 
al., 2009 
11. Andersson 
et al., 2012 
12. Paxling et 
al., 2010 
13. Robinson et 
al., 2010 
1.  Borkovec 
et al., 1993 
2.  Dugas et 
al., 2010 
3.  Hayes 
Skelton et 
al., 2013 
4.  Hoyer et 
al., 2009 
5.  Öst et al., 
2000 
6.  Wells et al., 
2010 
1.  Andersson et 
al., 2012 
2.  Leichsering 
et al., 2009 
1.  Borkovec et 
al., 1993 
2.  Neman et al., 
2013 
3.  Stanley et 
al., 1996 
4.  Kozycki et al. 
2010 
5.  Rezvan et 
al., 2008 
6.  Neman et 
al., 2011 
7.  Westra et 
al., 2009 
8.  Andersson 
et al., 2012 
9.  Chen et 
al., 2012   48 
Table 5: Continued 
 
  CBT versus 
Waitlist 
CBT versus 
applied 
relaxation 
CBT versus  
psychodynamic 
Psychotherapy** 
CBT versus 
other treatment 
comparator** 
CBT versus 
CBT with other 
additional 
element** 
Psychodynamic 
psychotherapy 
versus waitlist** 
Behavioural 
activation 
versus waitlist** 
Study  14. Titov et al., 
2009 
15. Titov et al., 
2010 
16. Romer et al., 
2008 
 
           
Pooled pre-
treatment 
severity (PSWQ) 
1.  51.63 
2.  58.52 
3.  62.81 
4.  57.83 
5.  61.85 
6.  55.17 
7.  67.46* 
8.  64.34 
9.  62.38 
10. 70.35 
11. 68.75 
12. 69.05 
13. 64.30 
14. 66.22 
15. 65.71 
16. 69.98 
 
1.  67.57 
2.  62.38 
3.  69.00 
4.  58.52 
5.  59.58 
6.  67.70 
1.  68.75 
2.  61.21 
1.  67.57 
2.  68.83 
3.  60.57 
4.  70.41 
1.  57.83 
2.  67.55 
3.  67.00 
1.  68.75  1.  65.40 
Severity of Worry (End of Treatment) 
Overall MD  
(95% confidence 
interval) 
-10.33 
(-12.57 to -8.10) 
-4.59 
(11.54 to 2.36) 
-2.05 
(5.47 to 1.37) 
-4.04 
(9.69 to 1.60) 
1.11 
(-3.64 to 5.85) 
-1.00  -9.08   49 
 
Table 5: Continued 
 
Note. *pooled pre-post difference. ** Reported narratively, not suitable for pairwise meta-analysis, MD: Mean Difference, SMD: Standardised Mean Difference. 
 
   
  CBT versus 
Waitlist 
CBT versus 
applied 
relaxation 
CBT versus  
psychodynamic 
Psychotherapy** 
CBT versus 
other treatment 
comparator** 
CBT versus 
CBT with other 
additional 
element** 
Psychodynamic 
psychotherapy 
versus waitlist** 
Behavioural 
activation 
versus waitlist** 
Overall SMD 
(95% confidence 
interval) 
-1.12 
(-12.57 to-8.10) 
-0.30 
(-0.84 to 0.22) 
-0.23 
(-0.61 to -0.16) 
-0.34 
(-0.76 to 0.08) 
0.11 
(-0.36 to 0.59) 
-0.11  -0.93 
Heterogeneity 
(I2) 
64%  87%  -  -  -  -  - 
N  931  251  106  70  79  52  49   50 
3.4.5 CBT versus other Treatment Comparator  
Four  studies  compared  CBT  with  a  treatment  comparator  that  could  not 
classified under any of the above categories.  Due to the variation in comparators 
the  studies  could  not  be  entered  in  a  meta-analysis.  Borkovec  et  al.  (1993) 
compared CBT to non-directive therapy in a working adult sample and reported a 
large improvement in worry on the PSWQ relative to non-directive therapy. The CBT 
condition  reported  a  reliable  improvement  in  self-reported  worry  (MD=  19.50); 
neither treatment condition post-treatment reached the PSWQ criteria for recovery. 
Stanley et al. (1996) compared CBT to a discussion group in an older adults sample 
reporting improvements in self-reported worry in both treatment conditions and that 
the discussion group condition was not statistically different to the CBT condition in 
its effectiveness in reducing worry.  Both treatment conditions reported a reliable 
improvement post-treatment but did not meet the criteria for recovery. Newman et 
al. (2013) compared two brief group 6-session group CBT (gCBT) treatments to a 
standard 12-session gCBT treatment, reporting that at post-treatment brief gCBT 
treatment with computer assistance was superior to brief gCBT and neither were 
superior to the standard 12-session gCBT intervention.  Reliable improvement was 
reported for gCBT treatment with computer assistance (MD= 17.37) and standard 
12-session gCBT (MD= 12.09)  no treatment met the criteria for recovery on the 
PSWQ. At 6 and 12 month follow up there was no significant statistical difference 
between any interventions in reported symptoms of worry.  Kosyzcki et al. (2010) 
compared  CBT  with  a  spirituality-based  intervention  (SBI),  which  focused  on 
acceptance and mindfulness, reporting improvements in worry for  both treatment 
groups, CBT was superior to SBI, but this was not statistically significant, as both 
interventions  reported  reliable  improvements  in  worry  post-treatment.  Treatment 
gains  were maintained at  follow  up  and  reported  large  within  group  effect  sizes 
(CBT: d= 1.22, 95% CI: 0.27 to 2.08; SBI: 1.08, 95% CI: 0.15 to 1.93) for reduction   51 
in worry. Despite the reported treatment effect neither treatment condition met the 
PSWQ criteria for recovery. 
3.4.6 CBT versus CBT with Additional Elements 
Three studies (Rezvan et al., 2008; Newman et al., 2011 and Westra et al., 
2009) compared CBT directly to CBT with an additional therapeutic element. Due to 
the  variation  in  comparators  the  studies  could  not  be  entered  in  meta-analysis. 
Revan  et  al.  (2008)  compared  CBT  to  CBT  with  interpersonal  therapy,  both 
therapies  led  to  a  reliable  improvement  in  worry  and  reached  the  criteria  for 
recovery post-treatment, there were no statistically significant differences between 
the  two  treatment  groups  at  post-treatment  or  follow  up.  Newman  et  al.  (2011) 
compared CBT to CBT with an interpersonal/ emotional-processing element. Both 
treatments lead to reliable reductions on the PSWQ but did not reach the criteria for 
clinical  recovery,  there  was  no  statistical  difference  between  either  treatment 
conditions post-treatment or at follow up. Westra et al. (2009) compared CBT with 
CBT following a motivational interviewing (MI) pre-treatment. Both treatments led to 
reliable improvements in self-reported worry and met the criteria of clinical recovery. 
The CBT plus MI group outperformed the CBT group post-treatment, this was not 
maintained at 6 and 12 month follow up. 
3.4.7 CBT Subgroup Analysis 
A subgroup analysis of CBT was conducted which assessed first wave CBT, 
second wave CBT, third wave CBT and iCBT (Figure 4). A separate analysis was 
conducted  for  an  older  adult  CBT  (Figure  5).    All  subgroup  analyses  are 
summarised in Table 6.  
3.4.7.1 First Wave CBT versus Waitlist 
Five studies directly compared first wave Beckian CBT with waitlist control 
conditions. Post-treatment there was a statistically significantly difference between 
conditions,  favouring  CBT  (MD=  -11.69,  95%  CI:  -15.22  to  -8.15).  There  was 
substantial heterogeneity (I2= 56%, Chi2= 9.07, p= 0.06).   52 
3.4.7.2 Second Wave CBT versus Waitlist 
Four  studies  directly  compared  second  wave  CBT  (Dugas  et  al..  1998; 
Ladoucer  et  al.,  2000;  Van  Der  Heiden  et  al.,  2012;  Wells  et  al.,  1999).  Post-
treatment  there  was  a  statistically  significant  difference  between  treatment  and 
waitlist favoring CBT (MD= -12.23, 95% CI: -16.48 to -7.97). There was moderate 
heterogeneity (I2= 48%, Chi2= 7.7, p=0.10). 
3.4.7.3 Third Wave CBT versus Waitlist 
A single trial (Romer et al., 2008) compared third wave CBT with waitlist 
directly. Romer et al. (2008) reported a mean difference of -14.75 points on the 
PSWQ post-treatment favouring third wave CBT. The difference between conditions 
demonstrated a large effect of treatment (d= 1.94, 95% CI: 1.04 to 2.74), however 
the sample size of the study was small (N=31) and has not been replicated. 
3.4.7.4 Internet CBT (iCBT) versus Waitlist 
Five studies directly compared iCBT to waitlist. Four studies compared a 
specific  CBT  intervention  for  GAD  (Andersson  et  al.,  2012;  Paxling  et  al.,  2011 
Robinson  et  al.,  2010;  Titov  et  al.,  2009)  and  a  single  trial  compared  a  trans-
diagnostic  CBT  treatment  for  anxiety  (Titov  et  al.,  2010).  The  study  reported 
outcomes by diagnostic group and was included in the analysis.  Post-treatment 
there was a statistically significant difference favoring iCBT (MD= -8.42, 95% CI= -
12.33 to -4.51).  Further analysis focusing on specific iCBT treatments for GAD, 
excluding Titov et al. (2010) did not alter the findings that iCBT was superior to 
waitlist  (MD=  -9.55,  95%  CI=  -13.36  to  -5.74).  There  was  however  evidence  of 
substantial heterogeneity (I2= 60%, Chi2= 9.91, p= 0.04). There was evidence of a 
large size effect in three trials (Paxling et al., 2011; Robinson et al, 2010; Titov et 
al., 2009) favouring CBT post-treatment (MD= -11.43, 95% CI = -14.88 to -8.47) 
with no heterogeneity (I2= 0%, Chi2= 0.73, p= 0.87) 
3.4.7.5 Older Adult CBT versus Waitlist   53 
Three studies compared CBT for older adults. Two studies (Stanley et al., 
2003,  2009)  reported  large  between  group  effect  sizes  post-treatment  favouring 
CBT (d= 1.03, 95% CI: 0.50 to 1.55; d= 0.91, 95% CI: 0.52 to 1.29.respectively) and 
one study (Wetherall et al., 2009) reported a moderate between group effect size 
favoring CBT (d= 0.64, 95% CI: -0.02 to 1.27). Combining all studies, post-treatment 
there was a statistically significant difference between treatment and waitlist control 
favoring CBT (MD= -9.08, 95% CI =11.82 to 6.34) with no heterogeneity (I2= 0%, 
Chi2= 0.36, p= 0.83). 
3.4.8 Psychodynamic versus Waitlist 
A  single  study  (Anderson  et  al.,  2012)  compared  Internet  based 
psychodynamic  psychotherapy  with  waitlist.  Psychodynamic  therapy  reported  a 
large within group effect on the PSWQ and a reliable post-treatment change on the 
PSWQ  (MD=  -7.86,  d=  1.16,  95%  CI=  0.56  to  1.73)  for  Internet  based 
psychodynamic psychotherapy. At three-month follow up there was small effect for 
psychotherapy with it being reported as only marginally better than waitlist.  
3.4.8 Behavioural Activation for Worry (BAW) versus Waitlist 
A single study (Chen et al., 2013) directly compared BAW to a waitlist.  The 
study  delivered  group  BAW  and  was  adapted  from  Addis  and  Martell’s  (2004) 
manual. Post-treatment difference favored BAW condition with a mean reduction of 
9.08 on the PSWQ in comparison to waitlist, this equated to large post-treatment 
effect (d= 0.85, 95% CI= 0.43 to 1.61). The change in reported worry in the BA 
condition  indicated  a  reliable  improvement  in  worry  but  did  not  reach  clinical 
recovery. However, this study is based on a small sample size (N= 49) and the 
authors reported that an administrative error resulted in 10 participants in the waitlist 
condition (n= 24) not completing the post-treatment PSWQ. The authors conducted 
multiple  imputation  (Rubin,  1996)  to  account  for  missing  data;  this  may  have 
introduced additional bias and it is likely that additional studies will alter the current 
conclusions  in  regards  to  the  effect  of  BAW  as  a  treatment  of  GAD.   54 
Table 6: Study information CBT subgroup comparisons 
  1st Wave CBT 
versus Waitlist 
2nd Wave CBT 
versus Waitlist 
iCBT versus 
Waitlist 
Older Adult 
CBT versus 
Waitlist 
No of Studies   6  3  5  3 
 
Study  (1)  Hoyer et al., 
2009 
(2)  Rezvan et 
al., 2008 
(3)  Stanley et 
al., 2003 
(4)  Stanley et 
al., 2009 
(5)  Wetherell et 
al., 2003 
(6)  Zinbarg et 
al., 2007 
 
(1)  Dugas et 
al., 2003 
(2)  Dugas et 
al., 2010 
(3)  Ladoucer et 
al., 200 
(4)  Van Der 
Heiden et 
al., 2012* 
(1)  Andersson 
et al., 2012 
(2)  Paxling et 
al., 2011 
(3)  Robinson et 
al., 2010* 
(4)  Titov et al., 
2009 
(5)  Titov et al., 
2010 
 
(1)  Stanley et 
al., 2003 
(2)  Stanley et 
al., 2009 
(3)  Wetherell et 
al., 2003 
 
Pooled pre-
treatment 
severity  
(PSWQ) 
(1)  58.52 
(2)  57.83 
(3)  61.85 
(4)  55.17 
(5)  64.34 
(6)  70.35 
 
(1)  51.63 
(2)  62.38 
(3)  62.55 
(4)  67.46 
 
(1)  68.75 
(2)  69.05 
(3)  64.30 
(4)  66.22 
(5)   65.71 
 
(1)  61.85 
(2)  55.17 
(3)  64.34 
 
 
Pre-Post 
treatment 
difference 
(PSWQ) 
(1)  2.70 
(2)  15.75 
(3)  10.20 
(4)  8.80 
(5)  7.60 
(6)  16.10 
 
(1)  10.96 
(2)  7.67 
(3)  18.94 
(4)  12.77* 
 
(1)  2.10 
(2)  11.57 
(3)  12.37 
(4)  9.39 
(5)  1.54 
 
(4)  10.20 
(5)  8.80 
(6)  7.60 
 
Severity of Worry (PSWQ End of Treatment)   
 
Overall MD 
 
-10.13 (-14.27 
to -5.99) 
 
-12.23 (16.48 to 
-7.97) 
-8.42 (-12.33 to -
4.51) 
-9.08 (-11.82 to 
-6.34) 
Overall SMD 
  
-1.08 (-1.61 to -
0.54) 
 
-1.03 (-1.37 to -
0.69) 
-0.78 (-1.13 to -
0.44) 
-0.89 (-1.17 to -
0.60) 
Heterogeneity  
(I2) 
 
74%  48%  65%  0% 
N  309  246  355  218 
 
Note. *pooled pre-post difference, MD – Mean Difference, SMD – Standardised Mean Difference  
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Figure 4: Post-treatment mean difference CBT compared to waitlist   56 
 
Figure 5: Post-treatment mean difference older adult CBT 
3.5 Network Meta-Analysis 
Of the 28 studies included in the review 27 studies were synthesised with 
network meta-analysis (NWA). A single study (Robinson et al., 2013) was excluded, 
as  the  study  did  not  link  to  at  least  one  other  comparator  in  the  network.  The 
network  of  evidence  included  data  from  1,545  participants  and  consisted  of  43 
between conditions comparisons. Most of the evidence in the network was for the 
waitlist versus first wave CBT, waitlist versus iCBT and second wave CBT – IoU. 
The  network  highlighted  that  there  was  a  limited  amount  of  evidence  for  13 
comparisons due to a single comparison between conditions being possible within 
the network. As such conclusions are tentative and future evidence is likely to lead 
to changes in the conclusions drawn. Figure 6 summarises the network of evidence, 
reflecting all available within and between study comparisons and the number of 
patients  investigated  for  each  treatment  condition.  The  thickness  of  the  line 
represents the number of comparisons (the thicker the line the greater the number 
of  comparisons)  and  the  circle  represents  the  number  of  participants  in  each 
condition (the larger the circle the greater the number of participants).   57 
 
Figure 6: Network of evidence of all studies 
  The post-treatment difference in mean change in worry as measured by the 
PSWQ  is  summarised  in  Table  7.  Negative  values  in  the  table  indicate  change 
favouring  treatments  in  the  columns,  whereas  positive  values  indicate  change 
favouring  treatments  in  the  rows.  The  difference  in  self-reported  worry  between 
treatments ranged from 0.76 to 23.8 points on the PSWQ. All active treatments out-
performed the waitlist condition with a difference ranging from 2.96 to 23.80 points 
on the PSWQ. CBT based on MCT reported the largest post-treatment difference 
followed  by  CBT  based  on  IoU  and  enhanced first  wave  CBT.    Psychodynamic 
psychotherapy reported the least change in comparison to the waitlist.  Overall CBT 
based  on  MCT  consistently  out-performed  all  other  active  treatments  with  post-
treatment  differences  on  the  PSWQ  ranging  from  11.59  to  23.80,  however  this 
effect  was  based  on  two  studies  and  should  be  interpreted  with  caution. 
Psychodynamic  psychotherapy  out-performed  waitlist  reporting  a  small  post-  58 
treatment  difference  on  the  PSWQ  (2.96)  and  was  inferior  to  all  other  active 
treatments 
  The performance of individual treatments within the network is summarised 
in Table 8. The overall ranking of treatment indicated that CBT based on MCT was 
the best treatment with 98% certainty, however as previously stated this is based on 
two  studies  only  and  must  be  interpreted  with  caution.  CBT  based  on  IoU, 
enhanced first  wave  CBT, third wave CBT, first  wave  CBT and were all ranked 
above waitlist and there was considerable overlap of confidence intervals between 
interventions but none overlapped with waitlist.  BA, iCBT, non-directive supportive 
intervention  and  psychodynamic  therapy  had  large  confidence  intervals,  which 
overlapped  with  waitlist  and  indicated  heterogeneity  in  the  sample.    The  NWA 
supported the standard pairwise comparisons.  
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Table 7: Table of mean change on PSWQ (and 95% credibility intervals) of psychotherapeutic interventions in NWA 
Therapeutic 
Intervention/ 
Control 
Condition 
 
Wait 
list 
1st Wave 
CBT 
AR  Enhanced 
1st Wave 
CBT 
Non 
Directive 
supportive 
intervention 
2nd Wave 
CBT -IoU 
2nd Wave 
CBT -MCT 
iCBT  Psycho-
dynamic 
3rd Wave 
CBT 
BA 
Waitlist    -9.844 
(-13.28 to  
-6.42) 
-8.08 
(-12.58 
to 
 -3.45) 
 
-12.22 
(-18.21 to 
 -6.27) 
-5.53  
(-12.19 to 
1.14) 
-12.33 
(-17.16 to  
-7.34) 
-23.8 
(-31.45 to  
-16.34) 
-7.29 
(-11.30 
to  
-3.20) 
-2.96  
(-9.32 to 
3.37) 
-10.50 
(-16.68 to 
 -4.23) 
-8.52  
(-18.25 
to 1.30) 
 
 
1st Wave CBT      1.79  
(-2.75 
to 
6.42) 
-2.37 
(-7.77 to 
3.01) 
4.31 
(-1.90 to 
10.58) 
-2.39 
(-8.17 to 
3.35) 
-13.95 
(-22.01 to  
-6.08) 
4.92 
(-2.15 to 
12.15) 
6.88 
(0.48 to 
13.30) 
1.72  
(-6.34 to 
9.90) 
3.70 
(-7.70 to 
15.23) 
 
AR        -4.56  
(-11.15 to 
2.71) 
2.53 
(-4.63 to 
9.68) 
-4.17 
(-10.21 to 
1.72) 
 
-15.74 
(-23.58 to 
-8.12) 
0.76 
(-5.29 to 
6.81) 
5.10 
(-2.39 to 
12.50) 
 
-2.44 
(-8.80 to 
3.92) 
-0.47 
(-0.46 to 
-11.24) 
Enhanced 1st 
Wave CBT 
        6.68 
(-1.42 to 
14.85) 
-11.59 
(-21.09 to -
2.20) 
-11.59 
(-21.09 to -
2.20) 
4.92 
(-2.15 to 
12.15) 
9.35 
(1.08 to 
17.43) 
1.72 
(-6.34 to 
9.90) 
3.70 
(-7.70 to 
15.23 
 
Non Directive 
supportive 
intervention 
          -18.27 
(-28.13 to  
-8.58) 
-18.27 
(-28.13 to  
-8.58) 
-1.80 
(-9.47 to 
6.00) 
2.57 
(-6.19 to 
11.27) 
-4.97 
(-13.49 to 
3.58) 
-2.98  
(-14.80 
to 8.84) 
 
2nd Wave 
CBT - IoU 
            -11.57 
(-19.37 to  
-3.90) 
4.94 
(-1.39 to 
11.37) 
9.27 
(1.39 to 
17.23) 
1.73 
(-5.83 to 
9.46) 
3.71 
(-7.44 to 
14.66) 
 
2nd Wave 
CBT - MCT 
              16.51 
(8.06 to 
25.23) 
20.84 
(11.22 to 
30.66) 
13.30 
(4.08 to 
22.82) 
15.28  
(3.06 to 
27.72) 
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Table 7: Continued  
Therapeutic 
Intervention/ 
Control 
Condition 
 
Wait 
list 
1st Wave 
CBT 
AR  Enhanced 
1st Wave  
CBT 
Non 
Directive 
supportive 
intervention 
2nd Wave 
CBT -IoU 
2nd Wave 
CBT -MCT 
iCBT  Psycho-
dynamic 
3rd Wave 
CBT 
BA 
iCBT                  4.33 
(-2.57 to 
11.14) 
-3.208 
(-10.59 to 
4.17) 
-1.23 
(-11.79 
to 9.35) 
 
Psycho-
dynamic 
                  -7.54  
(-16.09 to 
1.08) 
-5.55  
(-17.17 
to 6.10) 
 
3rd Wave CBT                      1.98 
(-9.61 to 
13.55) 
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Table 8: Ranking of treatments and probability of best treatment 
 
Treatment  Mean Ranking (SD)  95% Credibility 
Interval 
Mean Probability of 
Best Treatment 
(SD) 
 
2nd Wave CBT – 
MCT 
 
1.0 
(0.19) 
1 to 1  0.981 (0.14) 
Enhanced 1st Wave 
CBT 
 
3.5 (1.67)  2 to 8  0.007 (0.09) 
2nd Wave CBT – IoU 
 
3.5 (1.53)  2 to 7  0.002 (0.03) 
3rd Wave CBT 
 
4.7 (2.04)  2 to 9  0.002 (0.05) 
1st Wave CBT 
 
5.1 (1.31)  3 to 8  0.001 (0.08) 
BA 
 
6.1 (2.80)  2 to 11  0.008 (0.09) 
AR 
 
6.6 (1.61)  3 to 9  0.00 (0.04) 
 iCBT 
 
7.1 (1.63)  3 to 10  0.00 (0.07) 
Non Directive 
Supportive 
Intervention 
 
8.2 (1.82)  4 to 11  0.00 (0.09) 
Psychodynamic 
 
9.5 (1.32)  6 to 11  0.00 (0.05) 
Waitlist  10.7 (0.50)  10 to 11  0.00 (0.0) 
 
4. Discussion 
4.1 Summary of Aims of Review 
This review examined the effectiveness of psychological therapies for GAD 
in addressing pathological worry as measured by the PSWQ.  All studies in the 
review reported that psychological treatment led to reductions in self-reported worry 
post-treatment,  with  large  within-group  effect  sizes.  Treatment  gains  were 
maintained at follow up, suggesting that psychological treatments were sustained. 
However  due to the substantial variation between studies’ follow  up time points, 
which  ranged  from  three  months  to  two  years,  this  data  was  not  able  to  be 
incorporated into a formal meta-analysis. 
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4.2 Summary of Risk of Bias 
The risk of bias of studies showed a large variation in the quality of reporting 
for  methodological  domains  of  study  design  and  outcomes.  Overall  50%  of  the 
studies in the review did not report adequate information for a clear assessment of 
bias to be made in regards to sequence generation or allocation of concealment. 
The majority of studies (57%) did not report clear information to determine if raters 
of outcome assessments were blinded to treatment conditions. Only 36%  of the 
studies  in  the  reviews  adequately  reported  information  of  blinding  for  outcome 
assessors. However, the majority of studies in the review were assessed as being 
at low risk of bias for selective reporting of data and incomplete data (78% and 64% 
respectively)  as  the  majority  of  studies  reported  intent-to-treat  (ITT)  data  and  a 
single study (Wetherell et al., 2011) additionally reported individual patient data for 
all  study  outcomes.  Other  sources  of  bias  were  reported  as  low  in  64%  of  the 
studies  as  they  reported  use  of  a  treatment  manual  protocols  and  independent 
ratings of adherence. A single study (Andersson et al., 2012) also controlled for 
therapist allegiance. The risk of bias assessment supported conclusions of previous 
reviews that the available evidence is mixed and of variable quality with a large 
proportion of studies being of a moderate to low quality (Hunot et al., 2007; NICE, 
2011);  there  were  also  indications  of  the  presence  of  substantial  heterogeneity 
between studies. 
4.3 Summary Findings of Pairwise Meta-Analysis  
4.3.1 CBT 
The findings from the analysis gave limited support to previously reported 
reviews  (Covin  et  al.,  2008;  Harahan  et  at  al.,  2012;  NICE,  2011)  that  CBT 
treatment was more effective when compared with waitlist and resulted in reliable 
change on the PSWQ (Fisher, 2006).  The data suggested that those who received 
a CBT treatment scored a mean of 10.83 points lower on the PSWQ in comparison 
to waitlist.  Subgroup analysis showed that iCBT interventions, which were shorter   63 
than  standard  CBT  interventions  and  required  less  clinician  input,  had  smaller 
reductions on the PSWQ when compared to waitlist. In comparison to waitlist, first 
generation  CBT,  second  wave  CBT  and  third  wave  CBT  reported  larger  post-
treatment differences. This tentatively suggested that face-to-face CBT was slightly 
more  effective  than  iCBT.  There  was  also  a  trend  towards  more  recent  CBT 
approaches  (second  wave  CBT,  third  wave  CBT)  reporting  increased  mean 
differences between CBT and waitlist post-treatment.  Older CBT treatments were 
also analysed separately as in previous reviews (Colvin et al., 2008), the findings 
supported  previous  analysis  with  older  adults  reporting  a  lower  post-treatment 
difference on the PSWQ when compared to a waitlist condition. Moderator analysis 
using meta-regression did not find statistically significant effects for the percentage 
of medication  use, mean  severity  of  self-reported  worry  at  baseline  and  year of 
publication.    However,  the  moderator  analysis  for  medication  was  limited  to  the 
percentage of participants using medication during the trial. Trials did not report in 
adequate detail the type of medication used or the dosage of medication. Therefore 
the  moderator  analysis  was  unable  to  control  these  factors  and  is  limited  in  its 
sensitivity as a result. 
In comparisons of CBT against other treatments the findings from this review 
provide some support for the findings of previously reviews (Colvin et al., 2008; 
Harahan et al., 2012; Hunot et al., 2007; NICE, 2011).  CBT did not demonstrate 
either  superiority  or  inferiority  to  AR.   The  differences  reported  between  studies 
ranged from 1 to 5 points on the PSWQ favouring CBT.  A study (Wells et al., 2010) 
reported a 26  point  difference on the PSWQ favouring CBT post-treatment. The 
overall conclusions of comparison were not altered when this study was excluded, 
although  heterogeneity  was  reduced.  A  possible  explanation  for  the  lack  of 
difference seen between CBT and AR treatments could be that the majority of CBT 
treatment  incorporates  elements  of  applied  relaxation  in  addition  to  cognitive 
therapy. In effect both treatments allow individuals reduce and manage levels of   64 
physical arousal, which lead to a physical state that triggers worry (Borkovec, 1994; 
Borkovec,  Alcaine  &  Behar,  2004)  resulting  in  less  worry  being  reported.  CBT 
approaches  may  add  alternative  strategies  for  managing  previously  threatening 
strategies and facilitate habituation through behavioural approaches. 
The limited evidence available also suggests that CBT was neither superior 
nor inferior to psychodynamic therapy with two studies reporting large within-group 
effect sizes and small between-group effect sizes post-treatment. However, it is of 
note that in the Leichsering et al. (2009) study that CBT sessions were matched to 
the psychodynamic condition of 30 sessions and therefore may not reflect clinical 
treatment in the UK as NICE (2011) recommends CBT treatment of 12-15 sessions.  
CBT  was  neither  superior  nor  inferior  when  compared  to  other  active 
treatments  or  CBT  with  an  additional  element.  Studies  reported  reliable 
improvements on the PSWQ post-treatment and large within-group effect sizes for 
both CBT and the comparator treatment, improvements were maintained at follow 
up. One study (Westra et al., 2009) reported that CBT with motivational interviewing 
was superior to standard CBT, however this difference was not maintained at follow 
up.  
4.3.2 Psychodynamic Psychotherapy 
  The effectiveness of psychotherapy as a treatment in comparison to waitlist 
was  limited  as  a  single  small  study  (Andersson  et  al.,  2012)  compared  Internet 
based  psychodynamic  therapy  to  waitlist.  The  study’s  findings  suggested  that 
psychodynamic  therapy  had  a  large  effect  in  reducing  self-reported  worry  post-
treatment. This was not maintained; as psychodynamic therapy was only marginally 
better than waitlist at follow up.  
4.3.3 Behavioural Activation for Worry 
The  effectiveness  of  behavioural  activation  in  the  treatment  of  GAD  and 
pathological worry is limited, as only a single study (Chen et al., 2013) to date has 
compared  BAW  to  waitlist  control.  The  study  reported  large  reductions  in  worry   65 
post-treatment  and  a  large  treatment  effect.  However,  methodological  limitations 
and  lack  of  replication  limited  the  ability  to  draw  any  firm  conclusions  of 
effectiveness.  
4.4 Network Meta-Analysis (NWA) 
  The NWA allowed the comparison of all available direct and indirect post-
treatment data. The network of evidence indicated that most evidence available was 
for first wave CBT treatments versus waitlist, first wave CBT versus enhanced first 
wave  CBT  and first  wave  CBT  versus  AR. The  network showed  that there  was 
limited evidence from psychodynamic psychotherapy, second wave and third wave 
CBT.  Three  therapies  (non-directive  supportive  interventions,  BA,  and 
psychodynamic  therapy)  did  not  differentiate  themselves  from  waitlist,  95% 
credibility intervals suggested that the treatment effects were no different to waitlist. 
Of the therapies that did differentiate themselves from waitlist meta-cognitive based 
CBT therapy demonstrated a consistent superiority over all comparator treatments 
reporting a post-treatment difference on the PSWQ in excess of 10 points. Meta-
cognitive based CBT was estimated by the network meta-analysis to probably be 
the best treatment for worry out of the available evidence given the available direct 
and  indirect  evidence,  as  the  treatment  effect  did  not  overlap  with  the  95% 
credibility intervals of any other treatment or waitlist.  
4.5 Recovery and Remission 
Within the studies in the review there was a consistent discrepancy between 
clinician rated measures of GAD and self-report symptoms of worry. Clinician rated 
measures  reported  post-treatment  recovery  ranging  from  26%  to  72%,  whereas 
only three studies reported a clinically reliable change in self-reported symptoms of 
worry  and  was  of  a  non-clinical  level  (Meyer  et  al.,  1990).  It  is  striking  that the 
majority  of  individuals  receiving  psychological  treatment  for  GAD  still  appear  to   66 
report  pathological  levels  of  worry  post-treatment  despite  clinician  assessment 
reporting  that  individuals  no  longer  met  GAD  criteria.    Given  that  persistent, 
excessive and out of control worry is a central symptom of GAD (Behar, Di Marco, 
Hekler,  Mohlman  &  Staples,  2009)  this  suggests  that  current  psychological 
treatments  for  GAD  do  not  reliably  relieve  pathological  worry  for  the  majority  of 
participants as measured by the PSWQ. It may be that treatments are effective in 
addressing  somatic  symptoms  of  GAD,  reducing  arousal  levels  that  trigger 
uncontrollable worry, as a threat state is not reached. It is also possible that the 
habitual  and  over-learnt  responses  that  characterise  the  use  of  worry  as  an 
emotional avoidance strategy (Borkovec et al., 2004) require a longer period of time 
to  become  established.  Follow  up  data  provided  some  limited  support  for  this 
hypothesis.  Three studies reported non-pathological levels of worry post-treatment 
and the number of studies reporting non-pathological levels of worry increased at 
six months (5 studies) and again 12 months (6 studies), however the majority of 
studies included in the review still reported the presence of pathological worry at 
follow  up.    Alternatively  there  may  be  a  disproportionate  focus  in  clinician 
assessment on the reduction in somatic anxiety symptoms. This may lead to an 
under detection of GAD symptoms as worry is not assessed to the same degree as 
physical symptoms which has been previously highlighted as an issue in primary 
care settings (NICE, 2011; Tyrer & Baldwin, 2006). It highlights the possibility that 
clinicians are still considering worry as a consequence of anxiety rather than an 
underlying  process  that  maintains  worry.  Therefore  reduction  in  somatic  anxiety   67 
symptoms  is  equated  to  a  reduction  in  worry.  This  may  account  in  part  for  the 
waxing and waning profile of GAD as current psychological treatment appears to 
leave individuals with residual symptoms of pathological levels of worry as current 
treatments may not address well enough the underlying worry mechanisms in GAD 
and lead potentially to a higher likelihood of relapse. The network provided support 
for this hypothesis, as meta-cognitive therapy, a second wave CBT approach, was 
rated  by  the  network  as  probably  the  best  treatment.  This  may  be  due  to  the 
approach  addressing  underlying  processes  such  as  attentional  bias  and  meta-
cognitive beliefs about worry. 
4.6 Methodological issues and Limitations 
  This review has several limitations; the decision to include only randomised 
designed  trials  of  which  the  majority  were  RCT  may  not  fully  represent  actual 
clinical  practice  and  limit  the  overall  generalisability  of  findings.  Additionally  the 
study  sample  sizes  were  small,  with  only  four  studies  (Robinson  et  al.,  2010; 
Stanley et al., 2009; Van der Heiden et al., 2012 and Westra et al., 2009) having a 
sample  size  over  a  hundred  participants  at  commencement  of  the  study.  As  a 
consequence  several  studies  were  underpowered  and  were  described  as  pilot 
studies. This highlights the need for large-scale studies in this area.  The quality of 
reporting varied for the included studies with only six studies reporting a CONSORT 
compliant  trial  design  with  a  pre-registered  trial  protocol.  A further  three  studies 
reported  a  participant  flow  CONSORT  diagram.  The  level  of  reporting  of  key 
methodological aspects such as randomisation and concealment varied. Half the 
studies did not report sufficient detail to allow a judgment of the potential level of 
bias, which was unclear in the majority of studies.    68 
Studies varied in the reported follow up periods, with the majority of studies 
reporting  time  points  ranging  from  three  to  12  months.  During  this  time  many 
studies reported further substantial attrition of participants and did not control for 
other confounders such as further treatment and medication usage, which weakens 
the conclusions that can be made about treatments long-term effectiveness.  
The majority of studies employed a delayed treatment design, which meant 
that waitlist control data was only available to the end of treatment. This prevented 
the  comparison  of  treatment  follow  up  data  with  a  non-treatment  group,  as  a 
consequence natural recovery as a potential confounder could not be definitively 
excluded, limiting the conclusion about long-term effectiveness. However, it must be 
considered that withholding treatment for the prolonged periods in long-term follow 
up is unethical and is a limitation faced by all treatment trials.  
Nine of the studies included in the review recruited participants from clinical 
samples  with  the  remaining  employing  a  community  sample.  The  majority  of 
community studies employed a convenience sampling approach, which may limit 
the validity of findings when compared to real world clinical population. The majority 
of studies also excluded other co-morbid disorders and this may further limit the 
generalisability  of  findings  into  real  world  clinical  practice,  as  GAD  is  often  co-
morbid  with  another  Axis  I  disorder  and  pure  GAD  is  relatively  rare  clinical 
occurrence (NICE, 2011).   
There are also several limitations of the review that are common to meta-
analysis such as the assumption that studies are drawn from the same population.  
The review found that there were indications of the substantial heterogeneity in the 
overall class of intervention for CBT; this was retained to a degree in the individual 
classifications of subtypes.  
Network meta-analysis makes an additional assumption to allow conclusions 
to  be  drawn  from  the  direct  and  indirect  evidence.    It  assumes  that  particular 
treatments are similar in procedure and rationale, which allows them to be grouped   69 
together.  The  grouping  together  of  treatments  that  contain  important  differences 
may lead to an underestimation of efficacy and the intervention’s effectiveness. The 
review  also  did  not  control for researcher  allegiance  bias,  which  may also  have 
introduced a source of bias.  Also due to the difference in reporting of data from 
trials, imputation was employed as only a small number of trials reported change 
data,  and  with  the  majority  reporting  post-treatment  effect  any  assessment  of 
difference between change and post-treatment effect is not reliable and may be a 
possible source of bias within the network. Given these limitations the conclusions 
from the network are tentative.  
4.7 Future Directions 
The findings of the review suggest several areas of further research in the 
psychological treatment of GAD.  Given the relatively small size of trials it is clear 
that  more  large  well-conducted  trials  that  adhere  to  CONSORT  standards  are 
required to allow a more definitive assessment of psychological treatment for GAD 
and worry. There is also a need for further trials of alternative treatments to CBT to 
establish the effectiveness of other psychological treatments, as there is a paucity 
of  well-conducted  trials.  The  network  meta-analysis  also  confirmed  a  paucity  of 
trials in the network of evidence and showed that the majority of trials are compared 
to a waitlist only rather a head-to-head comparison with another active treatment 
and a control. In order to address heterogeneity further differentiation of treatments 
active  elements  and  delivery  may  allow  for  a  reduction  in  heterogeneity  as  this 
would further high quality control trials with high levels of methodological reporting.   
Also of interest would be further investigation in post-treatment level of worry 
as a relapse predictor of GAD given that the majority of treatments in the review do 
not lead to a sub-clinical level of self-reported worry post-treatment (Behar, Alcaine, 
Zuelig and Borkovec, 2003).  
4.8 Conclusions   70 
Although the findings from this review are tentative as they are based on a 
small number of studies with a number of methodological issues and limitations in 
quality, the current review broadly supports the findings of previous reviews, that 
psychological treatment of GAD leads to a reduction in levels of pathological worry.  
CBT was superior to waitlist, CBT and AR were equally effective and there was 
limited evidence for the effectiveness of psychodynamic and behavioral activation 
approaches.  The review also tentatively suggested that newer second wave CBT 
approaches to GAD treatment lead to increased reductions post-treatment in worry. 
The network meta-analysis suggested that MCT was probably the best treatment of 
GAD, although this is based on data from only 64 individuals.  
 However, despite the evidence that psychological therapy leads to a reliable 
change  in  worry  post-treatment, few  studies  reached  a  level  that  would  indicate 
clinical recovery post-treatment. 
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Abstract 
Aims: The pilot study investigated the feasibility and acceptability of a Low Intensity 
(LI)  guided  self-help  intervention  for  excessive  worry  and  generalised  anxiety 
disorder  (GAD).  The  Understanding  Worry  (UW)  intervention  was  adapted  from 
current CBT theory and presented in a framework adapted from the COM-B model 
of intervention design (Michie, Van Stralen & West, 2011). The study also sought to 
evaluate  clinical  effectiveness  of  the  new  intervention  in  relation  to  the  current 
generic  LI  intervention.  Method:  A  randomised  trial  comparing  two  groups: 
Treatment as Usual (TAU) and Understanding Worry (UW). The study planned to 
recruit 40 patients from primary care NHS clinical settings. However, due to delays 
in recruitment only 24 were recruited and randomised to treatment conditions. The 
indicators of acceptability and feasibility were a patient consort diagram, attendance 
and attrition rates and patient ratings of satisfaction (CSQ-8) at the completion of 
treatment. The main clinical outcomes were the PSWQ, PHQ-9, GAD-7 and WSAS. 
Mixed Methods Linear Modeling was used in analysis to utilise all available data 
and was selected due to the small data set. Results:  Patient flow indicated that 
there was a clinical need for a specific worry intervention. Attendance, cancellations 
and  DNAs  were  not  significantly  different  between  the  two  treatment  groups, 
X2=(2,N=102)= 1.665, p= 0.44 suggesting the UW treatment was equally acceptable 
as  TAU.  Clinical  outcomes  showed  a  reduction  in  worry  and  anxiety  in  both 
conditions but with TAU reporting larger gains. There was no significant difference 
in post-treatment scores between UW and TAU. Conclusions: The findings of the 
current evidence suggests that there is a clinical need for an LI intervention that 
focuses  on  addressing  worry  and  GAD  symptoms  within  primary  care  services. 
Findings also indicate that an intervention adapted from the current HI theory can 
be  delivered  by  PWPs  in  routine  practice  but  requires  further  development  and 
refinement.  
   84 
1. Introduction 
Generalised anxiety disorder (GAD) is one of the most frequently occurring 
psychological  disorders,  affecting  an  estimated  8.9  million  people  in  Europe  per 
year (Lieb, Becker, & Altamura, 2005, Wittchen, 2002). GAD is characterised by 
excessive and uncontrollable worry about everyday events. Individuals may also 
experience  somatic  symptoms  such  as:  increased  muscle  tension,  fatigue, 
disrupted sleep, impaired concentration and increased irritability (DSM-IV, 1994). 
Epidemiological studies suggest that symptoms adopt a waxing and waning profile, 
with the severity of GAD symptoms increasing in response  to life stressors, and 
episodes of the disorder commonly persisting for over 10 years (Kessler, Keller and 
Wittchen, 2001). GAD is therefore considered to be a pervasive anxiety disorder, 
with symptoms that are chronic and unremitting in nature (Tyrer & Baldwin, 2006; 
Yonkers et al., 2000). Those who suffer with GAD are reported to experience a 
significantly diminished quality of life, reduced work productivity, and impaired social 
functioning (NICE, 2011). They also constitute a patient group that is highly costly to 
health services as they are more likely to make frequent medical appointments and 
undergo diagnostic testing (Massion, Warshaw, & Keller, 1993). The cost and level 
of  disability  associated  with  GAD  is  reported  to  be  comparable  with  that  of 
depression (Kessler, 2000). 
  Despite being the most common anxiety disorder that presents in primary 
care, accounting for 5% of primary care consultations GAD is under-recognised by 
General  Practitioners  (GPs)  and  undertreated  (NICE,  2011).  It  is  estimated  that 
recognition rates by GPs and primary care practitioners are 34.4% for pure GAD 
and 43% for GAD when it is comorbid with depression (Wittchen & Jacobi, 2005). 
The  current  poor recognition  rates of  GAD  in primary  care  settings  are  likely  to 
occur for several reasons.  A major contributor to the poor recognition of GAD is the 
diagnostic  uncertainty  of  GAD.  There  has  been  substantial  debate  concerning 
whether GAD is an independent anxiety disorder or a component of major mood   85 
disorder  (MDD)  (Mennin,  Heimber,  Fresco  &  Ritter,  2008).  Both GAD and  MDD 
share  common  symptoms  of  fatigue,  restlessness,  impaired  concentration  and 
disturbed sleep (Zbonzienk et al., 2012). However, what differentiates GAD from 
MDD  is  the  presence  of  excessive  and  uncontrolled  worry  (Ladoucer,  Blasi, 
Freeston  &  Dugas,  1998).  Given  the  often  diffuse  picture  of  somatic  symptoms 
reported by GAD sufferers in the consulting room, GPs may more readily attribute 
the pattern of symptoms to a general malaise and subsequently neglect to explore 
the role of uncontrolled worry or anxiety (Arroll & Kendrick, 2009). Therefore, it is 
possible  that GPs more  readily  diagnose  depressive  disorders  while  the  anxiety 
component remains undetected. The challenge in the accurate recognition of GAD 
has significant implications for individuals’ access to evidence-based treatment. It is 
estimated that only one in four individuals in Europe with mental health disorders 
receive  professional  support  and  only  10%  of  those  are  offered  any  form  of 
treatment (Wittchen, Jacobi & Rhem, 2011). Individuals who receive treatment are 
more likely to be offered medication, rather than psychological interventions such as 
cognitive behavioural therapy (CBT) (Stein et al., 2004). It can be argued that due to 
the high rate of under detection this figure is likely to be inflated in the case of GAD 
and this represents a group within society with a large unmet treatment need and 
high health costs. 
  In an attempt to address the significant unmet treatment needs associated 
with common anxiety and depression disorders, the UK government has provided 
unprecedented  investment  in  NHS  primary  care  mental  health  services  with  the 
Improving Access to Psychological Therapies (IAPT) program. The IAPT initiative 
sought to provide nationwide access to evidence-based psychological therapies that 
are recommended by National Institute of Clinical Excellence (NICE) (Department of 
Health, 2011). The IAPT service model adheres to a stepped care approach where 
the level of intervention is determined by the severity of reported symptoms, with 
the least restrictive and lowest burden treatment being initially offered to the patient   86 
(Sobell & Sobell, 2000). In order to effectively provide treatment for large numbers 
of individuals the IAPT model provides both Low Intensity (LI) and High Intensity 
(HI) psychological treatments. Approximately three quarters of individuals accessing 
IAPT services receive treatment at the LI treatment level.   
  HI psychological treatments within IAPT focus on the provision of CBT and 
are  delivered  by  CBT  therapists  or  other  appropriately  trained  staff.  HI  CBT 
interventions  are  derived  from  cognitive  behavioural  models  of  anxiety  disorders 
and are discrete, time-limited, highly structured interventions, which often follow a 
clear treatment protocol. The collaborative intervention identifies the links between 
thoughts, feelings and behaviours and their link to symptoms or problem areas for 
the individual. The interventions focus on learning coping skills to target problem 
behaviours, beliefs or thoughts. HI therapies are usually delivered face-to-face and 
consist of 12 to 15 weekly sessions, which are one hour in duration (NICE, 2011).  
  In contrast LI psychological therapies are shorter in duration, less resource 
intensive and consist of a smaller number of sessions, typically four to six, and are 
20  to  30  minutes  in  duration.  LI  interventions  typically  involve  less  face-to-face 
contact and are delivered by trained practitioners who may not have a formal health 
professional  or  HI  CBT  qualification,  such  as  graduate  mental  health  workers 
(GMHWs)  or  Psychological  Wellbeing  Practitioners  (PWPs).  The  style  of  LI 
treatment  approaches  differs  markedly  from  the  traditional  HI  formal  therapy 
interventions. The focus for the LI practitioner is to provide a coaching role and to 
support the individual to independently apply CBT techniques using written self-help 
material,  computer  delivered  CBT  (cCBT)  or  through  the  facilitation  of  psycho-
educational groups (Bennet-Levy et al., 2010).  
  HI CBT interventions for GAD have changed substantially over the last 20 
years,  are  well  defined  and  have  a  clear  theoretical  framework  from  which 
treatments have been developed. GAD CBT treatments can be categorised into first 
wave interventions, which focus on addressing unhelpful thinking styles including   87 
the view of the self as inadequate and unable to cope, avoidance and address the 
consequences  of  worry  rather  than  the  process  of  worry  itself  (Beck  &  Emery, 
1985). Second wave CBT models seek to address the process of worry (Dugas, 
Gagon,  Ladoucer  &  Freeston,  1998;  Dugas  &  Robichaud,  2007;  Wells,  1999). 
These CBT approaches conceptualise worry as a coping strategy in response to 
external events or non-cognitive internal states that are perceived as threatening. 
These recent models posit that worry is maintained by a combination of positive and 
negative beliefs about worry itself and this leads to the individual feeling unable to 
employ  problem-solving  skills  in  relation  to  practical  problems.  These  models  of 
GAD suggest that individuals experience feelings and situations of uncertainty as 
threatening,  intolerable,  catastrophic  and  to  be  avoided.  The  second  wave  CBT 
approaches  seek  to  address  emotional  and  behavioural  avoidance,  educate 
individuals about the affects and physical symptoms of worry, increase confidence 
in  problem  solving  abilities,  modify  unhelpful  beliefs  about  worry  and  increase 
tolerance  to  uncertainty.    Numerous  systematic  reviews  of  HI  psychological 
treatments for GAD have concluded that CBT is an effective treatment (Borkovec & 
Ruscio, 2001; Hunot et al., 2007; NICE, 2011, Hanrahan, et al., 2012). In the most 
recent review of psychological therapy for GAD, Cujipers and colleagues (2014) 
reported a large treatment effect for CBT in comparison to waitlist controls (Hedges’ 
g:  0.90,  CI;  0.75-1.05) and  that  the  number  of  needed  to  treat for  a successful 
outcome using a CBT treatment was two. This suggests that CBT is an effective 
psychological intervention for GAD.  
  In contrast the evidence-base for LI interventions for anxiety and depression 
is  mixed.  LI  interventions  for  depression  have  an  established  evidence-base  of 
effectiveness  (Gellatly  et  al.,  2007)  and  are  primarily  based  on  current  effective 
treatments,  which  include  psycho-education,  behavioural  activation,  activity 
scheduling, cognitive restructuring and problem solving (Bennett-Levy et al., 2010). 
For example, these interventions show a clear link to the contemporary literature in   88 
the behavioural treatment of depression (Jacobson et al., 1996, 2001). In contrast, 
LI  anxiety  interventions  have  sought  to  apply  a  generic  approach  to  anxiety 
disorders and consist of a combination of psycho-education, cognitive restructuring, 
graded  exposure  and  de-arousal  strategies  without  a  clear  tailoring  to  specific 
anxiety presentations (White, 1995; White, 2000; Williams, 2003; Williams, 2010). 
This approach within LI interventions appears to be at significant odds with the well-
developed HI intensity disorder specific treatments. Currently the disorder specific 
approaches to anxiety have so far failed to be successfully integrated into the canon 
of LI interventions. Current LI anxiety interventions adopt generic first wave CBT 
approaches  in  the  treatment  of  GAD.  These  interventions  focus  on  worry  as  a 
consequence of anxiety and do not address worry as a response to uncertainty or 
as a process that maintains anxiety. Therefore the currently utilised LI treatments 
for GAD do not reflect current theoretical understandings of the disorder or current 
treatment approaches for GAD. This gap in the development of anxiety disorder 
specific LI interventions has led to a position where current LI interventions are less 
clearly defined, generic and as a consequence the evidence of effectiveness is not 
as well established (Titov, Andrews & McEvoy, 2010). This perspective is further 
supported by a systematic review of the literature of LI treatment for GAD that was 
conducted  as  part  of  the  recent  NICE  (2011)  guideline  for  the  psychological 
treatment  of  GAD.  The  review  concluded  that  the  evidence  was  small  and 
heterogeneous  and  it  was  therefore  difficult  to  make  firm  conclusions  about  the 
effectiveness of LI interventions for GAD.  
  LI anxiety interventions are in need of development to bring treatments for 
anxiety  disorders  in  line  with  HI  disorder  specific  models  of  treatment.  The 
developing  of  a  disorder  specific  LI  intervention  for  excessive  worry  and  GAD 
requires  a  systematic  approach  that  addresses  the  core  maintaining  processes 
within GAD and leads to behavioural change. Behavioural Change Theory (BCT) 
(Michie, Van Stralen & West, 2011; Michie & Johnston, 2012) offers a systematic   89 
approach to intervention design that is appropriate  to the therapeutic aims of LI 
interventions.  At  the  heart  of  BCT  is  the  COM-B  model,  which  describes  a 
behavioural  system  that  can  lead  to  change.  The  system  comprises  of  three 
elements: capability, defined as the individual’s knowledge and skills that make the 
behaviour possible; opportunity, which refers to factors outside the individual that 
prompt  behaviour  and  motivation,  which  is  defined  as  decision  making  and 
regulation of behaviour.  Identifying interventions and coherently integrating these 
elements within an overall treatment plan can increase an individual’s capacity to 
change behaviour and subsequently reduce distress. In utilising the COM-B model 
approach  to  psychological  interventions  by  identifying  distinct  exercises  or 
techniques,  which  address  and increase  capacity, motivation and opportunity for 
alternative behaviours, GAD symptoms can be reduced and unhelpful responses to 
worry and anxiety can be changed and maintained.  
  The focus of this study was to seek to (a) develop a coherent intervention for 
excessive worry and GAD symptoms, which was grounded in current conceptual 
models,  which  could  be  delivered  by  PWPs  at  an  LI  treatment  level  and  was 
acceptable to patients. The intervention development initially focused on identifying 
the current conceptual models (Behar et al., 2009) and identifying key processes in 
worry and GAD. The key areas identified were uncertainty (Dugas et al., 1998), 
behavioural avoidance and emotional avoidance (Borkovec & Ruscio, 2001), poor 
problem solving (Dugas et al., 1998), meta-cognitive beliefs and cognitive thought 
suppression  (Wells,  1999).  Following  the  identification  of  the  key  processes  a 
review of existing LI and HI treatment material and protocols was undertaken and 
interventions  were  dismantled  into  discrete  elements  of  psycho-education, 
behavioural,  relaxation,  cognitive  and  worry  specific  strategies.  These  elements 
were  further  divided  in  to  specific  tools  and  exercises,  such  as  goal  setting, 
cognitive restructuring, and exposure (see Appendix 3).  After this phase the COM-
B model was then applied in the selection of elements with a specific emphasis on   90 
behavioural change that increases the capability, motivation and opportunity in the 
key areas identified which were suitable for delivery in an LI treatment format.  The 
resulting intervention consisted of six modules that addressed psycho-education of 
worry,  overcoming  intolerance  of  uncertainty,  overcoming  avoidance,  practical 
approaches to responding to worry, problem solving and relapse prevention. The 
modules  had  a  clear  focus  on  supporting  individuals  to  change  behaviour  in 
response  to  worry,  anxiety  and  uncertainty  and  did  not  address  cognitive 
approaches to GAD, such as challenging meta-cognitions about worry as this was 
considered to not be suitable for LI treatment.   
  The current study sought to examine whether this approach to intervention 
development  could  be  successfully  applied  to  develop  a  GAD  specific  LI 
intervention. The study sought to test whether LI workers could feasibly deliver such 
an intervention in a routine IAPT setting and to establish whether the intervention 
was acceptable to patients and led to a reduction in self-reported symptoms. The 
study  also  considered  how  the  outcomes  of  a  GAD  specific  LI  intervention 
compared with the existing generic anxiety based LI interventions currently used in 
usual treatment. The testing of the intervention sought to answer the following four 
questions: 
1)  Is  it  feasible  to  develop  a  GAD  specific  LI  Intervention  informed  by  the 
current theory and deliver it with PWPs in routine practice? 
2)  Is the intervention practical and acceptable to individuals who are treated 
with the GAD specific intervention at LI level? 
3)  Is  the  GAD  specific  intervention  comparable  to  current  generic  LI 
interventions for anxiety that are applied to those with a GAD presentation? 
4)  Is the GAD specific intervention clinically effective in reducing anxiety and 
worry and is this change reliable and clinically significant? 
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2. Method 
2.1 Participants 
   The study sought to recruit 40 individuals into the trial, however due to time 
constraints  24  participants  were  recruited.  Participants  were  individuals  seeking 
help from two London primary care IAPT services between January 2014 and April 
2014. Both services were provided by a large NHS Foundation Trust.  
  Participants were eligible for this study if they were (a) aged 18 years old or 
above; (b) presented with excessive worry and anxiety as a primary problem; (c) 
presented  with  mild-to-moderate  symptoms  of  anxiety  or  general  anxiety  as 
indicated  by  a  score  greater  than  4  on  the  Generalised  Anxiety  Disorder 
questionnaire (Lowe et al., 2008); (d) were deemed suitable by IAPT staff for a LI 
intervention; (e) had consented on the referral to be approached for research and (f) 
had  agreed  to  randomisation.  Participants  were  excluded  from  the  study  if  they 
presented with a primary problem of generalised anxiety or worry which was of a 
severity that required High Intensity (HI) treatment; a primary presenting problem of 
depression,  obsessive-compulsive  disorder  (OCD);  post-traumatic  stress  disorder 
(PTSD); social phobia and panic disorder; current use of anti-psychotic medication; 
currently receiving psychology treatment; alcohol or drugs dependency, cognitive 
impairment  or  declined  randomisation.  Provisional  diagnosis  was  determined  by 
information provided by an initial screening interview conducted by a PWP, which 
incorporated  the  IAPT  (2011)  screening  prompts,  and  patient’s  self-reported 
questionnaires.  A  qualified  clinician  prior  to  the  offer  of  treatment  confirmed 
provisional diagnosis. 
2.2 Ethics 
Ethical approval was granted by the NHS Heath Research Authority, Brent 
Research  Ethics  Committee  (Appendix  3),  the  Research  and  Development 
department of the local trust where the study was conducted (Appendix 4) and the   92 
Joint  Research  Office  at  University  College  London  who  insured  the  study 
(Appendix 5). 
2.3 Procedure 
Participants  were  recruited  from  January  2014  and  April  2014,  from  two 
primary  care  IAPT  Services,  both  services  were  provided  by  a  large  NHS 
Foundation Trust. The study adopted a randomised assignment repeated measures 
pre-post test design using individual participants as randomisation units. 
  Participants  who  were  suitable  for  the  study  were  identified  by  eight 
Psychological Wellbeing Practitioners (PWPs) during the service’s standard initial 
triage  assessment.  If  individuals  met  the  study’s  inclusion  criteria  and  had 
consented to be approached for research they were approached by the PWP to 
participate  in  the  study.  Participants  received  a  participant  information  sheet 
(Appendix 6) and completed a consent form (Appendix 7). All PWPs approaching 
individuals had received training from the intervention’s developer in regards to the 
study and the intervention. If participants consented to participate in the study they 
completed  baseline  measures  and  were  randomised  to  receive  either  the  GAD 
specific intervention (UW) or the IAPT services standard generic LI treatment as 
usual  (TAU).  At  each  treatment  contact  participants  completed  the  primary  and 
secondary outcome measures. Data was collected using the IAPT service Patient 
Care  Management  Information  System  (PC-MIS)  (http://www.pc-mis.co.uk). 
Supervision  was  provided  by  PWP  clinical  supervisors,  additionally  the 
intervention’s developer provided supervision in two three-hour group supervision 
sessions and via email. 
2.4 Randomisation 
An  independent  researcher  (CW)  not  involved  with  the  research  project 
created  the  study  randomisation  sequence.  The  sequence  was  generated  using 
Stata/IC  Version  12.1 for  Mac using the ralloc command with random permuted 
blocks  of  varying  size,  stratified  by  sex  and  person  doing  the  allocation.  An   93 
independent Trainee Clinical psychologist (JB) allocated participants to treatment 
conditions  via  email.  The  author  was  blind  to  the  randomisation  sequence  and 
subsequent  allocation  of  participants  until  the  data  analysis  of groups had  been 
completed. 
2.5 Interventions 
2.5.1 Treatment as Usual 
The IAPT services routine LI treatments consisted of four to six sessions of 
guided self-help, sessions were 20 to 30 minutes in duration and treatment followed 
the  service’s  “stress  and  worry  booklet”  and  the  service’s  delivery  protocol. The 
stress and worry booklet contained generic CBT approaches for managing stress 
such  as  time  management,  balancing  demands  and  relaxation  techniques.  The 
stress and worry booklet’s focus on worry was limited to the worry tree, which is a 
tool to identify if worry is actionable, and worry time, which is a technique to attempt 
to limit and contain worry to a fixed period during the day.  
2.5.2 Understanding Worry (UW) Intervention 
The UW intervention consisted of six workbooks, each addressing a different 
treatment area for GAD. The workbook’s content focused on applying tools and 
management  strategies  that  facilitated  behavioural  change  and  developing 
alternative  behavioural  responses  to  worry.  The  intervention  did  not  address 
cognitive aspects of GAD such as beliefs about worry as this was considered to be 
more appropriate for intervention at HI level of treatment. The workbooks followed a 
clear structure, which included: psycho-education of the main topic of the module, a 
vignette example and a tool or tools to address the area. Modules also included a 
review  of  the  learning  and  an  assignment  to  complete  between  the  support 
sessions. Participants were provided with workbooks prior to support sessions with 
a PWP, with the explicit emphasis that they complete the booklets before support 
sessions. A summary of the content of each module is described in Table 1.   94 
  Participants  were  also  offered  between  four  to  six  structured  support 
sessions with a PWP. Support sessions were between 25 to 45 minutes in duration 
and  followed  a  clear  session  outline,  which  is  summarised  in  Table  2.  Support 
sessions focused on the reviewing of material and learning for a single module, 
supporting the participant in applying new learning, identifying and collaboratively 
solving any barriers, identifying how the learning would lead to behavioural change, 
agreeing  the  between  session  task  and  agreeing  the  next  workbook  to  be 
completed. The PWP also provided a standard text prompt between sessions to 
encourage participants to adhere to between session tasks and to complete the 
next module’s material.   
  In relation to the workbooks participants were required to compete two core 
workbooks,  Understanding Worry,  which  focused on psycho-education for  worry, 
goal setting and the identification of which workbooks were most relevant to the 
participant.  The  Planning  for  the  Future  workbook  focused  on  consolidating  the 
learning over the intervention, identifying high risk situations and relapse prevention 
planning. The remaining four modules were selected collaboratively between the 
participant  and  PWP  to  allow  the  treatment  to  be  tailored  to  the  need  of  the 
individual and to allow the individual to focus on the areas that were causing most 
difficulty.    95 
Table 1. Outline of Understanding Worry intervention workbooks 
 
Workbook  Description 
Understanding Worry  Psycho-education  of  worry  and  anxiety,  introduction  to  the 
adapted IoU model of GAD, identifying motivation to change, goal 
setting,  identification  of  workbooks  to  complete  in  subsequent 
support sessions. 
 
Understanding 
Intolerance of 
Uncertainty 
Psycho-education of intolerance to uncertainty, the impact on 
worries and unhelpful ways of managing uncertainty, building 
tolerance to uncertainty using behavioural exposure. 
 
Understanding 
Avoidance 
Psycho-education of behavioural and emotional avoidance, the 
impact on worries and unhelpful ways of managing avoidance, 
building tolerance to avoidance using behavioural exposure and 
imaginal exposure. 
 
Practical Ways to Deal 
with Worry 
Psycho-education identifying practical and hypothetical worry, 
strategies to manage with hypothetical worry, relaxation, 
attentional training and worry time.  
 
Practical Problem 
Solving 
Psycho-education of how to recognise problems and common 
unhelpful approaches to problem solving, problem solving in 
seven stages. 
 
What have I Learnt? 
Looking Towards the 
Future 
Review of learning from all workbooks. The workbook prompts 
the individual to identify previous beliefs and behaviours and how 
these have changed. The workbook also identifies high risk 
situations of relapse and facilitates the development of a relapse 
prevention plan.  
 
 
Table 2: Support session structure outline 
Session Element  Description 
 
Agenda Setting 
 
Collection  of  measures,  review  of  assignment;  review  of  new 
material key areas and between session assignment setting. 
 
Review Between 
Session Assignment 
Discussion of what the individual learnt about their worry, how this 
differed from expectations, if there were any difficulties and how they 
will apply the new learning in the future. 
 
Review of New 
Material 
What  is  the  individual’s  understanding  of  the  psycho-educational 
material and how does this fit with their experience of worry? What is 
the  individual’s  understanding  of  the  rationale  of  the  tool  that 
provides  an  alternative  behaviour?  Can  the  individual  apply  the 
learning to address their own worry? 
 
Review  What learning will the individual take away from the workbook and 
session?  What  will  they  do  differently  as  a  result  of  their  new 
understanding?  
 
Between Session 
Assignment 
Agree between session assignment using SMART goal settings and 
address how this will contribute to moving towards identified goals of 
the individual.    96 
2.6 Outcome Measures 
The  primary  outcome  measure  was  the  Penn  State Worry  Questionnaire 
(PSWQ) (Meyer, Miller, Metzger & Borkovec, 1990). The PSWQ is a 16 item self-
report questionnaire; psychometric data shows that it is a reliable and valid measure 
of  worry  in  GAD  and  is  able  to  distinguish  those  with  GAD  from  other  anxiety 
disorders (Meyer et al., 1990).  It is reported to have high consistency and temporal 
stability (Brown & Barlow, 1992; Fresco et al., 2003). 
  The  secondary  measures  consisted  of the  IAPT minimum  dataset (IAPT, 
2011b): 
  The  nine-item  Patient  Health  Questionnarie  (PHQ-9)  (Kroenke,  Spitzer  & 
Williams, 2001). The PHQ-9 measures symptoms of depression based on the DSM-
IV criteria for major depressive disorder. A score of 10 on the PHQ-9 has been 
identified as threshold for the identification of DSM-IV depression. The PHQ-9 has 
high internal consistency with a Cronbach’s alpha of 0.89 (Kroneke et al., 2001). 
The PHQ-9 has demonstrated validity for measuring depression (Kroneke, et al., 
2001) and has been validated in a UK depressed population (Cameron, Crawford, 
Lawton & Reid, 2008).  
  The  seven-item  Generalized  Anxiety  Disorder  Questionnaire  (GAD-7) 
(Spitzer  Kroneke,  Williams  &  Lowe,  2006)  is  based  on  the  DSM-IV  diagnostic 
criteria for GAD. The GAD-7 questionnaire has been reported to have good internal 
consistency; Cronbach’s alpha is 0.92  (Lowe et al., 2008). However, the GAD-7 
does not have good discriminating validity, showing sensitivity to both social phobia 
and  panic  disorder  and  has  been  increasingly  used  in  research  as  a  generic 
measure of anxiety and convergence with other measures of anxiety (Clarke et al., 
2009).  
The five-item Work and Social Adjustment Scale (W&SAS) (Mundt, Marks, 
Shear & Greist, 2002) measures the perceived impairment of functioning in relation 
to the problem experienced over five domains (work, home management, social   97 
leisure activities, private leisure activities and family and relationships). Mundt et al. 
(2002) suggests that a score greater than 18 indicates moderately-severe to severe 
functional  impairment,  scores  between  eight  to  18  indicate  mild-to-moderate 
impairment in functioning. A score of seven and below indicates a sub-clinical level 
of impairment.  
  The eight-item Client Satisfaction Questionnaire (CSQ-8) (Attikson & Zwick, 
2003)  enquires  about  the  opinions  of  respondents  and  their  conclusions  of  the 
services they are receiving or have received. Response options are based on a 
four-point  scale  ranging  from  “quiet  dissatisfied”  to  “very  satisfied”.  Studies  of 
reliability of the CSQ-8 have indicated a coefficient alpha, ranging from 0.83 to 0.93 
(Attkisson, & Greenfield, 2004).  
2.7 Data Analysis 
2.7.1 Indicators of Feasibility and Acceptability 
To evaluate feasibility and acceptability a CONSORT diagram was created 
to provide a graphical summary of patient flow from initial screening to the end of 
the  patient’s  participation  in  the  study.  Summaries  of  the  number  of  sessions 
attended, dropout from each intervention, and withdrawal of consent were included. 
  Acceptability  was  evaluated  by  the  reported  patient  satisfaction  from  the 
CSQ-8  measure  for  each  intervention.  Satisfaction  outcomes  were  compared 
between  interventions  to  assess  if  there  was  a  statistically  significant  difference 
between patient satisfaction between the two interventions.  
2.7.1.2 Primary and Secondary Behavioural Outcomes 
Behavioural outcome measures pre- and post-treatment were compared for 
each  intervention  separately  and  between  interventions.  The  data  for  each 
intervention was assessed for clinically significant, reliable change and against the 
IAPT recovery benchmark (IAPT, 2014). Clinically significant and reliable change 
was  compared  between  interventions.    Effect  sizes  were  calculated  for  pre-post 
treatment  effects  and  compared  against  previously  reported  outcomes  for  this   98 
patient group. Potential inflation of type II error was controlled for through the use of 
appropriate corrections for multiple comparisons.  
  As a result of delays in the initiation of recruitment and time constraints of 
the study data collection, the majority of patients were still receiving treatment by 
the data collection deadline, and data up to session four was available.  To address 
this Mixed Methods Linear Modelling (MMLM) was used to create a model of best fit 
for  the  data  of  the  22  participants  eligible  for  analysis.    MMLM  is  a  statistical 
approach, which can be applied to small, and unequal and incomplete data sets, 
which use repeated measures, and provides a tool to estimate fixed and random 
effects  using  all  observation  available  in  the  dataset.  MMLM  uses  likelihood 
algorithms (REML or ML) for estimation and creates a “complete” data set based on 
a hypothetical scenario, in which there is no missing observation in the dependant 
variable. A “complete” data set is generated by augmenting observed values on the 
dependant  variable  with  expected  values  of  the  sum  of  squares  and  sum  of 
products of the unobserved random effects and residuals (West, Welch & Galecki, 
2007). MMLM analysis was conducted using SPSS version 22 and models of best 
fit  were  determined  by  using  a  likelihood  ratio  test  (LRT)  to  select  the  most 
parsimonious  model.  The  significance  of  the  LRT  is  determined  by  use  of  chi-
squared distribution and appropriate degrees of freedom. If the difference is large 
the more complex model is favoured, if the difference is small the null hypothesis 
model or nested model is favoured. The model of best fit was then used to generate 
predicated scores for missing values in a modified Intent-to-treat (ITT) analysis for 
patients who had not completed four treatment sessions. ITT was considered in 
regards to predicted change scores. 
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3. Results 
3.1 Patient Flow 
  Four hundred and twenty four individuals were screened for suitability for the 
study between 1st January 2014 and 10th April 2014 via the IAPT services initial 
triage assessment. Of the individuals screened 46 met the study inclusion criteria 
and were approached to participate in the study and 24 consented to participate 
and were randomly assigned to either the Understanding Worry (UW) or Treatment 
as Usual (TAU). Two individuals withdrew consent after randomisation and did not 
complete  pre-treatment  measures  and  were  not  eligible  for  analysis.  Three 
individuals  did  not  start  treatment  but  completed  pre-treatment measures.  Three 
participants dropped out of treatment and 22 participants were eligible for analysis.  
Figure 1 summarises the study patient flow.     
3.2 Demographic Data 
  Table  3  summarises  the  available  demographic  data  of  patients  who 
participated in the study as an overall sample and by allocated treatment arm. In the 
overall sample 77.3% were female and were referred to IAPT via their GP. The 
majority  of  the  sample  was  in  of  employment  (59.1%)  and  were  white  British 
(59.1%).  The  most  common  provisional  diagnoses  at  assessment  were  GAD 
(59.1%), moderate depression (18.2%), mixed anxiety and depression (13.6%) and 
recurrent depression (4.5%). Post-randomisation there was a mean difference of 
5.28  years  between  the  UW  and  TAU  groups.  The  main  reason  for  difference 
between the two groups was that five of the participants in the UW condition were 
under  24  years  of  age  and  half  of  the  group  were  over  30  years  old  with  two 
individuals above the age of 50.  There was very little difference between conditions 
in relation to primary diagnosis, employment and ethnicity.  
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Figure 1: Consort diagram 
 424 Patients screened for study at assessment (01/01/2014- 10/04/2014) 
45 Patients suitable for inclusion 
24 Patients consented to randomisation 
 
Not Suitable (n= 375) 
  HI assessment (n=81) 
  Signposted to counseling (n=63) 
  Signposted to drugs and alcohol service (n=11) 
  Signposted to specialist services (n=12) 
  Signposted to family services (n=2) 
  Signposted to employment services (n=5) 
  Signposted to other community service (n=22) 
  Signpost to Psychotherapy (n=6) 
  LI Depression treatment (n=92) 
  LI Stress Treatment (n=20) 
  LI Panic Treatment (n=14) 
  LI Sleep Treatment (n=10) 
  Other LI Treatment (n=10) 
  Declined service (n=15) 
  Not Suitable (n =11) 
  Reason not reported (n=4) 
 
 
TAU  (n= 14) 
 
 
Understanding 
Worry  
  (n= 10) 
Eligible for analysis (completed baseline) 
n=13 
 
Did not start treatment (n=2) 
Completed planned treatment (n= 3) 
Dropped out session 1 (n= 1) 
Stepped Up (n=1) 
In treatment (n=6) 
21 Patients declined consent to the study 
  Stepped up to HI (n=2) 
  Requested workshop (n=3) 
  Request depression treatment (n=2) 
  Requested cCBT (n=1) 
  Requested community linking (n=1) 
  Requested standard treatment (n=2) 
  Drop out after initial appointment (n=1) 
  Requested a group intervention (n=1) 
  Reason not stated (n=9) 
Withdrew consent after 
randomisation (n=1) 
 
Withdrew consent after 
randomisation (n=1) 
 
Eligible for analysis (completed 
baseline) n= 9 
  
Did not start treatment (n=1) 
Completed treatment (n=1) 
Dropped out after session 1 (n=2) 
Dropped out session 2 (n=1) 
Dropped out at session 3 (n=1) 
Stepped up (n=1) 
In treatment (n=2)   101 
Table 3: Demographic description of participants  
    Overall 
Sample 
  TAU  Understanding 
Worry 
 
Variable  Sub-variable  N  %  n  %  n  % 
 
Gender 
 
Male 
 
 
5 
 
22.7 
 
4 
 
30.8 
 
1 
 
11.1 
  Female  17  77.3  9  69.2  8  88.9 
 
Age  Mean Age 
(SD) 
 
31 
(10.01) 
 
  28.85 
(7.09)  
  34.11 
(13.18) 
 
  Range 
 
19-59    19-44    22-59   
Referral 
Source 
GP  17  77.3  11  84.6  6  66.7 
  Self  5  22.7  2  15.4 
 
3  33.3 
Provisional 
Primary 
Diagnosis 
GAD  13  59.1  8  61.5  5  55.6 
  Mixed Anxiety 
& Depression 
 
3  13.6  1  7.7  2  22.2 
  Moderate 
Depression 
 
4  18.2  2  15.4  2  22.2 
  Recurrent 
Depression 
 
1  4.5  1  7.7  -  - 
  Not Reported  1  4.5  1 
 
7.7  -  - 
Medication 
Use  
Yes  7  31.8  3  23.1  4  44.6 
  No  15  68.2  10 
 
76.9  5  55.6 
Employment 
Status 
Employed 
 
13  59.1  8  65.1  5  55.6 
  Unemployed 
 
6  27.3  3  23.1  3  33.3 
  Receiving 
Benefits 
 
1  4.5  1  7.7  -  - 
  Homemaker or 
Carer 
 
2  9.1  1  7.7  1  11.1 
Ethnicity  White British  14  63.6  7  53.8  7  77.8 
 
  White Other  4  18.1  4  30.8  -  - 
 
  Asian 
 
1  4.5  1  7.7  -  - 
  Mixed Other  3  12.6  1  7.7  2  22.2 
Note: SD: Standard Deviation 
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3.3 IAPT Caseness Pre-treatment 
   Pre-treatment every patient scored eight or above on the GAD-7 meeting 
the IAPT criteria (IAPT, 2011) for clinical caseness; 14 patients (63.6%) scored 10 
or above on the PHQ-9 meeting clinical caseness and 14 patients (63.6%) met the 
criteria of IAPT caseness on both PHQ-9 and GAD-7 measures.  All patients who 
completed baseline measures scored above 44 on the PSWQ, indicating substantial 
levels of worry and what would be seen as above caseness of GAD. 
3.4.1 Indicators of Feasibility 
3.4.1.1 Recognition and Detection 
  Over a 15-week period PWPs identified 10.8% of referrals as experiencing 
excessive worry and anxiety as a primary problem. This represented the second 
largest patient group after low mood, indicating that there is an adequate level of 
clinical need to justify a specific LI intervention for worry and GAD. However, it is 
likely  that  the  number  of  referrals  identified  over  this  time  period  is  an 
underestimation of individuals who experience worry or GAD as a primary problem.  
Pre-treatment PSWQ scores in the overall sample were high (M= 69.55, SD= 6.10), 
with all individuals in the trial reporting an initial PSWQ score above 60.  
3.5 Behavioural Outcome Measures  
Due to the small sample, as a result of data collection time constraints, all 
available session data for patients who attended a minimum of two clinical contacts 
were included in the analysis using a Mixed Model Linear Modeling (MMLM).  Table 
4 summarises the pre-treatment and up to the last recorded clinical contact for all 
patients with a minimum of two clinical contacts. Table 5 summarises the adjusted 
means and change score for imputed ITT data up to session four. ITT data will be 
considered in relation to the predicted change scores of each treatment arm. 
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MMLM,  using  all  available  session  data,  indicated  that  there  was  no 
significant effect of treatment group on self-reported worry, F (1,22)= 0.91, p= 0.35 
but a significant effect of time, F (4,38)= 3.740, p= 0.01. Within group effect sizes 
were 0.38 (95% CI: -0.41 to 1.14) and 0.72 (95% CI: -0.09 to 1.49) for UW and TAU 
respectively; there was also a medium between group effect size (d= 0.56, 95% CI: 
-0.32 to 1.41). ITT analysis based on the predicted values from the MMLM model 
predicted reductions in PSWQ score at session four of 12.24 points (95% CI: 8.06 
to 16.42) in the TAU condition and 7.68 points (95% CI: 3.39 to 11.97) in the UW 
condition.  The  difference  between  treatment  conditions  (MD=  4.56)  was  not 
significant, t (20)= 1.64, p= 0.12.  
  Based on the reliable change index (Jacobson & Truax, 1991) previously 
reported  by  Fisher  (2006),  a  change  of  seven  points  on  the  PSWQ  constitutes 
reliable  change  in  reported  symptoms.  Recovery  was  defined  as  meeting  the 
reliable change criteria in addition to reporting a score below the measures clinical 
cut-off  of  45.    Two  patients  (22.2%)  from  the  UW  condition  reported  a  reliable 
improvement in worry. Whereas in the TAU condition five patients (38.5%) reported 
reliable improvements in worry and one patient (7%) reported a reliable increase in 
worry. One patient in the TAU condition met the criteria for recovery.  
3.5.2 PHQ-9 
MMLM, using all available session data, indicated that there was no effect of 
treatment groups for self-reported symptoms of depression, F (1,22)= 0.06, p= 0.94 
or time, F (4,38)= 0.764, p= 0.55. Both within group effect sizes for both the TAU 
(d= 0.05, 95% CI: -0.81 to 0.72) and UW conditions (d= 0.19, (-0.74 to 1.11), there 
was also a small between group effect size (d =0.23, 95% CI: -0.63 to 1.07). ITT 
analysis predicted a change score at session of 2.17 (95% CI: -0.55 to 2.17) in TAU 
and  2.61  (95%  CI:  0.01  to  5.22)  in  the  UW  condition.  The  difference  between 
treatments (MD= -0.44) was not statistically significant, t(20)= -2.50, p= 0.81.   104 
At the last clinical contact one patient reported a reliable improvement in 
depressive symptoms and one patient reported a reliable deterioration in the UW 
condition. In the TAU condition, one patient reported a reliable deterioration. 
3.5.3 GAD-7  
MMLM,  using  all  available  session  data,  indicated  that  there  was  no 
significant effect of treatment group on self-reported symptoms of anxiety, F(1,22)= 
091, p= 0.35 but a significant effect of time, F(4,38) 3.740, p= 0.01. Within group 
effect sizes were 1.30 (95% CI: 0.23 to 2.24) and 0.88 (95% CI: 0.05 to 1.65) for 
Understanding Worry and TAU respectively, there was also small between group 
effect size (d= 0.20, 95% CI: 0.66 to 1.05). ITT analysis predicted a change score of 
7.87  (CI:  5.27  to  10.47)  for  TAU  and  6.57    (95%  CI:  3.75  to  9.39)  in  the  UW 
condition, the difference in predicted change scores  (MD= 1.31) between to the two 
treatments was not statistically significant, t (20)= 0.74, p= 0.47.  
Four patients (44.4%) in the UW condition achieved reliable reductions in 
anxiety  and  five  patients  (38.4%)  in  the  TAU  condition  reported  a  reliable 
improvement in TAU condition. 
3.5.4 WSAS  
MMLM  using  all  available  session  data  indicated  that  there  was  no 
significant  effect  of  treatment  groups  in  regards  to  functioning,  F(1,22)=  0.034, 
p=0.86 but a significant effect of time, F(4,31)= 2.87, p= 0.04. There was a medium 
within group effect size (d= 0.30, 95% CI: -0.48 to 1.07) for TAU condition and a 
medium between group treatment effect size (d= 0.34, 95% CI: -0.53 to 1.19).  The 
ITT model predicted a change score at session of four in the TAU condition of 3.86 
(95% CI: 0.57 to 7.15) and 2.34 (95% CI: -1.28 to 5.83) in the UW condition. A 
comparison of the difference in predicted change scores (MD= 1.51) indicated that 
there was no statistical difference between treatment conditions, t (20)= 0.66, p= 
0.50. No patients in either arm met the criteria for reliable clinical change.  
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Table 4: Outcome measures pre-treatment to last clinical contact: Means, standard 
deviations, confident intervals and effect sizes (Cohen’s d) for each group (N=22) 
 
Outcome 
Measure 
Group  Pre-
Treatment 
Last 
Clinical 
Contact 
Mean 
Change 
 
Within 
Group ES 
Between 
Group 
ES 
    Mean (SD)  Mean (SD)   (95% CI)  (95% CI)  (95% CI) 
PSWQ  TAU  69.00 
(5.77) 
62.00(12.43) 
 
7.00 
(1.12 to 
12.88) 
 
0.72 
(-0.09 to 
1.49) 
0.56 
(-0.32 to 
1.41) 
  UW  70.33 
(6.76) 
 
67.86 
(6.23) 
4.43 
(0.97 to 
7.78) 
 
0.38 
(-0.41 to 
1.14) 
 
PHQ-9  TAU  11.23 
(5.42) 
 
11.54 (7.56)  -0.31 
(-2.46 to 
1.85) 
  
-0.05 
(-0.81 to 
0.72) 
0.23 
(-0.63 to 
1.07) 
  UW  11.00 
(4.58) 
 
10.00 (5.48) 
 
0.14 
(-3.21 to 
3.50) 
 
0.19 
(-0.74 to 
1.11) 
 
GAD-7  TAU  15.31 
(4.27) 
 
10.31 
(6.81) 
5.00 
(1.95 to 
8.05) 
 
0.88 
(0.05 to 
1.65) 
0.20 
(-0.66 to 
1.05) 
  UW  13.67 
(3.46) 
 
9.14 
(3.53) 
4.71 
(0.49 to 
8.94) 
 
1.30 
(0.23 to 
2.24) 
 
W&SAS  TAU  16.62 
(7.07) 
14.31 
(8.16) 
 
2.31 
(-0.29 to 
4.80) 
 
0.30 
(-0.48 to 
1.07) 
0.34 
(-0.53 to 
1.19) 
  UW  17.00  
(9.95) 
16.96  
(7.03) 
0.57 
(-4.34 to 
3.20) 
0.01 
(-0.92 to 
0.93) 
 
 
Note. UW – Understanding Worry, TAU – Treatment as Usual, ES –Effect Size 
3.7 IAPT Recovery  
  Recovery  data  was  reviewed  for  all  individuals  who  attended  two  clinical 
contacts. IAPT recovery is defined as a pre-treatment score on the PHQ-9 above 
nine or a score on the GAD-7 above 7 and a post-treatment scope or below 10 on 
the PHQ-9 and below eight on the GAD-7 (Richards & Borglin, 2011). Using this 
criterion,  three  patients  (33.3%)  in  the  Understanding  Worry  condition  and  four 
patients (30.8%) in the TAU treatment met the criteria for recovery.    106 
 
 
Table 5: ITT Pre-treatment to Session 4: Adjusted Means, standard deviations, 
confident intervals and effect sizes (Cohen’s d) for each group (N=22) 
 
Outcome 
Measure 
Group  Pre-
Treatment 
Session 4  Adjusted 
Mean 
Change 
 
Within 
Group 
Adjusted 
ES 
Between 
Group 
Adjusted 
ES 
    Adjusted 
Mean (SD) 
Adjusted 
Mean (SD) 
 (95% CI)  (95% CI)  (95% CI) 
PSWQ  TAU  69.00 
(5.77) 
 
56.76 
(8.96) 
12.24 
(8.06 to 
16.42) 
 
1.62 
(0.69 to 
2.45) 
0.81 
(0.10 to 
1.66) 
  UW  70.33 
(6.76) 
62.65 
(3.48) 
 
7.68 
(3.39 to 
11.97) 
 
1.43 
(0.43 to 
2.39) 
 
 
PHQ-9  TAU  11.23 
(5.42) 
 
9.06 
(5.79) 
2.17 
(-0.55 to 
4.89) 
 
0.39 
(-0.40 to 
1.15) 
 
0.08 
(-0.77 to 
0.93) 
  UW  12.11 
(5.21) 
9.50 
(4.29) 
 
2.61 
(0.01 to 
5.22) 
 
0.55 
(-0.42 to 
1.46) 
 
GAD-7  TAU  15.31 
(4.28) 
7.44  
(4.76) 
 
7.87 
(5.27 to 
10.47) 
 
1.74 
(0.79 to 
2.58) 
0.09 
(-0.77 to 
0.93) 
  UW  13.67 
(3.46) 
 
7.10 
(2.33) 
6.57 
(3.75 to 
9.39) 
 
2.23 
(0.97 to 
3.28) 
 
W&SAS  TAU  16.62 
(7.07) 
12.75 
(6.18) 
 
3.86 
(0.57 -
7.15) 
 
0.58 
(-0.22 to 
1.35) 
0.32 
(-0.55 to 
1.16) 
  UW  17.00 
(6.94) 
14.65 
(5.70) 
2.34 
(-1.28 to 
5.83) 
0.37 
(-0.58 to 
1.28) 
 
 
Note. UW – Understanding Worry, TAU – Treatment As Usual, ES –Effect Size  
3.8 Indicators of Acceptability 
3.8.1 Attrition and Attendance 
Prior to the start of treatment five individuals dropped out or withdrew from 
the study. Two individuals, one from each intervention arm, withdrew consent to 
participate and received the service’s standard treatment. Two individuals from the 
TAU condition did not start treatment. In the Understanding Worry condition one 
individual did not start treatment.  The overall attrition rate from randomisation was   107 
22.7%, as a total of five individuals dropped out of treatment, the attrition rate for 
UW condition and TAU condition were 7.6% and 33.3% respectively. However, it is 
of note that an individual in  the  UW condition dropped out of treatment  as they 
emigrated from the country, taking this into account the attrition rates between the 
two conditions equated to one patient in the UW condition and two patients in the 
TAU, indicating that attrition was similar across both treatments. 
   The  pattern  of  attendance  is  summarised  in  Table  6.  There  was  no 
difference in pattern of attendance, cancellation or did not attend (DNA) between 
treatment  conditions,  X2=  (2,  N=102)=  1.665,  p=  0.44,  suggesting  that  both 
treatments were equally acceptable.  
Table 6: Summary of attended clinical contacts, cancellations and DNAs (N=22) 
 
  Overall Sample  TAU  Understanding 
Worry 
  Mean (SD)  Mean (SD)  Mean (SD) 
Attended Clinical 
Contacts 
 
3.09 (1.02)  3.45 (0.82)  2.89 (1.05) 
Cancellations 
 
1.09 (1.02)  1.27 (1.27)  1.00 (0.71) 
DNA 
 
0.36 (0.58)  0.27 (0.65)  0.44 (0.53) 
 
3.8.2 Implementation 
   The  number  mean  of  days  individuals  had  to  wait  between  scheduled 
clinical appointments for both treatments exceeded 14 days, and was longer in the 
Understanding  Worry  condition  (Mean=  21.75,  SD=  13.49)  than  in  the  TAU 
condition (Mean= 17.02, SD= 6.08). There was no significant difference between 
treatments in the mean number of days between appointments, F (1,20)= 1.26, p= 
0.28.  
   The  number  of  sessions  offered  to  individuals  in  treatment  varied  with 
individuals in the UW condition (Mean= 3.56, SD= 1.74) receiving fewer treatment 
sessions offered than in the TAU condition (Mean= 5.23, SD= 1.58). There was a 
significant difference between the two treatment groups in regards to the number of   108 
sessions offered (F (1,20)= 5.47, p= 0.03). However, this may be accounted for by 
more individuals being randomised into the UW condition later in the study, which 
limited the number of sessions that could have been offered within the duration of 
the study, and the reported difference should be treated with caution.  
  The majority of both treatments were delivered via face-to-face sessions, 
with 76.5% and 77.6% of clinical contacts being face-to-face in the UW condition 
and TAU condition, respectively. There was no difference between treatments in 
regards to the type of session offered (X2=1, 101)= 0.17, p=0.90.  
3.8.3 CSQ-8 
  During  the  duration  of  the  study  four  individuals  completed  planned 
treatment and completed a CSQ-8. In the UW condition one individual completed 
treatment  and  reported  a  satisfaction  score  of  24  out  32.  In  the  TAU  condition 
patients reported a satisfaction score of 31, 23 and 24 and a mean satisfaction 
score  comparably  to  the  UW  condition  (Mean=  26,  SD=  4.36).  This  tentatively 
suggests that individuals who completed treatment were similarly satisfied with the 
treatment they received. However conclusions are tentative and limited by the small 
sample size. 
3.8.4 Clinician Feedback 
  PWPs were asked to provide their feedback in their experience of delivering 
the new UW intervention, and 57% of clinicians completed the brief survey. PWPs 
reported the materials were easy to follow, that content was more in depth than 
TAU and the use of examples within the intervention helped individuals relate to the 
material. PWPs reported that the ability to select modules, the clear objectives, the 
examples  that  supported  the  psycho-education  material,  and  the  use  of  visual 
scales  to  measure  progress  were  all  strengths  of  the  intervention.  PWPs  also 
commented that they had increased in confidence as they delivered the intervention 
more  often  and  felt  more  knowledgeable  about  GAD.  However,  PWPs  also 
identified  that  given  the  limited  time  in  guided  support  sessions  the  modules   109 
contained  too  much  material  to  cover  in  detail  during  the  session  and  session 
preparation required more time than the TAU intervention. They also reported that if 
the individual had not completed the module material before the session it provided 
a challenge to cover the material in the allotted time. PWPs also felt that there was 
limited time to review the learning between sessions and the homework assignment 
and felt that perhaps more time could be allocated in sessions to this area.  PWPs 
commented  that  reducing  the  amount  of  information  in  the  modules  and  the 
provision  of  additional  training  would  be  future  improvements,  as  the  concepts 
underpinning the UW intervention were not currently taught in IAPT PWP training 
courses. 
4. Discussion 
The  study  sought  to  develop  and  pilot  a  LI  intervention  specifically  for 
excessive worry and GAD symptoms (UW). It was delivered by PWPs in a routine 
clinical  setting.  The  main  aims  of  the  study  were  to  assess  the  feasibility  and 
acceptability of the UW intervention and to establish an indication of clinical effect 
and performance in comparison to the current treatment. 
The  initial  question  of  whether  it  was  feasible  to  deliver  a  structured  LI 
intervention adapted from HI theory, which specifically addressed excessive worry 
and GAD symptoms, was supported. Referrals screened during the study period 
indicated that those with excessive and uncontrolled worry and GAD as a primary 
presenting  problem  represented  the  second  largest  patient  group  after  those 
presenting  with  low  mood.  This  demonstrated  that  there  was  a  current  level  of 
clinical need to justify a specific LI intervention focusing on excessive worry and 
GAD  symptoms.  Additionally,  the  clinical  need  identified  was  likely  to  be  an 
underestimate as pre-treatment scores on the PSWQ were high and exceeded pre-
treatment scores of previous published LI studies (Titov et al., 2010; Robinson et 
al., 2011) and were equivalent or higher than several published HI GAD treatment   110 
studies (Landoucer et al., 2000; Dugas et al., 2003; Dugas et al., 2010; Wells et al., 
2010).  This  suggests  that  individuals  with  less  severe  or  mixed  anxiety  and 
depression  presentation  were  not  reliably  identified  by  practitioners,  and  raises 
broader questions about the assessment of suitability for LI interventions as the pre-
treatment anxiety scores on the GAD-7 were at the high end of the moderate range. 
Several patients in the study may well have met the criteria for HI treatment rather 
than LI intervention according to the IAPT step cared model (IAPT, 2008), as 50% 
of the sample reported pre-treatment anxiety scores in the severe symptom range.  
This suggests PWPs in routine practice appear to be working with patients who are 
reporting clinical levels of severity that LI interventions were not conceptualised to 
accommodate, which suggests robust interventions at an LI are required. 
The question of whether the specific Understanding Worry (UW) intervention 
would  be  acceptable  to  patients  was  supported.  The  hypothesis  that  UW  was 
practical to delivery at an LI level was partially supported.  
There  was  no  difference  between  the  UW  and  TAU  in  patterns  of 
attendance, cancellation and DNA of clinical sessions. The attrition rates between 
the  treatments  were  comparable,  indicating  that  both  treatments  were  equally 
acceptable to patients. The four patients who completed the treatment as planned 
and  completed  post-treatment  satisfaction  measures  reported  a  high  level  of 
satisfaction  with  the  treatment  received,  which  suggested  that  UW  as  an  LI 
treatment  was  as  acceptable  as  TAU.    Attrition  after  the  start  of  treatment  was 
similar to previously reported rates of attrition in clinical interventions (Hunot et al., 
2007). However, the study’s patient flow showed a considerable number of suitable 
patients declining entry into the study and withdrawal after initially consenting to 
participate, demonstrating that those with worry and anxiety may be a challenging 
group to  recruit. It  is  possible  that  processes such  as  intolerance  of uncertainty 
contributed  to  difficulty  in  recruitment  into  the  study  and  may  highlight  a  wider 
clinical issue in the treatment of anxiety disorders.   111 
In relation to the implementation of the UW treatment, patients were offered 
fewer  sessions  than  in  the TAU  condition,  with  a  longer gap  between  sessions. 
Possible explanations for this discrepancy may be that PWPs felt less confident in 
the  delivery  of  new  material  and  implementation  of  the  treatment  protocol  and 
prioritised  TAU  treatment  sessions,  as  this  was  more  familiar,  which  resulted  in 
greater  clinical  contact  and  a  higher  treatment  effect.  However,  the  differential 
number of offered clinical contacts may be an artifact of the randomisation process 
given the small numbers in each arm. Reviewing the randomisation matrix after the 
data was analysed showed that a high number people were randomised to TAU in 
the early stages of recruitment. The consequence of patients being randomised to 
the UW condition later in the trial meant that there was less opportunity for sessions 
to be offered before the end of data collection.  
In  regards  to  the  delivery  of  the  intervention  PWPs  reported  positive 
experiences in the delivery of the UW intervention and highlighted the clear and 
consistent  format  and  focus  on  uncertainty  and  avoidance,  the  behavioural 
framework, the modular format, clear objectives,  clinical examples and the clear 
session framework as strengths of the intervention. However, PWPs believed that 
the amount of content in modules was too much to cover in support sessions and 
should be reduced. Practitioners also commented that there should be more time to 
focus on the learning from the between session tasks as this was challenging to 
facilitate given the high level of content to review in support sessions. It is possible 
that  refining  the  material  based  on  this  feedback  may  facilitate  increased 
effectiveness,  as  the  UW  treatment  may  become  more  focused,  accessible  to 
patients and practitioners.  
The question of whether the UW intervention was comparable to TAU was 
partially  supported.    The  available  clinical  data  and  ITT  modeled  data  both 
suggested that the UW treatment was no more effective than TAU. Both treatments 
showed  reductions  in  worry  and  anxiety  symptoms  at  the  last  observed  clinical   112 
contact and the ITT modeled data and indicated that change in worry and anxiety 
symptoms were greater in the TAU condition, but the difference between UW and 
TAU was not statistically significant. Treatment effect sizes were within previously 
reported confidence intervals for IAPT LI treatments (Richards & Borglin, 2011), but 
were slightly lower in comparison to previously reported controlled trials of LI GAD 
treatments (Titov et al., 2009; Robinson et al., 2010).  
The observed treatment effects could be explained in part by the differences 
in  treatment  dosage  between  treatments.  A  larger  number  of  TAU  patients 
completed planned treatment, with a shorter duration between treatment sessions, 
in comparison to UW. It can be argued those in TAU had the opportunity to engage 
more with treatment and received a higher dose of treatment than those in the UW 
condition  and as a result showed a greater improvement in reported symptoms. 
Whereas the UW condition in comparison received fewer sessions with longer gaps 
between  them,  as  a  result  patients  receiving  the  UW  treatment  may  have 
experienced a lower treatment dosage and consequently reported limited reductions 
in  symptoms.  Alternatively  the  differences  between  TAU  and  UW  could  be 
accounted for by the relative effects of experience and confidence in delivery of the 
interventions, as PWPs first experience of delivering UW treatment was limited to 
eight hours of training and zero hours clinical delivery prior to the start of the trial. 
The relatively weaker clinical effect of UW may reflect that PWPs were still in the 
process  of  understanding the  material  and  how  to  effectively  deliver  it  clinically. 
PWPs may not have held an understanding of the underlying theory as clearly and 
confidently as their understanding of the first wave CBT theory that underpinned the 
TAU condition. It is probable that the observed difference  in reported symptoms 
between  interventions  would  diminish  as  PWPs  confidence  and  understanding 
improved  through the further training  in  the  delivery  of  the  UW intervention  and 
training.    113 
However,  there  are  several  alternative  explanations  as  to  why  the  TAU 
condition reported larger reductions in self-reported symptoms of worry and anxiety 
in comparison to UW. It may be that a brief LI intervention which draws on second 
wave  CBT  approaches  for  GAD  is  no  more  clinically  effective  than  first  wave 
Beckian CBT approaches. This may be due to more complex concepts such as 
intolerance of uncertainty and emotional avoidance not translating well into an LI 
time-limited format and may reflect the level of practitioner training. Second wave 
CBT content for GAD may require a longer treatment duration input and a higher-
level  practitioner  to  be  delivered  effectively.  Additionally,  UW  treatment  did  not 
attempt to  address meta-cognitive aspects  of GAD such as beliefs about  worry, 
which could be have led to a reduction in clinical effectiveness as the complete 
model was not included in LI treatment. Given the complexity of cognitive work it 
was  considered  to  be  more  suitable  to  HI  interventions.  However,  any  firm 
conclusions in regards to effectiveness are limited by the study’s small sample size. 
The  final  question  of  whether  the  UW  intervention  would  lead  to  reliable 
change in anxiety and worry was partially supported. The ITT model suggested that 
individuals who received the UW condition would achieve a change score on the 
PSWQ  and  GAD-7  that  would  reach  the  criteria  for  reliable  clinical  change  by 
session four of treatment.  In the observed clinical contacts 22.2% showed a reliable 
improvement on the PSWQ and 44% showed a reliable improvement on the GAD-7 
measure.  In regards to clinical recovery, 33.3%  of those who received the UW 
treatment met the IAPT recovery criteria at their last clinical contact.  The relative 
low  levels  of  attended sessions  in  the  UW condition  (M=  2.89)  may  explain  the 
relatively low rate of recovery and it is likely this would have improved if patients 
had completed the UW treatment and received the planned treatment dose.  
Limitations 
  There  are  several  limitations  of  the  current  pilot  study.  Firstly,  as  a 
consequence of challenges in recruitment, the sample size is small and therefore   114 
the  current  study  is  statistically  underpowered.  This  limits  the  generalisability  of 
findings and all conclusions should be treated tentatively and with the appropriate 
level of caution. However, it is of note that despite the early ending of the study the 
obtained sample size was comparable with that of other published GAD pilot studies 
(Wetherall et al., 2011; Wells et al., 2010). A substantial limitation was the lack of a 
delayed treatment or active placebo control group, which means that the rate of 
natural remission of symptoms could not be established and cannot be discounted 
as a possible explanation for the observed symptom reduction. The pilot study used 
practicing clinicians as both assessors and therapists, which may have introduced 
demand  and  allegiance  effects.  Additionally  bias  may  have  been  introduced  as 
practitioners  delivered  both  interventions,  the  possibility  of  leakage  between 
interventions cannot be discounted as no formal measure of adherence was used 
and was only assessed via clinical supervision, which provided a limited check on 
intervention  fidelity.  Practitioner  and  participant  expectations  prior  to  intervention 
were  not  assessed  formally,  which  may  have  introduced  additional  bias.    Other 
sources of potential bias such as the use of medication and previous psychological 
treatments were not assessed in this study. The use of pure self-report measures 
rather than an independent diagnostic interview is also a potential limitation of the 
current  study  as  provisional  diagnosis  was  reached  using  the  IAPT  screening 
algorithm following assessment which is not a structured diagnostic interview. It is 
possible that reported provisional diagnoses of GAD were a consequence of the 
assessor’s bias and expectancy effects.  
Finally, due to time constraints data collection was stopped early. As a direct 
consequence  of  this  a  number  of  patients  in  both  arms  did  not  receive  the  full 
intervention as planned, therefore the cumulative treatment effect is uncertain.  Also 
it is possible that treatment arms did not receive equivalent dosages of treatments. 
Dedicated  trial  therapists  were  not  used  which  contributed  to  the  reported 
challenges  in  the  implementation  of the  intervention,  as  PWPs  were  required  to   115 
provide the study interventions alongside a full clinical caseload. Also the long-term 
clinical effect of both the TAU and UW interventions was not assessed in the pilot.   
Future Research 
  Further research that focuses on the replication of this pilot should focus on 
the further refinement of the treatment material and following that testing the impact 
of alternative forms of delivery such as group, pure self-help and Internet treatment. 
The use of dedicated and more comprehensively trained therapists may enable a 
more  robust  assessment  of  effectiveness  given  the  described  difficulties  in  the 
implementation  of  the  intervention  in  the  context  of  a  high  clinical  caseload. 
Research  should  also  seek  to  assess  the  long-term  effect  of  treatment  through 
follow up, and in order to be suitably powered to reliably detect large between group 
treatment effect should aim to recruit a minimum sample of 84 people. However, as 
the current study compared a novel treatment with an active treatment it is likely 
that any difference between treatments would be a small to medium effect. Trials 
that  would be appropriately powered to reliably detect a  medium  or  small  effect 
between  treatments  would  require  a  total  sample  of  580  and  5200  people 
respectively..  Due  to  the  difficulties  reported  in  the  recruitment  process  future 
studies  may  need  to  consider  research  design  carefully  and  the  use  of  a 
randomised cluster design may improve recruitment, as the prospect of individual 
randomisation appeared to be difficult to tolerate for those reporting high levels of 
worry. Future research may also choose to focus on whether underlying processes 
such  as  intolerance  of  uncertainty  using  the  Intolerance  of  Uncertainty  scale 
(Freeston,  Rhéaume,  Letarte,  Dugas,  &  Ladouceur,  1994)  predicts  treatment 
response  or  the  early  termination  of  treatment.  A  greater  understanding  of  the 
underlying  processes  of  worry  and  GAD  and  their  impact  on  engagement  may 
improve treatment retention and clinical outcomes.  
Clinical Implications   116 
  It is clear that those who experience pathological levels of worry and GAD 
symptoms are a challenging group to engage in treatment. The study also indicates 
within routine IAPT practice that the recognition of GAD symptoms may be limited 
only to those with high levels of worry.  Existing literature suggest GAD is often 
comorbid with other disorders, 29% to 62% of individuals with GAD are estimated to 
have  comorbid  depression  (Hoge, Ivkovic  &  Fricchoine,  2012)  and there  is  also 
significant comorbidity with other anxiety disorders (NICE, 2011).  This suggests 
that PWPs may require more training in the recognition and assessment of GAD.  
The  use  of  the  PSWQ  as  a  screening  tool  for  uncontrollable  worry  should  be 
considered  to  aid  identification  of  patients  with  excessive  worry  where  GAD  is 
suspected. Finally, the approach to intervention design adopted within the current 
pilot may provide a useful framework and further opportunities for the development 
of LI interventions for other disorders. 
Conclusion 
  The  primary  goal  was  to  establish  whether  a  specific  GAD  intervention 
based  on  HI  theory  could  be  delivered  by  PWPs  at  an  LI  treatment  level.  The 
findings of the current pilot  study suggest that there is a clinical need for an LI 
intervention that focuses on addressing worry and GAD symptoms within primary 
care IAPT services. Findings tentatively indicate that an intervention adapted from 
the  current  HI  approaches  can  be  delivered  by  PWPs  but  this  requires  further 
development,  refinement  and  the  provision  for  further  training.  The  study  also 
highlighted  several  challenges  of  implementing  intervention  research  for  anxiety 
disorders in clinical settings.  
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Introduction 
This  appraisal  will  critically  evaluate  the  empirical  study,  focusing  on  the 
background to the research, the conceptual issues in the intervention design and 
the challenges of conducting research in NHS clinical settings, particularly focusing 
on  recruitment  and  the  involvement  of  clinicians  in  the  research  process.  The 
appraisal will also consider future directions for research, clinical implications and 
the learning points from the research process. 
Background 
  After my undergraduate and postgraduate studies I worked for two years at 
a second wave IAPT site as a Psychological Wellbeing Practitioner (PWP) and a 
senior PWP.  During this time I was involved in the evaluation of a Low Intensity (LI) 
psycho-educational depression group and saw that the routine collection of clinical 
outcomes could be used to aid the development and evaluation of interventions’ 
clinical  effectiveness.  I  also  saw  how  the  IAPT  service  design  lent  itself  to  the 
testing and development of interventions in routine clinical settings. 
  During  my  clinical  work  it  became  apparent  that  there  was  a  gap  in  the 
provision of treatments that addressed excessive and distressing worry and GAD at 
an LI level.  My experiences of using the available tools taught on the IAPT training 
course  was  that  they  were  generic  and  advised  cognitive  restructuring,  worry 
containment and problem  solving.  Often when my colleagues or I attempted to 
apply these techniques in guided self-help sessions or psycho-educational anxiety 
groups it appeared that these tools triggered more worries and led to an increase in 
anxiety. The treatment outcomes for this patient group also seemed to be worse. 
This  group  of  patients  often  showed  minimal  improvement  on  IAPT  outcome 
measures, dropped out of treatment more frequently and were often re-referred to 
the service soon after discharge. It seemed that all the intervention had achieved 
was  to  provide  the  person  with  additional  tools  to  engage  in  worry  rather  than   127 
alleviate any distress or anxiety. As a consequence of this I, as my colleagues did, 
drew on other sources such as the Centre for Clinical Interventions  (CCI, 2014) 
GAD workbooks and supervision, which led to a  hodge-podge of material being 
selected  in  an  ad-hoc  manner  with  little  consistency.  Guided  self-help  sessions 
would sometimes stray into a diluted version of CBT rather than adhering to the 
conceptual ethos of LI interventions. The result was that I felt treatment techniques 
delivered for worry often did  not form a coherently treatment package and were 
varied across the service generally. I wondered if our service and other IAPT sites 
were  providing  no  more  than  a  ‘sticking  plaster  therapy’  for  this  patient  group 
(Martin & Helmore, 2006). Consequently when the opportunity arose to conduct my 
own research it was an area I wanted to focus on and hoped to establish if the 
current LI interventions for GAD could be improved by drawing on High Intensity 
(HI)  theory  and  adapted  into  a  structured  brief  intervention  that  adhered  to  the 
principles of LI treatment. 
 
Reflections on Conceptual Issues in Intervention Design 
  As I had to design the project myself, and it was not part of an existing 
project,  I  felt  it  was  important  to  initially  spend  time  meeting  with  local  IAPT 
services, PWPs and teaching staff on the PWP training course to gain a sense of 
their experiences of providing LI interventions for worry and GAD, especially since I 
had been of out the IAPT services since I started my clinical training.  In listening to 
them I noticed the same concerns were still present and this was still an area in 
need of development. However, there were a large variety of opinions regarding 
what was felt to be needed to address this gap and the way in which it should be 
delivered. It was also clear that there was a concern that any intervention developed 
adhered  to  the  LI  principles  and  was  not  CBT-lite.  This  diversity  of  opinion  is 
reflected in the emerging LI literature (Bennett-Levy Richards and Farrand et al.,   128 
2010).  This  presented  a  challenge  in  balancing  the  views  of  what  theoretical 
material the LI treatment should include and how this was best adapted.  
  To address this I adopted a pragmatic approach of reviewing the current LI 
interventions  for  GAD  and  worry  and  deconstructed  the  interventions  into  their 
individual  elements;  this  helped  give  a  sense  of  how  the  interventions  were 
structured, what were the most common elements and what was missing. I also 
reviewed the evidence for the theoretical CBT models of GAD, which allowed me to 
decide on a coherent theory to base the intervention on. This was the Intolerance of 
Uncertainty (IoU) model (Dugas et al., 1998), the model with the most established 
evidence base. Although this took longer than anticipated I hoped that it help to 
engage the PWPs who would be delivering the intervention, so they could see that 
this was a new intervention not just a repackaging of existing LI approaches but 
based on a clear model. I also hoped the modular structure would allow them to 
exercise their existing clinical skills and provide a treatment which was tailored to 
the patient but retained a clear structure. 
  This led to the issue of how to structure the material and how PWPs 
should deliver it so the intervention kept the CBT in the material and utilised PWPs 
skills  in  guidance,  support  and  scaffolding  of  the  patient’s  reflective  learning 
processes (Bennett-Levy et al., 2010). To achieve this I was aware that the material 
and  support  sessions  needed  to  focus  on  process  and  the  encouragement  of 
positive behavioural change. The Behavioural Change Theory (BCT) framework of 
intervention (Michie, Van Stralen & West, 2011) appeared to fit well with the ethos 
of  LI  intervention  and  the  COM-B  approach  ensured  that  each  element  in  the 
intervention  was  included  for  a  clear  definable  reason.  It  also  provided  a  clear 
rationale for the structure support sessions, which I hoped would allow PWPs to 
adopt the intervention as a whole rather than just the patient materials. The explicit 
focus on behaviour allowed the focus of worry to move away from the content and 
focus on process and behaviour.   129 
  The  initial  idea  for  the  intervention  was  a  fixed  six-session  structured 
intervention, which while providing a consistent intervention would almost certainly 
have lost individuals, as the material may not have been immediately relevant, and 
motivation  for  treatment  could  be  lost.  As  a  solution  a  modular  format  was 
constructed,  which  included  a  mandatory  psycho-educational  and  last  session 
review, with sessions in between benefiting from a flexible selection of modules that 
address  different  areas  of  GAD  such  as  uncertainty,  problem  solving  and 
avoidance. The advantage of this approach was that it provided a consistent format 
but allowed flexibility to tailor interventions to maximise engagement, as what was 
most meaningful for the individual could be addressed first. However, on reflection 
this choice of which areas to address may have inadvertently increased patients’ 
anxiety as it introduced uncertainty in where to begin. It is also possible that by 
offering a choice individuals may well have avoided the areas of the intervention 
that  would  bring  the  most  anxiety.    Additionally,  the  choice  element  in  of  the 
intervention  may  have  been  perceived  as  an  additional  burden  to  the  PWPs 
delivering  the  intervention  and  resulted  in  them  delivering  the  modules  they 
preferred.  I  attempted  to  address  this  by  consulting  with  PWPs  throughout  the 
design  of  the  materials  and  modified  the  material  in  line  with  the  feedback  I 
received. By doing this I aimed to engage and motivate the PWPs and encourage 
them to view the project as something other than an academic piece of work.  
  A  weakness  in  the  overall  design  of  the  intervention  was  that  it  did  not 
include any service user involvement.  In hindsight this may have provided valuable 
information and feedback to ensure the content of the intervention was engaging 
and  connected  with  the  experience  of  worry  and  GAD  in  a  way  that  supported 
motivation  for  change.    Also  I  was  aware  that  I  wanted  to  provide  a  clear 
explanation of the approaches in the intervention and as such brevity may have 
been sacrificed to an extent. This may have been off-putting and made working   130 
through the modules feel like a chore; service user involvement could have provided 
valuable guidance in this regard. 
Reflections on Conducting Research in Clinical Settings 
There were several challenges that became apparent during the course of 
the research. The main challenges that will be focused on are the methodological 
compromises made and the process of study recruitment.   
The research was conducted in a busy and strictly commissioned clinical 
setting, which as a consequence led to pragmatic constraints in study design and 
the recruitment process, as the process was required to fit within service’s existing 
assessment  and  treatment  targets.    Due  to  the  timescale  of  the  research, 
methodologies such as a cluster randomised trial design, where multiple sites would 
deliver one intervention, were not realistic given the service assessment system or 
the time scale of the study. Similarly the concern of waiting list breaches meant that 
a delayed treatment control or placebo condition could not be used. This meant that 
a natural rate of reduction in symptoms could not be measured and controlled, as 
worry  and  GAD  have  a  characteristic  waxing  and  waning  course  (NICE,  2011). 
Given  the  practical  restrictions  a  randomised  design  was  considered  the  most 
suitable for the piloting of the intervention, as this would reduce selection bias and 
threats  to  interval  validity  (Barker,  Pistrang  &  Cooke,  2002)  while  being 
implementable  within  the  service’s  normal  practice.  Despite  these  limitations  the 
main advantage was that the study compared the service’s existing treatment to the 
experimental intervention, which I hoped would provide immediate clinically useful 
information,  and  allowed  the  acceptability  to  be  assessed  directly  against  the 
service’s current treatment.  
The  recruitment  into  the  study  was  a  challenge  as there  were significant 
delays  in  gaining  ethical  approval  due  to  the  concerns  of  the  use  of  a  novel 
treatment  in  a  clinical  setting.  This  delay  resulted  in  recruitment  beginning  four   131 
months  later  than  planned.  Recruitment  into  the  study  was  slow  and  it  became 
apparent that PWPs were not completing the number of assessments that had been 
used in the preliminary calculation for recruitment. It also appeared that a bystander 
effect (Lantané & Nida, 1981) was partially present with recruitment rates varying 
between PWPs and this appeared to be exacerbated by the fact that PWPs were 
often working at different GP surgeries isolated from each other. This may have led 
to some PWPs leaving the task of recruitment to the other practitioners involved in 
the  study.    It  may  also  have  been  explained  by  the  service’s  highly  active 
contribution to research as PWPs were simultaneously recruiting for other studies, 
and experienced a level of general research fatigue. I tried to encourage and remind 
the PWPs by arranging meetings with them and sending regular emails to update 
them. However, on reflection my attempts to be supportive and to recapture the 
earlier motivation present in the intervention development and training phase and 
may have been perceived by the PWPs as nagging and inconsiderate of the high 
volume caseload that they consistently carried. I believe that I underestimated the 
amount of extra work that was created for the PWPs who I was relying on to recruit 
and  deliver  of  the  study  interventions.  My  intention  had  been  to  integrate  the 
research design as much as possible into the normal services practiced, by the 
addition of the PSWQ to session MDS, and by providing a clear manual and training 
in how to deliver the experimental intervention.  In the feedback I received from the 
PWPs during scheduled meetings and more casual conversations it appeared that 
delivering  the  experimental  intervention  required  more  preparation  than  I  had 
anticipated and that the style of the intervention was different to what they had been 
used  to.    In  hindsight  it  may  have  been  helpful  to  provide  more  training  in  the 
delivery of the intervention and include more experiential practice of reviewing the 
material. However, given the high workload and clinical commitments of the PWPs 
and  their  supervisors  it  was  not  possible  to  arrange  this.  Perhaps  establishing   132 
regular contact with their supervisors could have helped provide more support and 
guidance as the clinicians got used to the new intervention.  
Another major issue was recruiting suitable participants into the study. I had 
not expected that a primary care patient group would be so challenging to recruit 
into a research study. On meeting the PWPs to discuss recruitment they reported 
that often they would assess an individual and identify them as suitable but the 
patient would decline to participate in the study or would agree and then withdraw 
when contacted to collect the baseline measures. When I explored this with the 
PWPs they frequently reported individuals expressing worries that they would not 
be able to do the treatment to a good standard, would ruin the research by not 
getting better or would be at a disadvantage to the people who received the other 
intervention, or would want normal treatment as it had been delivered many times 
before.   
This reaction from participants surprised me, however on reflecting about the 
patient group that was the subject of the study this reaction to the uncertainty could 
have been expected. Research shows that those who experience GAD and high 
levels of worry tend to respond more negatively to uncertain situations, are more 
likely  to  interpret  them  as  threatening  and  demonstrate  higher  levels  of 
indecisiveness    (Koerner  &  Dugas,  2008;  Rassin  &  Muris,  2005).    Given  this 
dispositional  characteristic,  the  consent  process  may  have  been  highly  anxiety 
provoking and experienced as aversive. The prospect of an additional contact with 
the PWP to confirm consent and to collect the  initial study measures may have 
proved too much and led to a characteristic response of avoidance by dropping out 
of treatment or deciding to not enter the study.  This difficulty in the recruitment of 
individuals with GAD or high levels of worry appears to be widely reflected across 
the published GAD literature (NICE, 2011; Hanrahan et al., 2012) as the majority of 
studies  report  small  numbers  of  participants  entering  trials  and  substantial 
recruitment durations (Dugas, et al., 2003; Dugas et al., 2010; Hayes Skelton et al.,   133 
2013). It is possible that higher levels of intolerance of uncertainty may have led to 
those with a relative higher tolerance to uncertainty participating in research more 
readily than those with lower tolerance of uncertainty and arguably more severe and 
disabling GAD symptoms.  This may be an avenue for further study in regards to 
developing an understanding of how underlying constructs of GAD may contribute 
to  response  treatment  and  dropout.  This  understanding  may  aid  clinicians  in 
retaining  patients  in  treatment  once  they  have  made  contact  with  a  treatment 
service. It also may suggest that researchers in the future need to carefully consider 
study designs and recruitment procedures to ensure they do not introduce large 
amounts  of  uncertainty  that  may  reduce  the  likelihood  of  a  suitable  individual 
participating in the research study. 
 
Reflections on Clinical Implications and Future Directions of Research 
  The  empirical  study  has  tentatively  shown  that  it  is  possible  to  adopt  HI 
theory to a structured guided self-help LI intervention for GAD and worry, using the 
BCT  model  of  intervention  design  as  a  framework.  It  is  possible  that  further 
research could further develop this approach by exploring its application in respect 
to other disorders at an LI level in both a group and individual treatment format. 
However,  clinically  it  appears  that  a  clear  and  shared  understanding  of  what 
constitutes an LI intervention across IAPT sites and practitioners is still needed and 
perhaps  the  above  approach  to  intervention  design  can  aid  to  an  extent  this 
endeavor.    Additionally  given  the  experienced  difficulty  in  recruitment  it  may  be 
prudent for future research with GAD to adopt designs that minimise exposure to 
uncertainty  such  as  a  randomised  cluster  design  where  a  single  intervention  is 
delivered in a single site by dedicated clinical staff. 
Clinically the challenges of recruitment have highlighted the difficulties that 
services  may  experience  in  engaging  and  retaining  individuals  with  GAD  in 
treatment and research. This may give rise to the perception similar to Anorexia   134 
Nevosa  that  it  is  a  difficult  disorder  to  treat  and  research  due  to  problems  with 
dropout  and  recruitment  into  studies  (Agras  et  al.,  2004).  Further  research  that 
addresses how underlying dispositional characteristics of intolerance of uncertainty 
impacts engagement in both treatment and research could allow strategies to be 
developed that could support engagement and retention in treatment. An improved 
understanding of these factors may also aid the production of larger appropriately 
powered  studies  that  are  more  economically  viable  due  to  the  reduction  in 
recruitment time.  These findings may also apply more generally to other disorders 
such as OCD where intolerance of uncertainty is a significant factor.   
 
Learning Points    
  The main learning point taken from this experience of conducting research in 
clinical  settings  is  the  importance  of  groundwork.  This  is  essential  in  the  early 
stages of a project in terms of gaining a full understanding of a service and existing 
demands of the clinicians in order to ensure the successful  implementation of a 
study. Also I have learned the importance of considering how disorder process may 
actively impact the recruitment of individuals into the study and that this needs to be 
considered at the early stage of the research process. I will also take away the 
importance of maintaining contact with service leads and supervisors in addition to 
the clinicians delivering the intervention to ensure consistent support for the study. I 
have also learned that intervention design is more complex than I first expected and 
requires the balance to be struck between what is theoretically ideal and what is 
pragmatic and can be clinically delivered. Also service user input in the early stages 
of intervention design is important in ensuring the intervention accurately captures 
and addresses the experience of the disorder being treated.    135 
Conclusion 
  Whilst there are many other questions that could be addressed in this area, I 
hope  the  findings  presented  here  prove  useful  to  other  researchers  and  IAPT 
services who want to further develop the provision of LI interventions within IAPT for 
GAD and other psychological disorders. 
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Search filter combination strategy: 
1)  Generalised anxiety disorder filter + Randomised trial filter + General psychology 
terms. 
2)  Generalised anxiety disorder filter + Randomised trial filter + Low intensity terms. 
3)  Generalised anxiety disorder filter + Randomised trial filter + High intensity terms. 
Filter search terms: 
Filter  Terms 
Generalized 
anxiety 
disorder 
filter 
1.  Anxiety or anxiety disorders).sh. 
2.  Generali?ed$ anxiet$ Disorder$ or GAD NOT (Glutmic acid dexcarboxylase or 
gultmaic decarboxylase or gad sad) ti.ab. 
3.  (anxiety$ or anxious$ or (chronic$ or excessive$ or intens$ or intens$ or ongoing 
or persit$ or serious$ or sever$ or pathological or uncontrol$ or un control) adj2 
worry. Ab.ti 
4.  Or 1-3. 
Randomized 
trial filter 
1.  Randomi?ed Control$ Trial$ (ti.ab.) 
2.  Exp control group or control system 
3.  Randomized controlled trial .sh. 
4.   Or 1-3 
General 
Psychology 
Terms 
1.  Psychotherapy 
2.  psychotherap$ or psycho therap$ or psychotherapeutic or (non pharmacological or 
psychologic$) adj3 (approach$ or assist$ or coach$ or educat$ or instruct$ or 
intervene$ or manag$ or module$ or program$ or rehab$ or strategy$ or support$ 
or technique$ or therap$ or train$ ot treat$ or workshop$ or work shop$) adj2 
therap$.ti,ab. 
3.  1 or 2 
4.  psychotherapy, brief.sh 
5.  (brief or short term or time limited ) adj2 (intervention$ or program$ or psycho-
analy$ or psychotherapy$ or solution$ or therap$ or treat$) .ti.ab. 
6.  or 4-5 
7.  or 1-6 
LI Terms  1.  bibliotherapy.sh 
2.  (bibliotherap$ or biblio therap$ or (audio$ or book$ or booklet$ or brochure$ or cd 
or cd rom or cdrom or computer$ or cyber$ or internet$ or phone$ or sms$ or 
telephon$ or text or texting or video or virtual or web$ or workbook$ or work book$ 
or written%) adj5 (approach$ or assist$ or coach$ or educat$ or empower$ or 
psychoanal& or psychotherapy$ or help$ or instruct$ or intervene$ or manag$ or 
module$ or program$ or rehab$ or strategy$ or support$ or technique$ or therap$ 
or train$ ot treat$ or workshop$ or work shop$) or (listen$ or read$ or watch$) adj4 
(aido$ or book$ or booklet$ or brochure$ or cd$ or cdrom or computer$ or dvd$ or 
internet$ or manual$ or material$ or multimedia$ or multi media or pamphlet$ or 
poster$ or read$ or video$ or virtual$ or workbook$ or writtern or www) ab.ti. 
3.  Self adj (administer$ or care$ or change or direct$ or help$ or instruct$ or manag$ 
or regulat$ or reinforce$ or re inforc$ or self help$) .ti.ab. 
4.  Self adj (administer$ or care$ or chang$ or directed$ or help$ or instruct$ or 
manag$ or monitor$ or regulate$ or reinforc$ or re inforc$ or self help$ ti.ab 
5.  Guid$ self help or low intensity or brief intervent$ .ab.ti 
6.  Or /1-5 
7.  Exp health education 
8.  (adult$ or client$ or consumer$ or patient$ or participant$ or service use$) adj4 
(educat$ or empower$ or knowledge or information$ or instruct$ or promot$ or 
teach$ or train$) or (anxiet$ or anxious$ or worry or worring) adj4 (educat$ or 
empower$ or knowledge or information$ or instruct$ or promot$ or teach$ or 
train$) or booklet$ or brochure$ or leaflet$ or pamphlet$ or poster$ or workbook$ 
or psychoeducat$ or psycho educate$ or (oral or printed or written) adj5 (book$ or 
manual$ or material$ or multimedia or mutli media or video$) Adj5 (intervent$ or 
program$ or therap$ or treat$) .ti, ab. 
9.  Or 7-8 
10.  Hotlines.Sh   140 
11.   (call in or callin$ or call lin$ or help lin$ or helplin$ or hot lin$ or hot lin$ or phone 
in or phonein or caller$) adj3 (intervene$ or program$ or therap$ or treat$).ab.ti. 
12.  Or/10-11 
13.  Exp exercise 
14.  (active living or a?robic$ or exercise$ or physical$) adj3 (active$ or agil$ or 
educat$ or fitness$).ab, ti. 
15.  Or/ 13-14 
16.  (caccbt or ccbt or cbt). Id,kw. 
17.  (beating adj2 blues) or fearfighter or ffeducation or ff education or internet or 
moodgym or (living life adj2 full) or stress control or oc fighter or ocfighter or 
overcoming depression or pain online or (restoring adj2 balance) or standaloneff or 
stand alone ff or theraput$ learning program$. ab, ti. 
18.  (bt step$ or calypso$ or climate or climategp$ or climateschool$ or climatemh$ or 
climateclinic$ or climatetv$ or crufad$ or gpcare$ or ultrasis or (anxiety or anxious) 
adj3 package$. ad.,ti. 
19.  (anxiety$ or stress$ or worry$) adj3 (package$ or program$ or course$).ab.ti. 
20.  (etherap$ or e therap$ or telehealth or tele health) ab.,ti. 
21.  ( e communication$ or emcommunication$ or e consult$ or econsult$ or e visit$ or 
e visit$ or e therap$ or etherap$ or tele health or telehealth) ti.,ab. 
22.  (audio$ or cd$ or cd rom or computer$ or dvd or electronic$ or interactive$ or 
internt$ or multimedia or multi media or online or sms or telephone or text or 
texting or video$ or virtual$ or web$ or www) abj5 (advocacy or approach$ or 
coach$ or discussion$ or educate$ or exchange$ or guide$ or help$ or instruct$ or 
interact$ or intervene$ or learn$ or manag$ or meeting$ or module$ or network$ or 
online or participant$ or program$ or psychoanal$ or psychotherap$ or rehab$ or 
retrain$ or re train$ or self guide$ or self help or self-guide$ or selfhelp or skill$ or 
strategy$ or support$ or teach$ or technique$ or telephone$ or therap$ or train$ or 
treat$ or work shop& or workshop$) .ab, ti. 
23.  (audio$ or cd$ or cd rom or cdrom or computer$ or dvd or electronic$ or interactiv$ 
or internet$ or multimedia or multi media or online or sms or telephone$ or text or 
texting or video$ or virtual or web$ or www) abj2 (assist$ or based).ab,ti. 
24.  (audio$ or cd$ or cd rom or cdrom or computer$ or dvd or electronic$ or interactiv$ 
or internet$ or multimedia or multi media or online or sms or telephone$ or text or 
texting or video$ or virtual or web$ or www) adj5 (aid or aided or appointment$ or 
booking% or communicat$ or consult$ or deliver$ or feedback or forum or guided 
or imput$ or interactive$ or letter$ or message$ or referral$ or remind$ or send$ or 
transfer$ or transmit$ or visit).ab,ti. 
25.  audio$ or cd$ or cd rom or cdrom or computer$ or dvd or electronic$ or interactiv$ 
or internet$ or multimedia or multi media or online or sms or telephone$ or text or 
texting or video$ or virtual or web$ or www) adj 5 group$.ab.ti 
26.  (client$ or patient$) adj5 (audio$ or cd$ or cd rom or cdrom or computer$ or dvd or 
electronic$ or interactiv$ or internet$ or multimedia or multi media or online or sms 
or telephone$ or text or texting or video$ or virtual or web$ or www).ti,ab. 
27.  (client$ or patient$ or service user$ or health or information or web or internet) adj3 
portal$.ab,ti. 
28.  Or 16-27 
29.  exp psychotherapy 
30.  (audio$ or cd$ or cd rom or cdrom or computer$ or dvd or electronic$ or interactiv$ 
or internet$ or multimedia or multi media or online or sms or telephone$ or text or 
texting or video$ or virtual or web$ or www).ti.ab. 
31.  interactive voice response.ab,ti. 
32.  Or/ 30-31 
33.  29 and 32 
34.  Or/ 26 and 33 
35.  Or/1-12,34 
 HI Terms  1.  exp counseling/ 
2.   (counsel$ or (client or person) adj2 (centred or centered or focus?ed) or non 
directive$ or nondirective$ or rogerian) adj5 (approach$ or assist$ or coach$ or 
educat$ or instruct$ or intervene$ or manag$ or module$ or program$ or rehab$ or 
strategy$ or support$ or technique$ or therap$ or train$ ot treat$ or workshop$ or 
work shop$) or pastoral care or (individual or personal or talk$) adj (psycho$ or 
therap$) .ti,ab. 
3.  Or 1-2 
4.   Interpersonal relations and (psychotherapy$ or therap$ or treatment) .hw. 
5.  (Interpersonal$ or inter personal$ or interrelation$ or relation$) adj5 (approach$ or 
assist$ or coach$ or educat$ or instruct$ or intervene$ or manag$ or module$ or 
program$ or rehab$ or strategy$ or support$ or technique$ or therap$ or train$ ot   141 
treat$ or workshop$ or work shop$) or (interpersonal$ or inter personal$ or 
interrelation$ or relation$) adj5 (analy$ or approach$ or assit$ or coach$ or 
communication$ or counsel$ or educat$ or help$ or instruct$ or intervene$ or 
manage$ or module$ or network$ or program$ or psychoanaly$ or psychotherapy$ 
or rehab$ or skill$ or straterg$ or support$ or teach$ or technique$ or therap$ or 
train$ or workshop$ or work shop$) or (intermittent preventative adj (therap& or 
treatment$) adj social rhythm$).ti,ab. 
6.  Or/4-5 
7.   (patient acceptance or health care.sh) and (psychotherap$ or therap$ or 
treatment.).hw 
8.   acceptance adj (based or centred or centered) or acceptance adj2 (commitment or 
mindfulness) or act adj (psychotherapy$ or therap$) or (contextual adj2 approach$ 
or assist$ or coach$ or educat$ or instruct$ or intervene$ or manag$ or module$ or 
program$ or rehab$ or strategy$ or support$ or technique$ or therap$ or train$ ot 
treat$ or workshop$ or work shop$) or comprehensive distancing) ti.,ab. 
9.  Or/ 7-8 
10.  Exp behavior therapy or psychotherapy or rational emotive. sh. 
11.  (cognit$ or behavior?r or metacognit$) adj5 (analy$ or interven$ or modif$ or 
program$ or psychoanaly$ or psychotherapy$ or restructur$ or psychotherapy$ or 
restructure$ or retrain$ or technique$ or therap$ or train$ or treat$) or behavio?r$ 
activat$ or cbt).ti.ab. 
12.  Or/ 10-11 
13.   exp biofeedback 
14.  bifoeed$ or bio feed$ or neuro feed$ or psychophysiology$ or psycho physiology$ 
or (alpha or brainwave$ or electromyography or emg or physiological) adj2 feed$ 
.ab,ti. 
15.   /13 or 14 
16.   (expos$ adj3 fear) or (exposure or fear) adj3 (intervene$ or psychoanaly$ or 
psychotherapy$ or therap$ or treat$) or fear$ adj5 (decreas$ or diminish$ or 
extinct$ or lessen$ or prevent$ reduc$) adj5 (approach$ or assist$ or coach$ or 
educat$ or instruct$ or intervene$ or manag$ or module$ or program$ or rehab$ or 
strategy$ or support$ or technique$ or therap$ or train$ ot treat$ or workshop$ or 
work shop$) .ab, .ti 
17.  breathing exercise or mediation or relaxation.sh 
18.  or/ 16 or 17 
19.  exp psychoanalytic therapy or psychoanalysis.sh 
20.  free association or psychoanal$ or psycho anal$ or psychodynamic$ or psycho 
dynamic$ adj3 (approach$ or assist$ or coach$ or educat$ or instruct$ or 
intervene$ or manag$ or module$ or program$ or rehab$ or strategy$ or support$ 
or technique$ or therap$ or train$ ot treat$ or workshop$ or work shop$) .ti.ab. 
21.  exp group processes or exp psychotherapy, group or self help group or 
(community network or peer group or social  support) .sh. 
22.  (conjoint therap$ or family responsive or family relation$) or (couples or family or 
group$ or martial or marriage$ or support$) adj (based or cent$ or focu?ed) or 
(couples or famil$ or martial or marriage$) adj3 (approach$ or assist$ or coach$ or 
educat$ or instruct$ or intervene$ or manag$ or module$ or program$ or rehab$ or 
strategy$ or support$ or technique$ or therap$ or train$ ot treat$ or workshop$ or 
work shop$) .ab.ti 
23.  or/ 21-22 
24.   (anxiety$ or fear or stress or worry$) adj3 ( control$ or manag$) .ti.ab. 
25.  (multisystemic or systemic) adj2 ( intervene$ or therap$ or treat$). ab, ti. 
26.  dialectic$ ab, ti. 
27.  (signpost$ or sign post$) .ti, .ab. 
28.  problem based learning or problem solving.sh. 
29.  (identif$ or deal$ or resolve$ or solution$ or solv$) adj3 (difficult$ or problem$) or 
(skil$ adj3 problem) .ti.ab. 
30.  or/24-29 
31.  solution focused therapy.sh. 
32.  solution$ adj2 (build$ or focus$).ab,ti. 
33.  Or /31-32 
34.  Or/ 1-33 
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Study  Design  Trial Size   Comparison 
Group 
Intervention  Assessment 
Points 
Outcome 
Measures 
Reason for 
Exclusion 
 
Bell et al., 2012  RCT  83  Waitlist control  Computerised CBT  Baseline, 3 and 6 
months. 
PGI, WSAS, 
GADI, PSWQ, 
PDSS, LSAS, 
FNE, FQ, BAI, 
BDI-I. 
GAD subgroup 
not reported. 
Author did not 
respond to data 
request. 
Brenes et al., 
2012 
RCT  60  Non-directive 
supportive therapy 
Telephone delivered 
CBT 
Not reported.  Not reported.  Full RCT data not 
reported reflective 
article.  
 
Brenes et al., 
2012 (a) 
RCT  60  Non-directive 
supportive therapy 
Telephone delivered 
CBT 
Baseline, end of 
treatment and 12 
months. 
PSWQ, STAI, 
HARS, ASI, BDI, 
SF-36. 
GAD data 
subgroup not 
reported. Author 
did not respond to 
data request. 
Bressi et al., 
2010 
RCT  60  TAU  Short-Term Dynamic 
Psychotherapy 
Baseline, 12 
months. 
CGI, SCL-90, CSI, 
IPP. 
PSWQ not used in 
trial. 
 
Craske et al., 
2011 
RCT  1004  Usual Care  Combination CBT and 
pharmacotherapy 
Baseline, 6 and 12 
months. 
GADSS, PDS-SR, 
SPI, PTSD 
Checklist- CV. 
 
PSWQ not used in 
trial. 
Christensen et 
al., 2010 
RCT  N/A  Attentional Control  Internet based CB.  Baseline, post-
treatment, 6 and 12 
months. 
GAD-7, PSQW, 
PHQ, K-10. 
Protocol no 
published data for 
trial. 
 
Dear et al., 2011  Single Group open 
trial  
32  N/A  Internet CBT  Baseline, post-
treatment, 3 
months. 
MINI-v5,  DASS-
21, PHQ-9, 
PSWQ,SiAs6, 
GAD-7,PDSS-R, 
K-10. 
 
Not randomised 
trial. 
Delgado et al., 
2010 
Randomised 
assignment 
36  Progressive muscle 
relaxation 
Mindfulness  Baseline, end of 
treatment. 
PSWQ, BDI, 
STAI, PANAS, 
SHC, TMMS-24. 
Sample did not 
use diagnostic 
criteria, PSWQ 
below cut off.    144 
Study  Design  Trial Size   Comparison 
Group 
Intervention  Assessment 
Points 
Outcome 
Measures 
Reason for 
Exclusion 
 
Donegan et al., 
2012. 
RCT  57  AR  CBT  Baseline, end of 
treatment. 
ADIS, PSWQ, 
BDI, WAQ-SOM,. 
Secondary 
analysis of 
previously 
reported RCT. 
 
Gorini et al., 2010  Randomised 
assignment 
20  Non Biofeedback  Biofeedback  Baseline, post-
treatment. 
PSWQ, BAI, STAI, 
HAM-A. 
Biofeedback not 
psychological 
intervention. Pre-
post scores not 
reported.    
 
Herring et al., 
2012 
RCT  30  Waitlist Control  Aerobic exercise 
training  
 
Resistance exercise 
training 
Baseline, 2,4 and 6 
weeks. 
ADIS-IV, PSWQ, 
BDI. 
Physical exercise 
intervention, not 
psychological 
therapy. 
Johnson et al., 
2011 
RCT  131  Waitlist Control 
 
Internet CBT  Baseline, post-
treatment, 3 month. 
  Trans-diagnostic 
trial GAD specific 
data not reported 
for all arms. 
 
Johnson et al., 
2013 
RCT  129  Waitlist Control 
 
Internet CBT  Baseline, post 
treatment, 3 month. 
  Trans-diagnostic 
trial GAD specific 
data not reported 
for all arms. 
 
Kitchener et al., 
2009 
RCT  73  Waitlist Control 
 
Anxiety 
Management 
Stress control  Baseline, post- 
treatment, 1 month. 
GHQ-28, FQ, BDI, 
LSAS, GHQ-28. 
PSWQ not used in 
trial. 
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Study  Design  Trial Size   Comparison 
Group 
Intervention  Assessment 
Points 
Outcome 
Measures 
Reason for 
Exclusion 
 
Mohlman et al., 
2003 
RCT  42  Waitlist  CBT 
 
Enhanced CBT 
Baseline, post-
treatment. 
BAI, PSWQ, BDI, 
SCL- Anxiety, 
SCL-GSI. STAI-T. 
Use composite of 
anxiety and did 
not report PSWQ 
scores separately. 
Author did not 
respond to 
information 
request. 
 
Monnaze et al., 
2013 
Randomised 
assignment 
45  CBT  MCT  Baseline, post-
treatment. 
GADS, MCQ.  PSWQ not 
reported. Not 
published in 
English. 
 
Muntingh et al., 
2009 
Randomised 
assignment 
N/A  Care as Usual  Collaborative stepped 
care 
Baseline, 3, 9 and 
12 months. 
BAI, SF-36, EQ-
5D, PSQ, OASIS, 
PHQ-9, UCL. 
Study protocol not 
full published 
study. 
 
Newman et al., 
2013 
Randomised 
assignment 
49  Self-control 
desensitization 
CBT  Baseline, post- 
treatment, 6,12 and 
24 months. 
 
STAIT, HARS, 
PSWQ. 
 
Secondary 
analysis. 
Norton et al., 
2012 
Randomised 
assignment 
87  Relaxation  CBT  Baseline, pre-
treatment, post -
treatment. 
 
STAI, ADDQ, BAI, 
PDSS, GAD-IV, 
SPDQ. 
PSWQ not used in 
trial. 
Repetto et al., 
2013 
RCT  25  Waitlist control  
 
Virtual reality and 
mobile phone 
Biofeedback Virtual 
Reality and mobile 
phone  
Baseline, post-
treatment. 
PSWQ, BAI, STAI, 
HAM-A. 
Technological 
intervention not 
psychological 
intervention. 
 
     146 
Study  Design  Trial Size   Comparison 
Group 
Intervention  Assessment 
Points 
Outcome 
Measures 
Reason for 
Exclusion 
 
Roy-Bryne et al., 
2010 
RCT  1004  Usual Care  Combination CBT and 
pharmacotherapy 
Baseline, post- 
treatment, 6. 12 
and 18 months. 
 
BSI-12.  PSWQ not used in 
trial. 
Salzer et al., 
2011 
Randomised 
assignment 
59  CBT  Short Term 
Psychodynamic 
Psychotherapy 
Baseline 12 
months. 
HARS, PSWQ, 
BAI, HADS, BDI 
IIP. 
Follow up report 
of Leichsering 
2009 study. 
Secondary 
analysis. 
 
Schmidt et al., 
2012 
RCT  96  Waitlist control  False Safety Behaviour 
Elimination Therapy 
Baseline, post-
treatment, 6 
months. 
ASI, BDI, MI, DIS, 
SPRAS, CGI. 
PSWQ not used in 
trial. 
 
Seekes et al., 
2011 
Randomised 
assignment 
120  Usual care  Stepped Care  Baseline, 8, 12 and 
24 weeks. 
IDS, HADS, 
W&SAS. 
Model of care not 
specific 
psychological 
intervention. 
 
Smith, 2010  Single case  1  N/A  Short-term 
Psychodynamic 
Psychotherapy 
Baseline, post-
treatment, 3 
months. 
GHQ-12.  Single case 
design not 
randomised study. 
 
Treanor et al., 
2010 
Randomised 
assignment 
31  Delayed treatment 
Waitlist 
ABBT  Baseline, post-
treatment. 
DERS, ACS, 
ACQ-R, GAD 
CSR, PSWQ. 
Report identical 
data of Roemer et 
al. 2008 trial. 
Secondary 
Analysis. 
 
Titov et al., 2012  RCT  77  Waitlist  Internet CBT  Baseline, post-
treatment, 3 
months. 
DASS-21, PHQ-9, 
PSWQ, SP-12, 
PDSS-SR, NEO-
FFI-N. 
Trans-diagnostic 
trial. GAD specific 
data not reported 
for all arms. 
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Study  Design  Trial Size   Comparison 
Group 
Intervention  Assessment 
Points 
Outcome 
Measures 
Reason for 
Exclusion 
 
Wong et al., 2011  RCT  N/A  Usual care 
 
Psycho-education + 
usual care 
 
MCBT  Baseline, post-
treatment, 6 and 9 
months. 
PSWQ, BAI, CES-
D, SF-12. 
Trial protocol only, 
no published data 
of trial. 
Zager et al., 2012  RCT  18  Control group  ABBT  Baseline, post-
treatment. 
GAD-7, PSWQ, 
SF-12. 
Anxiety composite 
used. PSWQ not 
reported 
separately. Author 
did not respond to 
data request. 
 
Zager et al., 2013  Randomised 
assignment 
22  AR  ABBT  Baseline, post-
treatment. 
VLQ, AQQ, SF-
12. 
PSWQ not used in 
trial. 
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